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Heart rate variability (HRV), an indirect measure of cardiac autonomic function, is a 
powerful predictor of sudden cardiac death. Cardiac autonomic function is a neglected aspect of 
the pathophysiology of cardiovascular diseases (CVDs) in the field of nutritional sciences, with 
little published literature on effects of diet in this CVD risk factor. This thesis aimed at 
exploring the associations and impacts of some main dietary candidates that may influence 
HRV: long chain n-3 polyunsaturated fatty acids (LC n-3 PUFA) and energy intake restriction. 
The first study compared HRV in vegans with omnivore controls, representing 
populations with low and high LC n-3 PUFA status, respectively. The observed differences 
between groups were more complex than hypothesised. Vegans presented higher 24 h overall 
HRV due to greater sleep-day differences compared to omnivores, and lower beat-to-beat HRV 
in the day-time. Vegans also presented lower availability of LC n-3 PUFA lipid mediators that 
may influence anti-inflammatory capacity, especially in populations with underlying chronic 
inflammation presenting low tissue LC n-3 PUFA status. This led to the next study, which 
characterised the variability of LC n-3 PUFA status in chronic kidney disease patients 
commencing haemodialysis, a population with high burden of inflammation and CVD 
compared to the general population, with the aim of establishing a potential relationship with 
HRV. Haemodialysis patients in this study had particularly low proportions and narrow degree 
of variability of erythrocyte membrane eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), which precluded any meaningful findings in the relationship between tissue LC n-3 
PUFA status and HRV. Finally, the last study compared the effects of intermittent and 
continuous energy restriction diets (IER vs. CER) on HRV in centrally obese, independent of 
weight loss. The results showed no superior effects of weight loss via an IER diet compared to a 
CER diet on HRV, and suggested that weight loss itself may have a much greater effect on 
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Chapter 1 Introduction 
The overarching scope of this thesis was to explore the role of diet and/or nutritional 
status in the prevention of sudden cardiac death (SCD) by investigating its impact on the 
autonomic nervous system (ANS) activity, assessed by heart rate variability (HRV), in healthy 
and diseased states. The effect of whole diets or dietary components on ANS function has rarely 
been considered and most of the available evidence derives from studies on energy balance and 
long chain n-3 polyunsaturated fatty acid (LC n-3 PUFA). This thesis will therefore explore 
how LC n-3 PUFA status could affect HRV by including an observational pilot study in a 
healthy population with low (vegans) and high (omnivores) LC n-3 PUFA status and a cross-
sectional study in chronic kidney disease patients; and will explore how weight loss, either 
through continuous energy restriction or intermittent energy restriction could affect HRV by 








This introduction chapter will provide an insight into the relationship between the ANS 
and HRV, as the method chosen to assess the cardiac autonomic function, and the relevant 
dietary aspects, with the aim of recognising literature gaps and to provide background to the 
design of the studies included in this thesis. 
1.1 Cardiovascular disease 
Cardiovascular diseases (CVDs) are the leading cause of death worldwide and according 
to the World Health Organisation report, an estimated 17.5 million people died from CVDs in 
2012 which represents 31% of all global deaths. Of these deaths, an estimated 7.4 million were 
due to coronary heart disease (CHD) (1). Among cardiac deaths, SCD accounts for 
approximately 50% (2), and most studies suggest the presence of CHD in patients dying of SCD 
(3). Although mortality from CVD has been declining in the UK, there is a higher number of 
people living with the disease with rises in treatment and hospital admissions (4). However, 
SCD rates do not seem to be declining as much as overall CHD mortality (5), representing an 
area requiring prevention strategies. 
1.1.1 Sudden cardiac death 
There is no consensus on the definition of SCD. However, according to American 
College of Cardiology/American Heart Association/European Society of Cardiology Practice 
Guidelines, SCD is defined as an unexpected death in an apparently healthy subject without an 
obvious noncardiac cause that occurs within 1 h of witnessed symptom onset or within 24 h of 
unwitnessed symptom onset and is usually due to a cardiac arrhythmia (3). SCD is the largest 
contributor to mortality among haemodialysis patients, accounting for one fourth of deaths (6). 
The pathophysiology of SCD is explained mainly as an electric arrhythmogenic instability and 
is mostly due to ventricular arrhythmias (2).  
1.1.2 Arrhythmia  
The heart rhythm is started by automatic electric impulses derived from the sinoatrial 
node followed by impulse conduction to the ventricles where individual cardiomyocytes 
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establish coordinated contractions. When the electrical excitation of a certain area of the cardiac 
tissue is impaired, the heart develops arrhythmias which can lead to SCD (7).  
The cardiac action potential is a result of the sequential opening and closing of ion 
channel proteins in the cardiomyocyte membrane. The conduction of the action potential 
through the heart is dependent on the electrical coupling between the individual 
cardiomyocytes, which is mediated by gap junctions. In humans, the cardiac action potential has 
five different phases. After depolarisation from the sinoatrial node, the membrane potential is 
brought to the threshold and the voltage-activated sodium (Na+) channels open, diffusing the 
Na+ across the membrane into the cardiomyocyte. The resulting Na+ current causes further 
depolarisation of the membrane through a positive feedback loop, which is responsible for the 
fast upstroke of the action potential. The activation of the fast and slow potassium (K+) currents 
result in the early rapid repolarisation. This is followed by a prolonged plateau that results from 
a balance between the inward currents, formed by the voltage-dependent calcium (Ca2+) channel 
and Na+-Ca2+ exchanger, and outward currents, formed by the voltage-dependent K+ channels. 
The K+ currents predominate as the Ca2+ channels become inactivated, causing further 
repolarisation and turning the membrane potential into the K+ equilibrium potential. Finally, 
after full repolarisation, the membrane potential returns to its resting value (8).  
The life threatening ventricular arrhythmias can be initiated by two main mechanisms: 
abnormalities in impulse initiation (triggered activity and enhanced automaticity) and 
abnormalities in impulse generation (re-entry). Triggered activity can occur from the premature 
activation of cardiac tissues by afterdepolarisation, associated with prolonged action potential 
durations, or through delayed afterdepolarisation, when there is an intracellular Ca2+ overload 
(8). Enhanced automaticity from pacemaker cells (resulting from both voltage- and Ca2+-
dependent mechanisms) can increase the action potential discharge rate, resulting in increased 
heart rate (HR). Re-entry occurs when the electric impulse continues to re-excite the cardiac 
tissue (9). 
Ca2+ is the mediator between the electrical activity and the contractile force. When the 
cardiomyocytes receive the electric impulse, the transmembrane influx of Ca2+ via the voltage-
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gated Ca2+ channels leads to mechanical contraction through interactions of the actin and 
myosin (10). Abnormal Ca2+ dynamics, due to membrane damage causing Ca2+ overload, make 
cardiomyocytes exhibit spontaneous wave-like elevations of Ca2+ that propagate within the 
individual myocytes (Ca2+ waves), which induces re-entry and can lead to abnormal excitation 
in a certain area of the heart (7). Other from the electrophysiological derangements, cardiac 
arrhythmias can also result from molecular, cellular and/or structural abnormalities in the 
cardiac tissue, including altered gap-junctional communication, pathological alteration of the 
cardiac fibroblasts and structural alterations of the myocardium, respectively (7).  
Current treatments for arrhythmia include the placement of an implantable cardioverter 
defibrillator (ICD), which is only accessible to a small number of patients; neural ablation, 
which has a low long-term success rate; and pharmacological anti-arrhythmic therapy. The 
arrhythmias mechanisms vary largely and therefore different types of arrhythmias present 
distinct autonomic triggers with different targets for treatment and prevention (11). This may be 
the reason for conflicting results in treatment and prevention of arrhythmias, as a 
pharmacological therapy may be anti-arrhythmic in a patient with heart failure but may have a 
pro-arrhythmic effect in a patient with myocardial infarction (12). Increasing evidence suggests 
that the ANS plays a role in the pathophysiology of arrhythmogenesis as a trigger and 
predisposing factor (13). 
1.2 Autonomic nervous system 
Clinical evidence has shown the role of the ANS in the development and progression of 
CVD (14). 
1.2.1 Overview 
The neural regulation of the cardiac autonomic function is mainly effected through the 
interplay of the sympathetic and parasympathetic nervous systems (SNS and PNS, respectively). 
Together, these form the ANS that represents an interface between the central nervous system 
(CNS) and the body (15). The ANS is responsible for the regulation of the heart’s rate, rhythm, 
and contractility (13), allowing the cardiovascular system to adapt to the various daily life 
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activities (14). The sympathetic nerves innervate the heart and blood vessels, and the vagal 
parasympathetic nerves innervate the heart. Sympathetic activity to the heart is regulated by 
sympathetic nerve fibres that derive from major autonomic ganglia, including superior cervical 
ganglia, cervicothoracic (stellate) ganglia and thoracic ganglia, that originate from premotor 
neurons located in the brain stem and hypothalamus, whereas parasympathetic activity to the 
heart is regulated by the vagus nerve that originates in the nucleus ambiguus in the medulla 
oblongata (Figure 2) (16).  
 
Figure 2 – Cardiac autonomic innervation. Reprinted from (11) with permission from Elsevier. 
The sympathetic innervation to the heart originates from the superior cervical ganglia, 
cervicothoracic (stellate) ganglia and thoracic ganglia and the parasympathetic innervation 
derives from the vagus nerve. 
Although automaticity is intrinsic to different cardiac tissues with pacemaker properties, 
the electrical and contractile activity of the myocardium is largely modulated by the ANS (17). 
While the effect of vagal stimulation on the cardiac pacemaker cells is to cause 
hyperpolarisation and to reduce the rate of depolarisation, sympathetic stimulation causes 
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chronotropic effects by increasing the rate of pacemaker depolarisation. The ANS is, therefore, 
responsible for the tight regulation of cardiac excitability and contractile function (18).  
In healthy individuals, the sinoatrial node is entirely responsible for the regulation of the 
heart beat and is directly innervated by both vagal and sympathetic efferents. Sympathetic and 
parasympathetic nerves exert opposite but not symmetrical effects on the heart. The 
parasympathetic effect on reducing HR is mediated by the synaptic release of acetylcholine 
(presents a short effect latency and a high turnover rate) which exerts an almost immediate 
response allowing a beat-to-beat cardiac regulation. The sympathetic effect on raising the HR is 
mediated by the synaptic release of noradrenaline (presents a longer effect latency and lower 
turnover rate compared to acetylcholine due to being reabsorbed and metabolised relatively 
slowly) which exert a slower response and longer lasting effect in the resulting changes in 
cardiac autonomic regulation compared to the parasympathetic nerves (19). The SNS plays a 
role in increasing myocardial contractility and peripheral resistance whereas the PNS presents a 
limited effect in myocardial contractility. Otherwise from the antagonistic influences in the 
sinoatrial node, the SNS and PNS also modulate the electrophysiological properties of the heart, 
by influencing ion channel activity.  
In humans, the autonomic modulation is mainly regulated by the baroreflexes to control 
the circulatory homeostasis and this occurs via negative feedback. When the firing rate of the 
baroreceptors is increased by a rise in systemic arterial blood pressure, the cardiac vagal activity 
increases whereas the sympathetic activity decreases, resulting in a slower HR, decreased 
cardiac contractility and decreased peripheral vascular resistance. When the firing rate of the 
baroreceptors lowers by a decrease in systemic arterial blood pressure, the opposite 
haemodynamic changes occur (20). A reduced baroreflex control has been associated with 
increased SCD in patients after myocardial infarction (21). 
1.2.2 ANS dysfunction 
Cardiac autonomic dysregulation is a hallmark of CVD (22). The sympathetic and 
parasympathetic neural factors have been studied in a number of cardiovascular (including 
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hypertension and cardiac arrhythmias), metabolic (including obesity) and renal (including renal 
failure) diseases, with the attempt to define the role of the ANS as the underlying mechanism in 
disease as well as investigating potential therapeutic targets (23). The evidence on the 
sympathetic overactivation and parasympathetic abnormalities in the development of 
cardiovascular, metabolic and renal disease, including the potential unifying role of 
inflammation in autonomic dysfunction associated with these diseases, will be summarised 
below. 
1.2.2.1 Hypertension 
The pathogenesis of essential hypertension has been widely studied in both animals and 
humans, with the major mechanisms including the activation of the SNS and renin-angiotensin-
aldosterone system (24). Cardiac sympathetic overactivation may contribute to the 
development, maintenance and progression of hypertension (23). Assessment of sympathetic 
neural activity by microneurography, measurement of plasma norepinephrine or norepinephrine 
spillover (based on intravenous infusion of radiolabelled norepinephrine), has shown 
hyperactivation of sympathetic outflow to the kidneys, heart and skeletal muscle in several 
established hypertensive states (25,26). In addition, it was shown that the greater norepinephrine 
levels observed in hypertensive patients is due mostly to an increased release of the 
neurotransmitter from the adrenergic nerve terminals, as opposed to reduced adrenergic nerve 
terminals reuptake of the neurotransmitter (25). The mechanisms triggering the sympathetic 
overactivation remain uncertain and include the following hypotheses: functional impairment of 
arterial baroreflexes and chemoreceptors that exert inhibitory effects on central sympathetic 
drive; hyperinsulinaemia causing a pro-sympathoexcitatory effect on the CNS; or stimulation of 
SNS by circulating humoral factors, including angiotensin II and aldosterone (23). 
1.2.2.2  Cardiac arrhythmia 
The intrinsic cardiac nervous system receives input from both SNS and PNS and plays a 
key role in the regulation of the atrial and ventricular function (27). An imbalance of the ANS 
has a substantial impact on the induction and maintenance of atrial and ventricular arrhythmias 
(28). Figure 3 illustrates the arrhythmogenic effects of the SNS and PNS on cardiac 
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electrophysiology. Increased sympathetic activity in a canine model of SCD preceded 
immediately the occurrence of ventricular fibrillation and SCD (29).  
 
Figure 3 – Arrhythmogenic effects of the sympathetic and parasympathetic stimulation of the 
heart. Reprinted from (13) with permission from Elsevier. The interplay between PNS and SNS 
allow the constant adaptation of the cardiovascular system to physiological stimuli. Disruption 
of the PNS and SNS balance with an enhanced sympathetic stimulation has a significant impact 
on the initiation of ventricular arrhythmias through increased triggered activity and automaticity 
or by inducing re-entry. ACh, acetylcholine; NA, norepinephrine; VF, ventricular fibrillation. 
 
1.2.2.3 Overweight/obesity 
Overweight and obese individuals are at higher risk of CVD associated with the increased 
incidence of diabetes, dyslipidaemia, atherosclerosis, renal disease and hypertension (30). In a 
30 
 
previous study, it was shown that obese individuals were more prone to ventricular arrhythmia 
compared to lean individuals (31). In middle aged adults, obesity is one of the main contributors 
to an increased risk of SCD (32). Obese adults have raised urinary norepinephrine levels, 
indicating greater sympathetic outflow, compared to healthy individuals, and centrally obese 
adults (mostly visceral fat) presented a higher degree of sympathetic activation compared to 
individuals with subcutaneous obesity (33,34). Alvarez et al. showed a higher sympathetic 
activity in men with elevated abdominal visceral fat compared to age-, total fat mass- and 
abdominal subcutaneous fat-matched controls with lower abdominal fat (35). 
The underlying cause of the increased sympathetic activity in obesity is not fully 
understood and it is likely to be multifactorial (36). Nevertheless, many mechanisms have been 
proposed including, amongst others, inflammation, impaired baroreflex sensitivity, increased 
non-esterified fatty acids (NEFA) release from excessive visceral adipocytes, 
hyperinsulinaemia, hyperleptinaemia and the activation of melanocortin 4 receptors (MC4R) in 
the CNS, which play a role in body weight homeostasis by regulating appetite (37). Obesity has 
been associated with a chronic low grade inflammation, which may be induced by lipotoxicity 
through the secretion of pro-inflammatory cytokines by the adipose tissue (38), with a potential 
contribution to the increased sympathetic activity (the role of inflammation in the ANS is 
summarised below in section 1.2.3). In individuals with obesity that present with 
hyperinsulinaemia, the central sympathoexcitatory effects of insulin appear to be blunted 
leading to a sustained sympathetic activation through the insulin feedback loop (39). The 
arterial baroreflex activity was also found to be blunted in individuals with central obesity 
suggesting a causal role in the sympathetic overactivity observed in obesity (40). Leptin is a 
hormone secreted by adipocytes in direct proportion to adiposity levels and acts in the CNS to 
decrease food intake by decreasing appetite, and increase energy expenditure by increasing 
sympathetic activity, predominantly to the kidney and skeletal muscle, with a consequent 
increase in blood pressure (41). In obesity, leptin resistance has been shown to be selective, with 
hyperleptinaemia failing to regulate energy balance but maintaining its effects on the 
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sympathetic outflow and blood pressure, which may explain the tendency for obesity to induce 
sympathetic overactivity and hypertension (42).   
1.2.2.4 Chronic kidney disease 
Chronic kidney disease (CKD) is defined by KDIGO (Kidney Disease: Improving Global 
Outcomes) guidelines as abnormalities of kidney structure or function, that have persisted for at 
least 3 months, and present health implications (43). CKD severity is classified according to 
level of albuminuria and glomerular filtration rate (GFR) (Table 1), where the category G5 
(stage 5) of < 15 ml / min per 1.73 m2 represents kidney failure, which can be treated only by 
dialysis or transplantation (43).  
Table 1 - Glomerular filtration rate categories in chronic kidney disease. 
GFR category GFR (ml/min/1.73 m2) Terms 
G1 ≥90 Normal or high 
G2 60-89 Mildly decreased 
G3a 45-59 Mildly to moderately decreased 
G3b 30-44 Moderately to severely decreased 
G4 15-29 Severely decreased 
G5 <15 Kdney failure 
GFR, glomerular filtration rate. 
Cardiovascular disease is particularly prevalent in CKD (44), and accounts for 43% of all-
cause mortality among dialysis patients (45). It has been observed that the risk of SCD is 
doubled when a patient with CKD stage 5 starts dialysis (46) and in haemodialysis, SCD 
accounts for two thirds of all cardiac deaths and one fourth of all-cause mortality (45). Most of 
the CKD patients present with hypertension which plays a key role in the further deterioration 
of renal function and in the particularly high rate of cardiovascular events. The kidneys present 
afferent sensory signals and efferent sympathetic innervation, with sympathetic postganglionic 
fibres innervating all the essential renal structures. Renal sympathetic activity leads to volume 
retention via Na+ reabsorption and stimulates renin release with a consequent activation of the 
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renin-angiotensin-aldosterone system. Angiotensin II can then stimulate sympathetic nerve 
activity through central mechanisms (47). Sympathetic overactivation is present in CKD 
patients and it has been demonstrated by the increased concentration of plasma catecholamines 
as well as greater sensitivity to norepinephrine in these patients (48,49).  
In summary, an autonomic dysfunction characterised mostly by a sympathetic 
overactivity, and to a lesser extent, a reduced parasympathetic activity is associated with 
increased morbidity and cardiovascular mortality (50,51). Modulation of the ANS through 
pharmacological or non-pharmacological means improves patients’ survival (14). For this 
reason, it is important to investigate the possible modulatory effects of dietary determinants on 
autonomic balance on its own or as an adjunct therapy, as this could be a cost-effective and 
side-effect free way of lowering CVD risk. In addition, as inflammation is a unifying 
component of CHD, obesity and CKD, this might be an important mechanism whereby the ANS 
is compromised and may be mediated by diet and / or nutritional status. 
1.2.3 Autonomic nervous system and inflammation 
The ANS plays an essential role in the physiological regulation of basal conditions as 
well as in response to acute and chronic stressors. The ANS, primarily the SNS, is activated by 
stressors, including antigens from foreign substances and tissue damage, and regulates the host 
defence mechanisms. Immune organs and tissues are innervated by the postganglionic 
sympathetic neurons and the adrenal medulla is innervated by preganglionic sympathetic 
neurons, releasing the catecholamines, norepinephrine and epinephrine into the circulation. 
Therefore, the SNS can have either local or systemic effects on the immune system. On the 
other hand, the PNS doesn’t innervate the primary immune organs (thymus and bone marrow), 
but provides vagal afferents that transmit immune signals to the brain that regulate sympathetic 
outflow to immune organs (52). The information on tissue damage or antigen exposure leading 
to immune activation is conveyed to the CNS by the afferent visceral fibres, including those in 
the vagus nerves (53).  
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The acute inflammatory response is protective, allowing for repair of damaged tissue and 
elimination of invading organisms, and is self-limited leading to complete resolution with return 
to homeostasis. The acute inflammatory response starts with the migration of the immunocytes 
(specially neutrophils) to the site of inflammation, guided by chemokines and eicosanoid 
mediators, including prostaglandins and leukotrienes (54,55). The major phospholipids in 
human plasma and erythrocytes - phosphocholine and phosphoethanolamine - are also 
concentrated in macrophage plasma membranes and represent the largest phospholipid stores of 
dietary n-3 and n-6 PUFAs in cells and fluids involved in inflammatory responses (56). The 
fatty acid composition of membrane phospholipids in macrophages and endothelium will 
influence the inflammatory responses via conversion of the n-3 and n-6 PUFAs into their 
respective lipid mediators. The first step in the synthesis of the lipid mediators is the release of 
the esterified fatty acid – arachidonic acid (AA), linoleic acid (LA), ɑ-linolenic acid (ALA), 
docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) - from the membrane 
phospholipids by phospholipase enzymes. These fatty acids can be further metabolised by 
cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP) monooxygenases or 
undergo non-enzymatic oxidation with reactive oxygen species to generate numerous bioactive 
lipid mediators (57). These bioactive lipid mediators, including the specialised pro-resolving 
mediators (SPM) derived from the metabolism of LC n-3 PUFA, are actively involved in the 
resolution phase of inflammation, promoting the return to homeostasis (58). The resolution 
phase stimulates cessation of neutrophils infiltration into affected tissues and promotes the 
clearance of apoptotic cells, debris and microbes by the macrophages (59). However, when 
acute inflammation is not resolved or is excessive it can become chronic, leading to tissue 
damage and contributing to chronic diseases, such as cardiovascular and renal diseases (60). A 
study demonstrated in mice a novel interaction between pro-resolving lipid mediators and 
neutrin-1 regulated by the vagus nerve, which stimulates the resolution of the inflammation 
(61). Neutrin-1 is a neuronal protein that acts as a chemoattractant in axonal migration in 
peripheral tissues, contributing to local control of leukocyte migration (62).  
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In the site where an acute inflammatory response occurs, the bioactive oxygenated lipid 
mediators originating from essential fatty acids are of particular interest due to their nutritional 
regulation of the response (58). 
There is growing evidence of an increased risk of arrhythmia in inflammatory diseases 
(63,64). A study in patients with stable CHD and a history of myocardial infarction showed that 
those experiencing ventricular arrhythmia had significantly higher serum high sensitivity C-
reactive protein (hs-CRP), a marker of systemic inflammation, compared to those who did not, 
suggesting that inflammation might play a role in ventricular arrhythmia pathogenesis (65). 
Inflammation is a key component of the pathophysiology of atherosclerosis, which is the main 
underlying cause of CVD, and has been suggested to mediate the relationship between 
autonomic dysfunction and atherosclerosis (66). Briefly, atherosclerosis is an inflammatory 
disease that involves the endothelium and is characterised by a gradual accumulation of lipids 
and inflammatory cells within the intima of large arteries (67). It starts with the internalisation 
of low-density lipoproteins (LDL) in the intima with concomitant endothelial dysfunction and 
further infiltration and accumulation of LDL in the extracellular matrix; circulating monocytes 
are then recruited and attached to the vascular endothelium, followed by transmigration into the 
subendothelial space where they become macrophages; endothelial dysfunction facilitates 
platelet adhesion and activation (due to disruption of the endothelial-related antithrombotic 
properties), resulting in the secretion of chemotactic and growth factors, which stimulate 
migration, accumulation and proliferation of vascular smooth muscle cells and leucocytes in the 
intima resulting in plaque progression; the LDLs retained in the extracellular matrix become 
prone to oxidative and enzymatic modifications; oxidised LDLs further perpetuate the pro-
inflammatory state through further activation, recruitment and transmigration of monocytes and 
other inflammatory cells into the intima; the macrophages in the subendothelial space scavenge 
oxidised LDL, become lipid-rich and convert into foam cells and the accumulation of these lead 
to the formation of fatty streaks; when macrophages fail to remove accumulated cholesterol 
from the vessel, they become apoptotic and release cholesterol and pro-thrombotic molecules to 
the vessel wall, contributing to the plaque formation. As the atherosclerotic plaque progresses, 
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there is a decrease in vascular smooth muscle cells and formation of immature and leaky new 
vessels that render the lesions more susceptible to rupture. The plaque rupture exposes the 
thrombogenic substrates which promote platelet adhesion/activation and aggregation to the 
vascular surface and the activation of the coagulation cascade. This is followed by thrombus 
formation which can be clinically manifested as acute myocardial infarction or sudden death 
(68). Although the causes and risk factors for atherosclerosis are unknown, most cardiovascular 
risk factors, including high total and LDL cholesterol, low level of high-density lipoprotein 
(HDL), hypertension, diabetes, obesity, smoking and sedentary behaviour, may increase the risk 
of developing atherosclerosis and controlling these factors can delay or prevent atherosclerosis 
(68). In addition, atherosclerosis of the sinus node artery, which is involved in the normal 
functioning of the sinus node, has been associated with an increased risk of arrhythmia in a 
retrospective study based on patient’s coronary angiograms assessment of coronary artery 
disease (69). Recently, increased inflammatory activity (increased number of activated T 
lymphocytes and degeneration of adjacent ganglion cells) was found in the left stellate ganglia 
from patients with malignant ventricular arrhythmia (70), suggesting that increased 
inflammation may contribute to ventricular arrhythmia through increased sympathetic activity 
(71) A study in a canine ischemic model showed that injection of interleukin 1β (IL-1β) into the 
left stellate ganglia, which stimulated an increase in inflammatory state, increased the 
susceptibility and promoted ventricular arrhythmia under acute ischemic stress by neuronal 
remodelling of the left stellate ganglia and consequent increase in sympathetic activity (71). 
1.3 Assessment of the autonomic nervous system activity 
The autonomic function can be assessed through direct quantification or indirect 
assessment of sympathetic and/or parasympathetic activity. Direct quantification includes 
measurements of neurotransmitter levels, by analysing circulating catecholamines (mainly 
norepinephrine) and other metabolites modulated by the ANS; and sympathetic 
microneurography, which measures muscle sympathetic nervous activity (72). Indirect 
assessment includes measurement of HRV, which involves continuously recording HR, and 
baroreflex sensitivity, which comprises of measures of HR and blood pressure and requires the 
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intravenous administration of vasoactive drugs (72). Among these different techniques for 
assessing the ANS activity, HRV is often used for assessing cardiac autonomic function as it is 
non-invasive, thereby offering potential to be applied in the clinical setting with low patient 
burden (17). As an indirect method to assess ANS activity, it provides qualitative (and not 
quantitative) information on the relationship between HRV and cardiac autonomic regulation, 
i.e., a low or high HRV may reflect a decrease or increase in cardiac autonomic function, but 
does not quantify the actual cardiac nerve firing rate (73). 
1.3.1 Heart rate variability 
Heart rate variability is a term that refers to a range of parameters that reflect the 
variability in the length of the interbeat intervals (IBI), this is, the time intervals between 
adjacent QRS (Q, R and S being points on the R wave seen on an ECG during ventricular 
depolarisation, and R being the peak upward deflection) complexes (normal-to-normal (NN) 
intervals) (74). Relative increases in sympathetic activity cause shorter IBI and relative 
increases in parasympathetic activity cause the IBI to become longer (75). Overall, HRV is 
inversely correlated with HR, where a greater HRV is correlated with lower HR, and vice versa 
(76). However, HR represents only a mean value over time and by doing this it overlooks the 
irregular behaviour presented by the heart when examined as a beat-to-beat basis. These 
fluctuations between beats result from the interplay between sympathetic and parasympathetic 
nervous system and reflect functional capacity of various regulatory systems, including the 
cardiovascular system, to respond to physiological demands. Figure 4 illustrates the reciprocal 
relationship between HR and IBI. As HR increases, IBI and HRV decreases as there is less time 
between heartbeats for variability to occur. As HR decreases, IBI and HRV increases as there is 




Figure 4 - Example of the relationship between heart rate (dotted blue line) and IBI (RR interval) in the 
ECG (red line) variations over a short period of time. Adapted from (77). 
Low HRV indicates reduced functional regulation of HR by the ANS as it allows less 
compensatory changes in order to successfully respond to physiological demands, reducing the 
inherent self-regulatory capacity, adaptability and resilience (77). Low HRV  was previously 
associated with increased risk of SCD and suggested as a powerful predictor of SCD (74). A 
recent published prospective study, with a median follow up of 13 y. showed that low HRV was 
associated with an increased risk of SCD in the general population, independent of established 
cardiovascular risk factors (78). A low HRV has also been shown to be a strong independent 
predictor of mortality following an acute myocardial infarction (79,80) and risk of cardiac 
events in the general population (81).  
1.3.2 Heart rate variability parameters 
Heart rate variability can be quantified using time- and frequency-domain analysis and 
nonlinear methods. Table 2 summarises the HRV parameters that are the focus of this thesis. 
Time-domain analysis is based on the IBIs whereas frequency-domain analysis employ power 
spectral analysis that provides information about the distribution of power (variance and 
amplitude) as a function of frequency (time period). The values are expressed as the power 
spectral density, which is the area under the curve (peak) in a given bandwidth of the frequency 
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spectrum. A power spectral analysis commonly used is the fast Fourier transformation (FFT), a 
nonparametric method characterised by discrete peaks for each frequency components. 
Nonlinear methods also use fractal analysis to study the multivariable, nonlinear and 
nonperiodicity of HR dynamics. The Poincaré plot is formed of points that correspond to two 
consecutive IBIs and it explores the non-linear dynamics of HRV in a qualitative or quantitative 
manner (14). The qualitative method involves visual inspection of the plot pattern, which is 
usually a fan-like or comet-like shape, and it identifies ectopic beats and technical artefacts (15). 
Quantitatively, the Poincaré plot can be analysed through geometric procedures, where the 
transversal axis (SD1) indicates vagal-mediated short-term variability and the longitudinal axis 
(SD2) reflects overall variability as an inverse function of sympathetic activity (14). 
Table 2 – HRV parameters definition. Adapted from (74). 
Variable Definition 
Time-domain methods 
SDNN (ms) Mean of the standard deviations of NN intervals. Reflects the overall and 
circadian fluctuations in HRV. 
SDANN (ms) Standard deviations of the average NN intervals in all 5 min segments of the 
recording. Reflects long-term fluctuations in HRV. 
RMSSD (ms) Root mean square of successive differences of NN intervals.  Reflects short-
term changes in HRV and alterations in parasympathetic respiratory varia-
tion. 
pNN50 (%) percentage of adjacent NN intervals that differ by greater than 50 ms. Re-
flects short-term changes in HRV 
Triangular in-
dex (Ti) 
Number of all NN intervals divided by the maximum of the density distribu-
tion. Also referred to as HRV index. Reflects overall HRV. 
Frequency-domain methods 
LF (ms2) Low-frequency power (0.04-0.15 Hz). Modulated by baroreceptors. Reflects 
both parasympathetic and sympathetic activity. 
HF (ms2) High-frequency power (0.15-0.4 Hz). Reflects parasympathetic respiratory 
modulation. 
LF:HF ratio May reflect relative sympathetic to parasympathetic activity. 
VLF (ms2) Very low-frequency power (0.003-0.04 Hz). May reflect parasympathetic 
and renin-aldosterone activity. Represents the majority of total power in 
HRV. 
Non-linear methods 
SD1 (ms) Standard deviation of the Poincaré plot perpendicular to the line of indentity. 
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Refects short-term variability, primarily respiratory sinus arrhythmia. 
SD2 (ms) Standard deviation of the Poincaré plot along the line of indentity.  Reflects 
long-term variability. 
Poincaré ratio the ratio of the SD of beat-to-beat IBI variability (SD1) against the SD of 
long-term IBI variability (SD2) - Indicates normality of sinoatrial firing pat-
terns. 
 
Since the publication of the Task Force on HRV standards in 1996 (74), there hasn't been 
an update of the HRV standards guidelines, which is warranted as a vast amount of papers have 
been published since then describing new HRV methodologies and applications in different 
contexts.  
There are more methods that can be used in HRV analysis that are outside of the scope of 
this thesis as these have provided more knowledge on the complexity and mathematical 
characteristics of the variability rather than providing information on the sympathetic and 
parasympathetic control mechanisms. These include methods to estimate the fractal-like 
behaviour of HRV, such as the detrended fluctuation analysis (DFA), methods to quantify the 
entropy rate, such as approximate entropy and sample entropy and methods to measure non-
linear dynamical systems and chaotic behaviour (82). 
Some considerations need to be made about the use of HRV as the method to assess 
cardiac autonomic function. Firstly, studies assessing HRV vary in the duration of ECG/IBI 
recording, devices used, time period measured (day, night, 24 h), report different HRV 
parameters and vary in the methodology used in the data processing which makes comparisons 
between studies rather difficult. Secondly, there are disagreements in the literature on the 
validity of LF power and LF : HF ratio as a measure of sympathetic activity and sympathovagal 
balance, respectively. Earlier investigations have suggested LF to reflect predominantly 
sympathetic activity and based on this assumption the LF : HF ratio was proposed as a way to 
quantify the relationship between sympathetic and parasympathetic activity (73,74,83). 
However, growing evidence has shown LF to reflect both sympathetic, parasympathetic as well 
as other unidentified factors and therefore, LF : HF ratio would not reflect an acurate measure of 
cardiac sympatho-vagal balance (84). More recently, LF power has been suggested as a marker 
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of baroreflex function, rather than cardiac sympathetic activity (85,86). There is the need to 
standardise the methodology for analysing and reporting HRV parameters to make it possible to 
compare results between studies. In addition, future research should focus on the clinical 
applicability of HRV, such as determining cut-off points for CVD risk as well as assessing the 
value of HRV for risk predicting in addition to established risk factors, and how dietary 
determinants can potentially have a role in reducing CVD risk through modulation of HRV. 
1.4 Heart rate variability and inflammatory markers 
An inverse relationship has been found between HRV and inflammatory markers in both 
healthy subjects and those with CVD (87). In healthy adults, inverse correlation were found 
between interleukin-6 (IL-6) and C-reactive protein (CRP) and 10 min frequency-domain HRV 
parameters (HF and LF) (88) as well as CRP and 24 h RMSSD and pNN50 (75). In healthy 
adults, the relationship between HRV and IL-6 was also assessed during and after mental stress 
test but no significant correlations were found (89). However, signal processing difficulties in 
this study limited the amount of usable HRV data for analysis, which in turn limited the HRV 
results to a subsample of the cohort. The Cardiovascular Health Study with normoglycaemic 
adults aged 65 and older with a 15 y follow-up showed an inverse correlation between IL-6 and 
CRP, and 24 h and day-time SDNN and VLF power (90,91). In newly diagnosed and 
established diabetic patients, IL-6 presented an inverse correlation with SDNN (92). In patients 
with moderate to severe CKD, IL-6 was negatively correlated to 24 h SDNN, SDANN and VLF 
power, and positively correlated with LF power, but these were not statistically significant in 
the haemodialysis group, where adequacy of dialysis was associated to HRV (93). These results 
suggest that IL-6 may have an important role in the progression of kidney disease leading up to 
kidney failure. In patients after acute myocardial infarction, CRP levels were negatively 
correlated with 24 h SDNN, HF and LF power (94), and in patients with unstable angina 
pectoris, CRP levels were inversely correlated with SDNN, SDANN, VLF, LF and LF:HF ratio 
(95). In patients with suspected CHD, hs-CRP was associated with 24 h SDNN, and the 
association was strongest in those that had a prior myocardial infarction (96). However, in a 
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study with CHD patients using 5 min HRV analysis no statistically significant correlations were 
found between CRP and frequency-domain HRV (97). 
1.5 Dietary determinants of heart rate variability 
In the field of nutritional sciences, the effect of whole diets or dietary components on 
cardiac autonomic function as a risk factor for risk of mortality from CVD has rarely been 
considered. Consequently, there is a lack of studies, particularly in humans, assessing the effect 
of diet and / or nutritional status on HRV. Aspects of diet and nutrition that have been 
investigated with regards to HRV include energy balance (98–104), although the quality of the 
evidence base is weak in this field, and LC n-3 PUFA (104–112), where there have been a series 
of RCTs in healthy and patient populations from a group in Aalborg University Hospital, 
Denmark. Other potential dietary determinants of HRV that have limited amount of evidence 
published and hence are not the main focus of this PhD, include vitamin D and vitamin B12, 
where low levels or deficiency has been associated with lower HRV in healthy adults (113) and 
in children (114), respectively. The energy balance and LC n-3 PUFA are the dietary aspects 
that constitute the main focus in relation to HRV research and their findings are critically 
reviewed below.  
1.5.1 Energy balance 
The dynamic balance between the SNS, which is responsible for the mobilisation of 
energy, and the PNS, which promotes digestion and energy storage, responds to environmental 
stimuli, such as fasting, in order to adapt the energy metabolism to the body demands (115).  
1.5.1.1 Energy restriction in animal models 
The cardioprotective mechanism behind energy restriction remains to be elucidated in 
humans but evidence from animal studies suggest two potential mechanisms that could explain 
it: decreased mitochondrial production of reactive oxygen species, resulting in reduced 
oxidative damage to the cardiomyocytes; and increased cellular resilience to stress (116). 
Energy restriction in rats have shown to increase HRV and decrease oxidative damage to the 
cardiomyocyte as well as reduce inflammation in the ischemic zone following a myocardial 
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infarction (98). Oxidative stress plays an important role in ischemic injury to cardiomyocytes, 
which can lead to depressed myocardial contractility and arrhythmias (117). Rodents maintained 
on energy restriction have shown reduced amounts of oxidative damage to proteins, lipids and 
DNA in heart tissue, compared with rodents maintained on an ad libitum diet (118,119). Also, 
energy restriction have increased the level of heat-shock proteins and other protein chaperones 
in rodents’ heart tissue, showing an activation of cellular stress response pathways (120). Thus, 
energy restriction could be a potential mediator between reduced inflammation and improved 
cardiac autonomic function. 
1.5.1.2 Weight loss in human studies 
Weight loss is achieved through energy restriction by reduction in daily energy intake 
relative to total energy expenditure in order to promote a negative energy balance. Dietary 
interventions aiming at weight loss, mostly those that also include healthy lifestyle advice 
(increase in physical activity), have been shown to be effective in improving markers of 
cardiovascular disease risk (121–124). Evidence from several studies in obese individuals have 
reported improvements in HRV, both in time- and frequency-domain as well as short-term and 
long-term HRV parameters, after diet-induced weight loss (99–104) or bariatric surgery-induced 
weight loss (101,125–127). Studies on diet-induced weight loss showed increases in time- and 
frequency-domain HRV parameter using different recording durations (5 min (101), 10 min 
(104), 3 h (102), 18 h (100) and 24 h (99,103,128)), interventions of different lengths (ranging 
from 3 to 16 weeks), different study designs with different dietary approaches (very low calorie 
diet (VLCD), continuous energy restriction, mixed approaches) and with study populations with 
different degrees of overweight/obesity and different levels of cardiovascular risk (obese but 
otherwise healthy, with/without diabetes, including/excluding smokers, etc). Bobbioni-Harsh et 
al. showed statistically significant improvements in all 24 h time-domain HRV parameters after 
bariatric surgery-induced weight loss in a biphasic pattern with the rapid initial weight loss 
phase (assessed 3 months after surgery) having the greatest withdrawal in sympathetic activity 
(increased SDNN and Ti) and enhanced parasympathetic activity (increased RMSSD and 
pNN50), and the following slow phase of weight loss (assessed 12 months after surgery) having 
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a partial reactivation of sympathetic activity, shown by a decrease in SDNN and Ti, yet 
remaining significantly higher than baseline (before surgery) (127). In the same study, the 
patients after 12 months of surgery were compared to a stable weight control group that was 
age-, sex- and post-surgery BMI-matched, but no differences in HRV were found between 
groups. These results indicate that substantial weight loss improved cardiac autonomic function, 
but it is influenced by the BMI reached after surgery (127). Most of the weight loss studies in an 
obese sample assessing HRV lack a control group and due to their observational nature preclude 
the ability to assess a causal link between weight loss and decreased SNS activity / enhanced 
PNS activity. An RCT in healthy normal weight adults assessing the effects of weight gain 
followed by weight loss (8 weeks each) in frequency-domain HRV parameters, showed a 
statistically significant decrease in HF with an increase in LF and LF : HF ratio after weight 
gain, during both waking hours and sleep-time, that returned to baseline values after weight 
loss, whereas controls had no change in HRV (129), showing a reversible deleterious effect of 
weight gain on the autonomic function. However, these results cannot be directly extrapolated 
to the obese subjects as obesity reflects a long-term chronic weight gain. 
1.5.1.3 Fasting and ketone bodies 
To maintain a constant body weight, a balance of energy intake is required, alternating 
between feeding and fasting which trigger an increase or decrease in energy expenditure, 
respectively, by the action of the SNS. When feeding, sympathetic activity is enhanced resulting 
in increased HR and food-induced thermogenesis and when fasting, sympathetic activity is 
supressed resulting in decreased HR and activity (130). 
Ketone bodies (acetoacetate, β-hydroxybutyrate and acetone) become an alternative and 
important source of energy when glucose is in short supply, with their levels increasing during 
fasting. They are synthesized in the liver from acetylCoA derived mainly from fatty acid 
oxidation and then transported to extrahepatic tissues, including the brain, heart and skeletal 
muscle, through the blood stream (131). A study in rodents reported β-hydroxybutyrate to 
inhibit the SNS via antagonist effects on the G protein-coupled receptor 41 (GPR41), also 
known as free fatty acid receptor 3 (FFA3), which is abundant in the sympathetic ganglia in 
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mice and humans (132). However, another studied found the opposite, reporting β- 
hydroxybutyrate as a FFA3 agonist, and FFA3 expression and function was found to be 
unevenly distributed in the rat sympathetic ganglia (133). Whereas Kimura et al. (132) provided 
in vivo, cellular and biochemical evidence of β-hydroxybutyrate as an antagonist of FFA3, the 
experiments by Won et al (133) revealed agonist activity. It cannot be ruled out the fact that β-
hydroxybutyrate may act as a partial agonist depending on the context, such as drug 
concentrations and receptor saturation, and thus may produce different effects (133). In 
addition, the studies presented different experimental conditions, such as using rats vs. mice and 
different ages of the animals. Due to the mixed evidence, further studies are warranted to 
resolve these opposing results, as the former study could lead to a reduction in SNS activity but 
the latter in increased SNS activity. This would potentially translate into either improved or 
increased risk of CVD respectively. Although these studies present opposite findings on a 
potential link between β-hydroxybutyrate and SNS activity, evidence of this mechanism hasn’t 
been studied in humans. In addition, caution should be considered as rat or other animal studies 
do not always translate to human studies. Methodological issues arising from animal studies 
include the use of different animal species and strains, which present diverse metabolic 
pathways and drug metabolites thus resulting in variation in efficacy; the lack of standards in 
blinding and randomisation methods used; and the challenge to accurately determine the 
equivalent human dosages of investigational components given in animals due to different 
blood and body mass volumes, amongst others (134,135). Therefore, if β-hydroxybutyrate acts 
as a FFA3 antagonist as reported in the first study, this could be a potential mechanism whereby 
intermittent fasting might be effective in reducing SNS activity, hence lowering the risk of 
SCD. 
1.5.1.4 Physical Activity 
A meta-analysis of 12 and 13 studies showed a significant effect of aerobic exercise 
training interventions (at least 4 week duration) on IBI and HF (136), respectively. A 
prospective study assessing the effect of physical activity in normal weight, overweight and 
obese middle-aged and elderly subjects showed that regardless of weight, 24 h SDNN had the 
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greatest increase in subjects exercising regularly (≥ 2 h per week) (137). In addition, obese 
subjects exercising regularly presented higher 24 h HF and LF power and lower LF : HF ratio 
compared to sedentary obese subjects, even after adjusting for sex, age, diabetes, hypertension, 
use of β-blockers and smoking status (137). A small study in an elderly sample assessed the 
effect of a 14-week intervention with interval training on HR/IBI and time- and frequency-
domain HRV parameters over 24 h, day- and night-time, showing an increase in 
parasympathetic activity with the following results: significant increase in 24 h and day-time 
IBI with the respective decrease in HR; RMSSD and pNN50 significantly increased in the 
night-time and RMSSD also increased over 24 h and day-time; and HF and LF power 
significantly increased in the night-time while LF : HF ratio significantly decreased in the day-
time (138). 
1.5.2 Long chain n-3 polyunsaturated fatty acids 
There is some evidence suggesting an antiarrhythmic role of LC n-3 PUFA which is 
thought to be related to the reduction in cardiovascular mortality/SCD observed in some (139–
148) (but not all (149–155)) of the supplementation/dietary intervention studies. 
1.5.2.1 Metabolism and sources  
The major marine or LC n-3 PUFA are eicosapentaenoic acid (20:5n-3, EPA) and 
docosahexaenoic acid (22:6n-3, DHA), which can be endogenously derived from the 
downstream metabolism of α-linolenic acid (18:3n-3, ALA), an essential fatty acid. ALA can be 
converted to EPA and DHA through the action of desaturation and elongation enzymes, but the 
rate of this conversion is restricted to a narrow range in adults (156). . In studies using stable 
isotope tracers, the estimated conversion of ALA to EPA was up to 8% in men compared to 
21% in women and the conversion from ALA to DHA was shown to vary from undetectable 
amounts up to 4% in men and up to 9% in women (157). Consequently, these LC n-3 PUFA are 
mostly obtained preformed from the diet (158). Figure 5 shows the metabolic interconversion 




Figure 5 – Metabolic interconversion of n-6 and n-3 PUFA. Adapted from (157). 
The main dietary source of EPA and DHA is seafood, but they are also found in red meat, 
organ meat (liver and brain), in eggs and, in very small amounts, in dairy products (159). SACN 
have made recommendations for a minimum level of ﬁsh or LC n-3 PUFA consumption for the 
general population which includes a minimum of two portions of fish per week, one of which 
should be oily fish (160). One portion of white (≈ 150 g, cooked) and one portion of oily fish (≈ 
80 g, cooked) per week provide approximately 0.45 g LC n-3 PUFA per day. The food sources 
of LC n-3 PUFA are presented in Table 3. Oily fish, such as salmon, herring, anchovies and 
mackerel are the richest sources of EPA + DHA. The recommendations for EPA and DHA 




Table 3 – Food sources of LC n-3 PUFA. Reprinted from (144) with permission from Elsevier. 
 
1.5.2.2 Cardioprotective effects 
Many prospective observational studies and large secondary prevention RCT after 
myocardial infarction such as the DART study and GISSI-Prevenzione (139,140) have assessed 
the effects of ﬁsh or LC n-3 PUFA consumption on CVD outcomes. The GISSI-Prevenzione 
trial showed that treatment with LC n-3 PUFA supplements significantly reduced SCD within 4 
months after a myocardial infarction (139), and the reduction of life-threatening ventricular 
arrhythmias was suggested as the mechanism underlying such benefit. It is important to point 
out that over 90% of the patients enrolled in the GISSI-Prevenzione trial were concomitantly 
taking aspirin which its therapeutic actions are exerted through acetylation of COX-2, which in 
turn is involved in the synthesis of SPMs from EPA and DHA, namely E-series resolvins and D-
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series resolvins, respectively. This could have potentiated the anti-inflammatory effects of LC n-
3 PUFA which could have been the mechanism by which these cardioprotective effects were 
observed, however a recent study reported that the addition of aspirin to LC n-3 PUFA 
supplementation did not significantly change the extent by which LC n-3 PUFA 
supplementation alone increased precursors of E- and D-series resolvins as well as Resolvin E1, 
E2 and E3 (161). GISSI Heart Failure study did not show a reduction in SCD but it showed a 
reduction in all-cause mortality and hospital admissions attributed presumably to an arrhythmic 
cause (141). The DART study, a secondary prevention RCT in men following a myocardial 
infarction which studied the effect on total mortality of three dietary factors in eight different 
combinations (reduction of fat intake to 30% of total energy and increase of 
polyunsaturated/saturated ratio to 1.0; at least two portions of oily fish per week; and increased 
fibre intake to 18 g per day), including a group with no dietary advice, reported significantly 
reduced mortality in the patients randomly assigned to oily fish intake compared to those not 
given fish advice (relative risk [95% CI], 0.71 (0.54-0.93]) (140). From several meta-analyses 
performed, the overall ﬁndings indicate that consumption of ﬁsh or ﬁsh oil signiﬁcantly reduced 
the risk of CHD mortality, including fatal myocardial infarction and SCD, in populations with 
and without established CVD (142–146). Furthermore, higher doses of LC n-3 PUFA and 
longer duration of intervention were found to be protective against non-fatal CHD events, as 
reported in the JELIS trial which supplemented with purified EPA (162). These studies provide 
strong evidence of the cardiovascular benefits of LC n-3 PUFA consumption. A systematic 
review performed by Wang et al. concluded that increased consumption of LC n-3 PUFA from 
fish or fish oil supplements reduced rates of all-cause mortality, cardiac and sudden death (147). 
Another systematic review by Delgado-Lista et al. reported that LC n-3 PUFA, when 
administered as food or in supplements for at least 6 months, reduces cardiovascular events by 
10% (OR [95%CI]; 0.90 [0.85, 0.96]), cardiac death by 9% (OR [95%CI]; 0.91 [0.83, 0.99]) 
and coronary events by 18% (OR [95%CI]; 0.82 [0.75, 0.90]), while showing a trend for a lower 
total mortality (148). The authors concluded that LC n-3 PUFA are effective in cardiovascular 
and coronary events and cardiac death prevention, mainly in those with high cardiovascular risk 
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(148). A meta-analysis of 19 prospective studies that measured fatty acid composition, EPA and 
DHA were associated with lower risk of CHD (163). 
Although several epidemiological, observational and interventional studies provided 
evidence on the reduced risk of cardiovascular mortality and SCD with a high intake of LC n-3 
PUFA, especially in patients with previous myocardial infarction, there are other studies 
reporting contradictory results. The DART-2 study, a RCT in men with angina, reported a 
higher risk of cardiac and sudden death in those advised to eat oily fish, particularly those 
provided with fish oil capsules (149). The OMEGA multicentre study did not report any 
significant reduction in SCD or coronary events in patients that were supplemented with LC n-3 
PUFA in addition to the current guideline-adjusted therapy care, including the use of β-blockers, 
statins, angiotensin-converting enzyme inhibitors and revascularisation procedures. The results 
from this study add the possibility that LC n-3 PUFA might not provide additional benefits 
when patients are receiving already optimum conventional medical therapy (150). In addition, 
the authors of the OMEGA study acknowledged that the statistical power of 80% had not been 
reached (but instead a 44% statistical power) due to both an overestimation of the effect of LC 
n-3 PUFA and a lower than expected event rates. The more recent fish oil supplementation 
studies, including the Alpha Omega (EPA and DHA enriched margarine), ORIGIN, 
SU.FOL.OM3 and the RISK & PREVENTION trials did not show a reduction in major 
cardiovascular events in the intervention group (151–154). However, some considerations 
should be highlighted such as: the Alpha Omega comparison group used for statistical analyses 
not being a true placebo but a combination of placebo and ALA-containing margarines, and the 
fact that the dose of EPA and DHA provided being smaller compared to the earlier trials; 
SU.FOL.OM3 had an interval between the initial coronary event and randomisation of the 
participants into the study group of a median of 101 days; the ORIGIN patients the use of 
concomitant therapies may have prevented an effect from low dose of LC n-3 PUFA 
supplementation; RISK & PREVENTION trial was also acknowledges by the authors to not 
have reached statistical power sue to lower rates of the cardiovascular events (164). A meta-
analysis by Rizos et al. reported that overall LC n-3 PUFA supplementation was not associated 
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with reduced risk of cardiac or sudden death, rejecting the antiarrhythmic mediated LC n-3 
PUFA effect (155). Another systematic review and meta-analysis in adults with peripheral 
arterial disease reported no protective associassion between n-3 PUFA supplementation and 
clinical cardiovascular outcomes, including cardiovascular death (165). A recent evaluation of 
the quality of evidence on LC n-3 PUFAs and CVD concluded that there is a high strength of 
evidence of no effect of LC n-3 PUFA supplementation on risk of major adverse cardiovascular 
events, all-cause death and SCD, and low strength of evidence of no effect of LC n-3 PUFA 
supplementation on risk of CVD death, CHD death, total CHD and myocardial infarction, 
amongst others (166). Nevertheless, accumulated evidence has been underpowered to detect 
small underlying effects because these events are relatively rare and not always classified 
correctly, and thus need very big sample size to reach statistical power. The lack of protective 
effect from fish oil supplementation in the more recent trials in contrast to the beneficial effects 
of the earlier trials of fish oil supplementation and epidemiological studies, has led the more 
recent guidelines in management of patients with stable ischaemic heart disease to not include a 
recommendation for n-3 PUFA supplementation (167), and has been a focus of debate 
(168,169). The difference in outcome between the trials could be attributed to different LC n-3 
PUFA tissue levels at baseline, differences in the type and dosage of fish oils, differences in 
standard medical care that might be masking a potential benefit from LC n-3 PUFA (such as use 
of statins) and whether the trial design was for secondary or primary prevention. Bioavailability 
issues could be another reason for the lack of effect of fish oil supplementation as it has been 
shown that different chemical forms of EPA+DHA supplements have different bioavailability, 
with EPA+DHA bound to phospholipids likely to have the greatest bioavailability, and 
EPA+DHA bound to recombined triglycerides having greater bioavailability than natural 
triglycerides, and finally the least bioavailability when bound to ethyl esters (170). Moreover, 
the most common EPA+DHA supplements used in the intervention trials - ethyl esters - have 
been shown to have higher bioavailability when consumed with a high fat meal compared to a 
low fat meal (171). Since the more recent trials have advised the subjects to take their 
supplements with breakfast, which in many of the study population countries consists of a low-
fat meal, the poor bioavailability could have contributed to the neutral effects observed (168). 
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However, the lack benefit reported in the more recent trials does not necessarily mean that LC 
n-3 PUFA are ineffective in cardiovascular protection, but mean that they were not effective in 
the context in which they were studied (172). At the moment there are three ongoing CVD 
prevention studies aiming at providing further evidence on the effects of LC n-3 PUFA 
supplementation: ASCEND, a primary prevention RCT of 1 g/day LC n-3 PUFA (EPA and 
DHA as ethyl esters) and/or aspirin in 15,480 patients with diabetes and a combined primary 
outcome of serious vascular events (ClinicalTrials.gov Identifier NCT00135226); REDUCE-IT, 
a parallel arm, double blind RCT comparing 4 g/day of Vascepa (EPA ethyl ester) with statin 
therapy vs. statin alone in 8,000 reducing cardiovascular events in patients with 
hypertriglyceridaemia, established CVD or at high risk of CVD (ClinicalTrials.gov Identifier 
NCT01492361); and STRENGTH, a parallel arm, double blind RCT comparing 4 g/day 
Epanova (n-3 carboxylic acids) plus statins vs. corn oil placebo vs. statins in 13,000 adults with 
high CVD risk on major coronary events (ClinicalTrials.gov Identifier NCT02104817). 
1.5.2.3 Antiarrhythmic effects 
It has been shown that LC n-3 PUFA are preferentially incorporated in cardiomyocytes 
(173) and cardiac tissue EPA and DHA was highly correlated with erythrocyte EPA and DHA 
in humans (174). There are direct effects of LC n-3 PUFA on the generation and duration of the 
cardiac action potential that stabilise the cardiomyocyte membranes in studies on cell cultures 
(175). By inducing direct conformational changes of the cell membrane, the EPA- and DHA-
enriched cardiomyocytes have an effect on the ion channel function, as well as on other 
membrane-bound proteins. Consequently, there is an increase in the depolarising stimuli needed 
to induce an action potential, resulting in reduced automaticity. In addition, the recovery from 
the inactive state is promoted, with an increase in the refractory period. These two effects 
combined make the myocardium less excitable, hence less prone to an arrhythmic event (176). 
Another indirect effect of the LC n-3 PUFA on the cardiomyocyte membrane is the inhibition of 
the synthesis of AA which may result in altered production of eicosanoids. The alteration in the 
type and amount of eicosanoids generated, which in turn will originate different lipid mediator 
profiles, has been suggested as an explanation for the anti-arrhythmic properties of LC n-3 
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PUFA via the effects of these changes on intercellular Ca2+ release and Ca2+ channels (173). 
Another less direct mechanism proposed include an antiarrhythmic effect of LC n-3 PUFA 
mediated by a reduced agonist affinity for β-adrenergic receptors, observed in cultured rat 
cardiomyocytes exposed to varied arrhythmogenic agents in the absence of confounders such as 
neurotransmitters or hormones (177). This could be a potential mechanism whereby LC n-3 
PUFA could improve the cardiac sympathetic-vagal balance. 
The potential antiarrhythmic effect of LC n-3 PUFA has been tested in patients with an 
automatic implantable cardioverter defibrillator (small battery-operated pacing device 
implantable under the skin to help control life-threatening arrhythmias by delivering an 
electrical impulse when abnormal rhythms are detected) but the results reported were 
inconsistent, where Leaf et al. (178) suggested a beneficial antiarrhythmic effect but both Raitt 
et al and Brouwer et al found no effect of fish oil supplementation in reducing risk of 
ventricular arrhythmia (179,180). A meta-analysis by Brouwer et al. that included a combined 
analysis of three large RCTs in the USA and Europe did not support a protective effect of LC n-
3 PUFA from fish oil against ventricular arrhythmias in patients with an implantable 
cardioverter defibrillator (181). However, the data suggested that the effect from fish oil might 
be dependent on the underlying disease and consequent cardiac electrophysiological condition. 
This might explain the beneficial effect of fish oil in reducing death rates in the GISSI-
Prevenzione trial of patients with a recent myocardial infarction (139) but, on contrary, the 
increased death rates in the DART 2 trial of patients with stable angina (149). A systematic 
review by Leon et al. that included 12 RCTs showed no beneficial effect of fish oil 
supplementation on arrhythmic events or SCD but found a significant reduction in cardiac 
deaths, mostly related to a reduction in deaths from coronary events (182). However, 92% of the 
patients included in this systematic review on the effects of fish oil in SCD derived from two 
large trials (GISSI-Prevenzione and JELIS) and there was significant heterogeneity in the 
implantable cardiac defibrillator trials assessing arrhythmic events, which could have affected 
the validity of the analysis. Although the Alpha Omega trial did not find an effect of fish oils on 
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major cardiovascular events, a secondary analysis of the data showed a reduction in ventricular 
arrhythmias in the fish oil group (183). 
The contradictory results on the antiarrhythmic effect of LC n-3 PUFA found in human 
studies could be due to differences in the arrhythmogenic mechanisms underlying the different 
type of  populations included in the studies (184). Although having the antiarrhythmic 
properties described above, LC n-3 PUFA are capable of promoting re-entry in a susceptible 
cardiac tissue substrate (i.e. when pathological conditions trigger electrical and fibrotic 
remodelling of the myocardium), facilitating re-entrant arrhythmias (185). For this reason, the 
risk of having life-threatening ventricular arrhythmias can be either lowered or raised depending 
on the mechanism of arrhythmia initiation. Thus, when triggered activity presents as the 
predominant mechanism of arrhythmia initiation (such as after a myocardial infarction), the LC 
n-3 PUFA would have a beneficial effect in reducing arrhythmic events, whereas when re-entry 
presents as the main mechanism of arrhythmia initiation (such as in patients with ischaemic 
heart disease with no history of myocardial infarction), LC n-3 PUFA could induce arrhythmic 
events (184). This finding is important because the advice given towards an increased intake of 
LC n-3 PUFA supplements or oily fish should be tailored to individual patients considering the 
arrhythmogenic mechanisms associated with the underlying disease (185). 
1.5.2.4 Long chain n-3 PUFA and heart rate variability  
It has been proposed that HRV is influenced by LC n-3 PUFA. Table 4 shows compiled 
evidence from supplementation studies testing the effect of LC n-3 PUFA on HRV. Results 
from supplementation studies are inconsistent with some studies showing a positive effect 
(105,109,186), others showing an effect only in men (107) and others showing no effect 
(110,111). A 12 week RCT fish oil supplementation study has found a strong positive 
association between DHA in granulocytes and IBI, SDNN, SDANN and pNN50 measured over 
24 h Holter monitoring at baseline before supplementation, and increased HRV parameters after 
6.6 g LC n-3 PUFA supplementation only in men with low baseline HRV (SDNN below 
median – 150 ms), but not in women (107). Studies report different durations of HRV 
recordings which makes it more difficult to compare between studies since it has been shown to 
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affect HRV measures, mainly time-domain parameters such as SDNN, Ti and SDANN (74). 
Christensen group has run an RCT in 140 dialysis patients assessing the effect of 2 g fish oil vs. 
olive oil in 24 h SDNN but to date, the results haven't been published. A study by our group 
reported that the longer-phase HRV parameters, VLF power and SDANN, were increased 
during sleep-time following 1 year LC n-3 PUFA supplementation in middle-aged healthy 
subjects (186), underlying the importance of assessing the relationship between tissue LC n-3 
PUFA and HRV parameters.  
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Table 4 – Effect of LC n-3 PUFA on HRV parameters. 
Population studied 
Type of study, length and daily dose of 
LC n-3 PUFA vs. control oil 
HRV parameters LC n-3 PUFA effect on HRV parameter 
MI survivors (105) 
(n = 49) 
RCT, 12 weeks, 4.3 g EPA + DHA vs. olive 
oil 
24 h SDNN  
Haemodialysis patients (106) 
(n=29) 
Pilot RCT, 12 weeks, 5.2 g n-3 PUFA vs. 
olive oil 
SDNN 
positive correlation between n-3 PUFA 
content in cell membranes and HRV 
Healthy subjects (107) 
(n = 60) 
RCT, 12 weeks, 3g EPA + 2.9g DHA vs. 







dose-dependent effect of n-3 PUFA on HRV 
(M) 
MI patients (108) 
(n = 10) 
Cross-over trial, 4 weeks, 3g or 6 g n-3 
PUFA 
24 h LF, HF 
& LF : HF ratio 
↓ LF : HF ratio 
CHD patients with previous  
Myocardial infarction (109) 
(n = 18) 
RCT, 2 x 4 months, 225mg EPA + 585mg 
DHA vs. 50:50 mix corn & olive oil 
HF  
Stable post myocardial infarction 
patients (110) 
(n = 38) 
RCT, 12 weeks, 460mg EPA + 380mg 
DHA vs. usual care 
Time and frequency domain No effect 
Haemodialysis patients (111) 
(n = 30)  
RCT, 12 weeks, 920mg EPA + 760mg 
DHA vs. olive oil 
Time domain No effect 
Obese subjects (104) 
(n = 67) 
RCT, 12 weeks, 0 g vs. 0.52 g vs. 1.04 g vs. 
1.56 g DHA-rich fish oil 
Resting 20 min frequency-
domain HRV 
↓ LF : HF 
Dose-dependent effect 
Healthy with moderate 
hypertriglyceridaemia (112) 
(n = 26) 
RCT, 8 weeks, 0.85 g vs. 3.4 g EPA + DHA 
vs corn oil 
RMSSD 
HF 
 after 3.4 g EPA + DHA 
Trend after 3.4 g EPA + DHA 
(M) effect seen in Men only. 
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Finding dietary determinants that may have a positive impact on HRV may be a side-
effect free, cost effective and sustainable way of lowering the risk of CVD in different types of 
populations. 
1.6 Research question  
The primary research question of this PhD is: “Can diet and/or nutritional status modulate 
HRV and therefore reduce the risk of SCD?”. Specific questions include: “Are there dietary 
determinants of HRV in healthy, centrally obese and chronic kidney disease patients?”, and 
“What are the mechanisms that mediate the potential effects of diet on HRV?”. 
1.6.1 Aims and hypothesis  
The overarching hypothesis of this research is that diet may be a determinant of cardiac 
autonomic function, more specifically it is hypothesised that the LC n-3 PUFA status will be 
positively associated with HRV and that intermittent energy restriction will lead to greater 
increases in HRV when compared to continuous energy restriction. Thus, the aim of the 
doctoral research programme was to investigate relationships between HRV and aspects of diet 
that may influence sympathetic and parasympathetic activity. 
 Specific aim 1: investigate the relationship between tissue LC n-3 PUFA status and HRV in 
healthy and diseased populations. 
Specific aim 2: compare the effects of 2 weight loss strategies - intermittent fasting (weekly 48 
h very low energy diets) and continuous energy restriction (daily moderately low energy diets) – 
on HRV, and to investigate mechanisms that may mediate any differential effects observed.  
Objectives were met by running the following studies: 
1) OM3GA study – Observational pilot study in a healthy population comparing 
vegans with age/sex/BMI-matched omnivore controls, representing populations 
with low and high tissue LC n-3 PUFA status, respectively. 
Hypothesis: vegans have lower HRV and shorter IBI compared to omnivores. 
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2) FISHH study – Feasibility cross-sectional study in chronic kidney disease patients 
that recently started haemodialysis to characterise the variability of LC n-3 PUFA 
status and establish a potential relationship between LC n-3 PUFA and HRV. 
Hypothesis:  a biomarker of longer-term LC n-3 PUFA intake (EPA+DHA as a 
% of total fatty acid content of erythrocyte membranes) will be independently 
positively associated with HRV in patients with Stage 5 CKD. 
3) Met-IER study – RCT comparing the effects of intermittent and continuous energy 
restriction diets on HRV in centrally obese, and otherwise healthy individuals. 
Hypothesis: centrally obese adults will have greater increases in HRV following 
weight loss achieved by intermittent energy restriction (modified “5:2 diet”) 




Chapter 2 Methods 
2.1 Heart Rate Variability analysis 
2.1.1. Heart Rate Variability devices 
Heart rate variability was measured using the Actiheart monitoring equipment 
(CamNtech Ltd, Cambridge, UK) for the MARINA study (conducted prior to this PhD 2007-
2011), the reproducibility study, and the OM3GA and FISHH cross-sectional studies (conducted 
as part of this PhD programme between 2012 and 2015). Actiheart monitoring was the least 
invasive way at the time to measure inter-beat intervals for the analysis of HRV, the alternative 
being the Holter monitor, an ambulatory electrocardiogram (ECG) device which is about the 
size of a pack of cards (weighing up to 500 g) and therefore is worn on a belt around the waist. 
The final study of this PhD research (the Met-IER study, 2016) measured HRV using the 
eMotion Faros Sensor 180° device (Mega electronics Ltd, Finland), which became available just 
before the start of this last doctoral study and hence was used instead of the Actiheart monitors. 
The eFaros monitors not only were able to record ECG raw data but also presented a superior 
quality in recording the IBIs (with less noise and better signal) and the Cardiscope software for 
HRV analysis also revealed superior quality compared to the Actiheart software, mainly due to 
the decrease in the task subjectiveness.  
The Actiheart is a small, light-weight (<10 g) waterproof device with two sensors that 
records acceleration (counts per minute, cpm) as a measure of physical activity, HR, and all IBI, 
that is, the time-intervals between ‘R’ or ´normal´ spikes of the QRS (Q, R and S being points 
on the R wave seen on an ECG during ventricular depolarisation, and R being the peak upward 
deflection) complex, for approximately 24 h. Studies have shown Actiheart to be technically 
reliable and valid as a monitor of HR (187), producing values of HRV not significantly different 
from those produced from the Holter monitor (188).  
The eMotion Faros 180° is a small, portable, light-weight (13 g) and wireless 2-lead ECG 
recorder and transmitter that records ECG data internally (offline mode) or communicates 
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remotely via Bluetooth (real-time). It also records breathing and it has an in-built 3-axis 
accelerometer that records acceleration (cpm) as a measure of physical activity. 
2.1.2. Fitting the Actiheart and eMotion Faros devices 
Before fitting any of the devices, adequate skin preparation is needed in order to obtain a 
good quality recording, where the ECG signal captured is strong while having an overall low 
noise level. The skin preparation involved shaving of chest hair when needed, use of alcohol 
wipes to clean and dry the skin and use of an abrasive pad (UnilectTM) to remove the top layer of 
skin cells. Two ECG electodes (SP-50, 50 mm round, Pulse Medical) were placed on the chest 
to fit the monitors.  
For the Actiheart monitor, the first sensor was attached to an electrode and placed in the 
centre of the chest around the fourth intercostal space where the round end of the Actiheart was 
clicked to it. The second sensor was attached to another electrode and the wire was used to 
position the sensor as shown in Figure 6. The accelerometer component is located in the first 
sensor, and the Actiheart needs to be placed with the cable as horizontal as possible in order to 
obtain an accurate measurement of activity. A 10 degree tilt, as shown in Figure 7, would 
introduce 3% activity reading error. 




Figure 7 – Effect of tilting the monitor on the accelerometer orientation and consequent 
introduction of activity reading error.1 
The electrodes for the eMotion Faros monitor were placed along the electrical axis of the 
heart as shown in Figure 8. The placement of the electrodes followed the locations of electrodes 
right arm (RA) and left leg (LL) in the Mason-Likar modification of the standard 12 lead ECG 
(189): the negative electrode was placed in the right infraclavicular fossa (below the right 
clavicle), and the positive electrode on the left anterior axillary line, halfway between the costal 
margin and the crest of the ilium. The electrodes would be clipped to the cable endings of the 
monitor before attaching them to the chest. 
Figure 8 – eMotion Faros position in the chest. 
                                                     
1 From the Actiheart guide to getting started 4.0.37 (April 2010) 
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2.1.3. Recording of the IBI and HRV analysis using the Actiheart device 
After fitting the Actiheart device, a short signal test, involving a 5 minute walk with the 
participant, was performed to confirm that the level of R wave signal being picked up by the 
device was adequate to avoid artefacts due to either high noise level or a low R wave signal. 
The test involves making a short recording and analysing the signal using a built-in utility called 
Signal Test which provides a Pass/Fail indication of whether the signal is acceptable. During the 
signal test, once the subject has worn the Actiheart for the required length of time, data was 
downloaded to the laptop and analysed for the quality of the signal. Any areas of the recording 
that failed the test were displayed in red on the scan. If a recording has failed overall, it usually 
means that either the noise level was too high or the R wave was too low. Once an acceptable 
signal was obtained, a short-term recording2 was programmed and the monitors would be worn 
for 24 h. During the 24 h recording period, the ECG signal is electronically amplified with the 
resulting ECG signal sampled at 125 Hz. QRS detection is difficult, not only because of the 
physiological variability of the QRS complexes, but also because of the various possible types 
of noise in the ECG signal, including muscle noise and artefacts due to electrode motion. To 
detect the slope of the R wave in order to locate the QRS complex, a real time QRS detection 
algorithm is used (190). The Actiheart firmware then applies a detection threshold whose 
sensitivity is dependent on the amount of physical movement detected by the Actiheart. After 
completing the 24 h recording, data processing of the 24 h recordings was carried out to remove 
‘noisy’ data and artefacts and it was performed in three stages. Firstly, the data was downloaded 
to the Actiheart software (version 4.0.91, CamNtech Ltd, Cambridge, UK) to isolate the RR 
recordings and manually remove any missed beats. Once edited, the time-stamped raw IBI data 
was exported to Kubios HRV analysis software (Biosignal Analysis and Medical Imaging 
Group, Department of Physics, University of Kuopio, Finland) to apply further artefact 
corrections. Finally, after all amendments to the data have been made, the HRV data was 
compiled in a Microsoft Excel spreadsheet. 
                                                     
2 “Short term recording” mode allows recording of up to 440,000 heartbeats. A “Long term recording” 
can last between 11 and 21 days depending on set-up. 
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Data collection from the Actiheart device was fixed at 15 s epochs, but for post hoc 
analysis of time domain and frequency domain indices of HRV, 5 min epochs were selected to 
obtain parameters that reflect the circadian and longer term fluctuations. At the end of each 
epoch the RR interval durations for the last 16 IBIs are analysed to get a representative value 
and remove some of the main artefacts. The 16 IBI values are averaged and any RR intervals 
greater than +/- 25% of this average are removed. Finally, the remaining RR intervals are 
averaged and converted to beats per minute. 
The HRV parameters more sensitive to artefacts are the frequency domain measures and 
RMSSD (74). The artefacts can be caused by a lack of signal detection due to a loss of contact 
between the electrode and skin and it will show up as a missed beat (large spike upwards) on the 
tachogram. Although some of the artefacts are removed automatically by the Actiheart software, 
this software has a limited scope for artefact correction, which leaves most artefacts to be 
manually corrected using the Actiheart edit IBI data function. Missed beats where the apex of 
the spike was ≥ baseline + 500 ms were manually corrected as illustrated in Figure 9.  
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Figure 9 – Missed beats manual correction by double clicking on the artefact. 
 
After manually removing the artefacts with the Actiheart software and saving the 
corrections, edited time-stamped raw IBI data was imported to Kubios software which has an 
artefact correction function with different levels of correction that range between very low to 
very strong. Because the artefact correction uses interpolation to yield the missing or corrupted 
data, distortion of the results might occur at high correction levels. For this reason, a low 
correction was chosen to be applied to all data files. 
When files contained sections of poor quality data (identified with the Actiheart 
software), removal of these sections was performed in Kubios and data was merged to give the 






Figure 10 – Removal of poor quality data using Kubios software. Figure also shows a medium 
correction selected. 
 
After applying all corrections, the file was saved in a pdf and text form that allowed the 
transcription of the values of the HRV parameters of interest into an Excel spreadsheet for 








Figure 11 – Kubios output file showing the time domain, frequency domain (FFT spectrum 




2.1.4. Recording of the IBI and HRV analysis using the eMotion Faros 
device 
CardiscopeTM analytics (HASIBA Medical GmbH) is the software application used to 
program the eMotion Faros monitor and analyse the ECG data in order to obtain HR/IBI and 
HRV measurements. There are two recording modes, an online mode with real-time 
transmission operated by Bluetooth, and a datalogger mode to record ECG data offline. The 
online mode was used to visually examine the ECG recording in real-time to confirm that the 
monitor was picking up a good signal. Once a good signal was confirmed the measurements 
taken during the Met-IER study visits (resting and mental stressor tests) were performed in this 
mode. The offline mode was used to record 24 h ambulatory data. The ECG sampling rate was 
fixed at 250 Hz for both modes. The Cardiscope software automatically removed artefacts on a 
beat-to-beat basis, as well as any ventricular or ectopic beats, from the analysis. Each tachogram 
- depicting consecutive distances between R waves of the QRS complexes - alongside the ECG 
recording would be visually inspected (Figure 12) to ensure that no extra processing was 
needed. In the rare event of having to further process the ECG data this was done manually. 
Figure 13 illustrates the detection of an ectopic beat and automatic removal from the analysis 
by the software. 
Figure 12 – Visual inspection of tachogram (top) with ECG recording. Each green bar 




Figure 13 – Detection of the ectopic beat in the ECG recording (orange) by the software and 
automatic removal from the analysis (shaded colour in the tachogram). 
 
Once data was inspected, episodes were added to the tachogram in order to assign the 
following activities/periods: resting, mental stressor test, sleep-time, day-time and 24 h. HRV 
parameters were then calculated for each episode and data was exported directly to an Excel 
file. 
2.1.5. Actiheart vs. eMotion Faros  
The Actiheart monitor was very well tolerated by the participants, and most of them 
would even forget they were wearing it, so participant burden was close to null. The Actiheart 
device is waterproof allowing participants to shower, although under water the noise level is so 
high that data quality becomes poor and need to be removed from the analysis. One of the main 
concerns with the Actiheart recordings relates to the HRV data analysis which includes a 
substantial amount of manual data editing and processing that is needed to provide the final 
results. This may potentially introduce observer error and bias. Three types of ECG pads were 
tested in the reproducibility study and the ones that lasted at least 24h without falling off and 
had a better signal were the 4841P (Ambu®). Nevertheless, it was still difficult to obtain a good 
signal/noise ratio on a minority of participants, and these tended to be those with the lowest % 
body fat or BMI. Some loss-of-signal problems arose during sleep-time. It was concluded that 
better ECG pads could be helpful for minimising the amount of further manual data processing 
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so new ECG pads were tested with SP-50 (50 mm round, Pulse Medical) providing a better 
signal and lasting longer on the skin. For this reason the vegan, renal and Met-IER study used 
the Pulse Medical SP-50 ECG pads. Although the manual processing and editing of HRV 
analysis might introduce some human error, the same person analysed all the data reducing 
inter-individual error. Also, random recordings were selected to be analysed separately by Dr. 
Wendy Hall and the results were similar, showing a good degree of consistency between 
individuals. 
Actiheart measures HRV through the IBI, collecting only the time between QRS 
complexes and discarding the ECG recording, whereas the eMotion Faros measures HRV 
through ECG recordings, which is more accurate in terms of artefact correction because it is 
possible to see every QRS complex of the recording. Also, the Actiheart software is more likely 
to introduce errors as there is no ECG raw data that could be inspected to check for ectopic or 
ventricular beats. Also, when excluding noisy or poor quality data in the Kubios software, this is 
done by removing periods of data, as opposed to the Cardioscope software where data is 
excluded on a beat-to-beat basis, allowing more precise and accurate data processing. In 
addition, the recording quality assessed by the percentage of good/valid data in each recording 
was superior using the eMotion Faros monitor compared to the Actiheart.  
2.2. Blood pressure 
2.2.1. Seated blood pressure 
Seated blood pressure was measured three times with an A&D Medical UA-767Plus (San 
Jose, USA) upper arm automated blood pressure monitor with an appropriate cuff size in 
accordance with guidelines from the BHS. While taking the blood pressure measurements the 
participant was sitting with the legs uncrossed and feet flat on the floor, calm and instructed not 
to talk. The arm used to take the measurement was relaxed and supported by the table and the 
cuff was wrapped around the upper arm allowing space for a finger between the participant's 




2.2.2. Ambulatory blood pressure 
Ambulatory blood pressure (ABP) was measured using an upper arm A&D Medical TM-
2430 ABP monitor with an appropriate cuff size fitted to the non-dominant arm. When asked to 
wear the ABP monitor for 24 h, the subjects were shown how to adjust the cuff in case of 
movement and the monitor was programmed to automatically inflate the cuff and take readings 
every 30 minutes during the day (7am to 10pm) and hourly at night (10pm to 7am). The sleep 
time was adjusted for each participant according to the reported sleep hours in the activity diary. 
Once the monitors were returned, data was downloaded and any misreading or physiological 
anomalies were discarded in order to obtain the mean 24 h, day/awake time and sleep-time SBP 
and DBP data. 
2.3. Erythrocyte membrane and plasma fatty acid analysis 
Plasma fatty acid composition was determined based on the Lepage and Roy method 
(191), substituting toluene for benzene and using pentadecanoic acid as an internal standard. 
Briefly, a toluene/methanol solution was prepared with a ratio of 1:4 respectively by volume. 
The solution was then acidified by the addition of acetyl chloride (10% of initial vol) to 
generate the methylating reagent. A 100 µl aliquot of plasma was dispensed into a glass tube. 
This was followed by the addition of 2.2 ml of the methylating agent. Following incubation of 
the mixture at 60 ºC for 2 h to effect the formation of phosphoglycerides to fatty acid methyl 
esters (FAME), the mixture was neutralised with 5 ml of 6% w/v aqueous sodium carbonate. 
The resulting mixture was then subjected to centrifugation to effect phase separation. Finally, 
the FAME containing supernatant was aspirated off and transferred to a vial for gas 
chromatography (GC) analysis.  
Erythrocyte membrane phospholipid fatty acid composition was determined as previously 
described (192). A 2 ml aliquot was withdrawn from the glass tube and transferred to a glass 
vial for evaporation to dryness using a compressor for 1 h at 65 ºC. The resulting dried residue 
was reconstituted by adding 200 µl of hexane, followed by the addition of 100 µl of sodium 
methoxide in methanol solution (with calcium chloride as a drying agent). The resulting mixture 
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was incubated for 2 h to allow the transesterification of the FAME. Following the incubation, 
the supernatant was collected and transferred to insert vials to perform further analysis by GC. 
The FAME mixtures obtained from plasma and erythrocyte membranes were injected into 
a gas chromatograph (Agilent Technologies 6890) using H2 as a carrier gas flow set at 1 ml/min 
equiped with a flame ionization detector set at 250 ºC. The column used for the analyses was a 
25 m lenght x 0.22 mm internal diameter x 0.25 µm film thickness BPX70 capillary column 
(SGE, Melbourne, VIC, Australia). 
For the plasma FAME mixture, the injection was performed in split mode (50:1) and for 
the erythrocyte membrane FAME mixture the injection was performed in splitless mode, both 
with the inlet maintained at 240 ºC. Temperature programming was employed to optimise the 
separation. For the plasma FAME mixture, this was achieved by holding the initial column 
temperature at 160 ºC for 4 minutes (80 ºC for 2 minutes for the erythrocyte FAME mixture), 
followed by ramping at 10 ºC/min (15 ºC/min for the erythrocyte FAME mixture) to 200 ºC and 
holding at this temperature for 10 minutes to ensure complete elution. Fatty acids were 
identified by matching their retention times with those present in the reference standards run 
under identical conditions. Proportions of fatty acids as weight % were quantified by expressing 
the areas under the chromatographic peaks as a % of the total integrated area. 
2.4. Anthropometry  
2.4.1. Height 
Height was measured using a wall mounted stadiometer and recorded to the nearest 1 mm 
while participants were barefoot, including removal of socks, and standing upright with feet to-
gether. Heels, buttock and shoulders were against the measuring rod and arms were hanging 
freely with palms facing the thigh. The measurement was taken after the participant inhaled 
deeply while looking straight ahead.  
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2.4.2. Weight and percentage of body fat 
Weight and percentage of body fat were measured using a TANITA BC-418 segmental 
body composition analyser and recorded to the nearest 0.1 kg and 0.1%, respectively. 
Participant were barefoot, wearing light clothing (one layer of clothes) and were asked to empty 
their pockets and remove any accessories such as watches and rings.  
2.4.3. Waist and hip circumference 
A non-stretch measuring tape was used to measure waist and hip circumference to the 
nearest 0.1 cm while the participant was standing up right and breathing normally. Weight was 
evenly balanced on both feet, which were set apart equivalent to the shoulder width. The waist 
measurement was taken at the midway point between the iliac crest and the lowest rib with the 
participant’s waist uncovered or with very light clothing. For the Met-IER study, the waist 
circumference was measured around the umbilicus due to the overweight/obese and multi-
ethnicity nature of the population (193) and the fact that waist circumference thresholds for 
detecting high-risk of cardiometabolic disease were shown to be more sensitive at the level of 
the umbilicus (194). The hip circumference was taken at the widest point over the buttocks and 




Chapter 3 Methods development 
 This chapter consists of the work done in order to optimise and develop the HRV 
recording and analysis methods as well as provide further guidance for the primary PhD studies. 
Two studies are presented: the reproducibility study and the MARINA study. Results and 
considerations obtained from these studies used for planning the primary PhD studies are also 
presented. 
3.1 Reproducibility study  
3.1.1. Introduction 
Measuring HRV in free-living conditions is more challenging as opposed to measuring it 
under controlled conditions. As the free-living state will be of great importance in the doctoral 
studies presented in this thesis, it is important to explore the reproducibility of ambulatory HRV 
measurements and optimise the method used for collection and analysis before finalising the 
study design of the primary research studies. The free-living carries various challenges as it is 
not controlling for numerous factors that could potentially impact HRV such as physical activity 
levels. In a large prospective study in older adults, physical activity was independently 
associated with 24 h SDNN (195). In addition, a meta-analysis of intervention studies showed 
that aerobic physical activity significantly increased resting IBI and HF power in adults (136). 
For this reason, the effect of physical activity levels on HRV in the free-living will also be 
explored in this study.  
3.1.2. Study design and aims 
This was an observational cross-sectional study conducted at King’s College London 
(KCL) between January and May 2013 that aimed at investigating the reproducibility of the 
Actiheart monitor to assess HRV in free-living conditions among healthy subjects, by exploring 
the intra- and inter-variability of the different HRV parameters. A secondary aim included 
testing different types of pads to choose the best one for duration and signal/noise ratio. These 
included Ambu® 4841P short term ECG monitoring electrodes, Bio Prothec Inc. 
TELECTRODE T815 and UnilectTM 6110M hypoallergenic electrodes. Ethical approval was 
73 
 
obtained from KCL research ethic committee (BDM/12/13-37) and written informed consent 
was given by participants.  
3.1.3. Methods 
Twenty-four healthy men and women aged over 18 years volunteered to take part in this 
study. Those with a medical history of CVD (including atrial fibrillation), diabetes, cancer 
(excluding basal cell carcinoma), renal, liver, inflammatory bowel disease, history of substance 
abuse or alcoholism, pregnancy, and BMI > 35Kg/m2 were excluded. The volunteers were 
mostly PhD students and some research staff. Participants wore the Actiheart monitor for 3 to 4 
days (24 hours each). In the first study visit, standard measurements were made including 
height, weight, waist circumference, body composition by bioelectrical impedance to estimate 
% body fat, and seated blood pressure according to the guidelines of the British hypertension 
society (BHS). Volunteers were then fitted the Actiheart device in the morning period and were 
asked to wear it for 24 h. A diary was provided during the recording periods to keep a record of 
all the daily activities (activities/exercise, meals or naps). After 24 h of each visit participants 
were asked to attend the Metabolic Research Unit (MRU) for a 5-10 min visit to remove and 
return the device. Volunteers were asked to refrain from eating, drinking (except water) and 
vigorous exercise for at least 2 hours before they arrive at the research facility. HRV, HR/IBI 
and accelerometry data were analysed for the full length of recording time (minimum of 18 h, 
up to 24 h). HRV outcomes included time and frequency-domain parameters.  
3.1.4. Results 
Figure 14 shows the number of participants completing HRV measurements ranging 
from 1 to 4 days of measurements. Participants excluded from the analysis were due to not 
having a satisfactory 24 h recording, which includes at least 18 h of good quality data. 
Participants completing 4 days with good recordings were used to assess inter-individual 
variability and the full sample with at least one good recording was used to assess intra-




Figure 14 - Participants distribution according to the number of recordings completed and 
number of good recordings. 
 
Table 5 shows the characteristics of the 22 subjects that were included in the analysis. 
There were 5 males and 17 females with a mean age of 23.8 ± 2.3 and 27.1 ± 5.3 years, respec-
tively. Participants presented a normal BMI (indicative of healthy weight: 18.5-24.9 kg/m2 
(196)), % body fat, resting systolic blood pressure (SBP), diastolic blood pressure (DBP), and 
HR. 
Table 5 - Subjects’ characteristics who presented one to four good 24h recordings (n=22). 
 Male (n=5) Female (n=17) 
Age (years)  23.8 ± 2.3 27.1 ± 5.3 
BMI (kg/m2)  22.0 ± 3.2 21.0 ± 3.0 
% body fat  10.8 ± 5.7 24.3 ± 5.6 
Resting SBP (mmHg)  118 ± 8 99 ± 13 
Resting DBP (mmHg)  76 ± 7 71 ± 10 
Heart Rate (bpm) 71 ± 15 73 ± 10 
Results are expressed as mean ± SD. BMI, body mass index; bpm, beats 




3.1.4.1. Intra-individual variability 
To assess the impact of physical activity variability on HRV in the free living, an exam-
ple of a participant that has different activity levels in three different days was presented in 
comparison to a participant that kept activity levels similar throughout 3 days. Table 6 shows 
the CVs of the different HRV parameters from two different participants with different physical 
activity variability on three different days. Participant 1 presents high physical activity variabil-
ity and hence Table 6 displays 3 days of different activity levels (low, medium and high). Par-
ticipant 2 presents low physical activity variability and hence Table 6 displays 3 days of similar 
activity levels. Different levels of physical activity had a considerable influence on the variabil-
ity of the frequency domain parameters (LF, HF, LF : HF ratio and VLF) as shown by the high-




Table 6 – Impact of physical activity levels in 24 h free-living HRV monitoring. 




Low Medium High 
CV 
(%) 
Activity (cpm) 155 326 523 55.0 
HR (bpm) 79 81 83 2.3 
IBI (ms) 782 779 751 2.3 
SDNN (ms) 133 145.2 148 5.8 
SDANN(ms) 109 123.3 118 6.3 
pNN50 (%) 26.5 25.4 28.5 5.8 
RMSSD (ms) 53.9 50.9 60.9 9.3 
Ti 26.5 31.4 45.0 27.9 
LF (ms2) 1608 1633 2189 18.2 
HF (ms2) 1211 1112 1750 25.3 
LF:HF ratio  1.33 1.47 1.25 8.2 
VLF (ms2) 8530 10479 13190 21.8 
SD1 38.1 36.0 43.1 9.3 
SD2 184 202 205 5.8 
SD1:SD2  
(Poincaré point) 




Low Low Low 
CV 
(%) 
Activity (cpm) 242 206 209 9.2 
HR (bpm) 70 64 69 4.8 
IBI (ms) 946 1015 936 4.5 
SDNN (ms) 293 278 263 5.3 
SDANN(ms) 268 248 237 6.2 
pNN50 (%) 37.3 40.5 34.8 7.6 
RMSSD (ms) 88.7 100.7 88.9 7.4 
Ti 57.7 58.7 46.8 12.1 
LF (ms2) 2915 3542 2937 11.4 
HF (ms2) 2816 3364 2826 10.4 
LF:HF ratio  1.04 1.05 1.04 0.9 
VLF (ms2) 59493 49999 49172 10.8 
SD1 62.7 71.2 62.9 7.4 
SD2 409 387 367 5.5 
SD1:SD2  
(Poincaré point) 
0.15 0.18 0.17 9.2 
CV, coefficient of variation; HF, high frequency; IBI, interbeat interval; LF, low frequency; 
pNN50, percentage of adjacent normal-to-normal intervals that differed by >50ms; RMSSD, 
root mean square of successive differences of normal-to-normal intervals; SD1, standard devia-
tion of the Poincaré plot perpendicular to the line of indentity; SD2, standard deviation of the 
Poincaré plot along the line of indentity; SDANN, standard deviations of the average NN inter-
vals; SDNN, mean of the standard deviations of the normal-to-normal intervals; Ti, triangular 
index; VLF, very low frequency. 
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3.1.4.2. Inter-individual variability 
Table 7 shows the results from the inter-individual variability of the different HRV pa-
rameters according to sex, and in the whole study sample. The most robust measurements - the 
ones with least variability - were HR and IBI. However, the HRV parameters presented a high 
inter-individual variability which means that these parameters might be correlated with other 
factors, such as dietary factors or biomarkers, that haven't been measured in this reproducibility 
study but will be measured in the main studies of this doctoral research.  
Table 7 – HRV parameters of the whole study sample – inter-individual variability. 
HRV parameters Male (N=5) Female (N=17) Total (N=22) 
CV 
(%) 
Activity (cpm) 405 ± 191 214 ± 71 249 ± 122 49 
HR (bpm) 81.6 ± 7.0 81.1 ± 5.9 81.2 ± 5.9 7.3 
IBI (ms) 798 ± 71 779 ± 69 783 ± 68 8.7 
SDNN (ms) 213 ± 33 160 ± 39 170 ± 43 25 
SDANN (ms) 192 ± 33 141 ± 36 150 ± 40 27 
pNN50 (%) 22.0 ± 5.6 21.0 ± 9.7 21.2 ± 9.0 43 
RMSSD (ms) 50.7 ± 8.9 57.9 ± 26.5 56.6 ± 24.3 43 
Ti 55.6 ± 14.8 41.7 ± 8.9 44.2 ± 11.2 25 
LF (ms2) 2033 ± 882 1370 ± 734 1491 ± 827 55 
HF (ms2) 930 ± 313 1072 ± 734 1055 ± 673 64 
LF:HF ratio  2.28 ± 0.82 1.53 ± 0.63 1.63 ± 0.69 43 
VLF (ms2) 30699 ± 9259 17177 ± 10222 19636 ± 11195 57 
SD1 35.8 ± 6.3 40.9 ± 18.8 21.2 ± 9.0 43 
SD2 299 ± 47 222 ± 54 236 ± 60 26 
SD1:SD2  
(Poincaré point) 
0.12 ± 0.01 0.18 ± 0.07 0.17 ± 0.07 38 
Results are expressed as mean ± s.d. 
CV, coefficient of variation; HF, high frequency; IBI, interbeat interval; LF, low frequency; pNN50, per-
centage of adjacent normal-to-normal intervals that differed by >50ms; RMSSD, root mean square of 
successive differences of normal-to-normal intervals; SD1, standard deviation of the Poincaré plot per-
pendicular to the line of indentity; SD2, Standard deviation of the Poincaré plot along the line of indenti-
ty; SDANN, standard deviations of the average NN intervals; SDNN, mean of the standard deviations of 
the normal-to-normal intervals; Ti, triangular index; VLF, very low frequency. 
3.1.5. Discussion 
The results of this study were important to help define the design of subsequent studies 
since it provided an insight of the difficulties associated with measuring HRV in free living 
conditions, namely the high inter- and intra-individual variability presented. This study helped 
define some of the variables that influence HRV readings including sex and physical activity. A 
recent meta-analysis on sex differences in HRV (197) showed that time-domain parameters 
were significantly lower in female subjects compared to male subjects, but females presented a 
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lower LF : HF ratio, which agree with this reproducibility study results. The marked variability 
observed may not always reflect sympathetic and parasympathetic activity during day-to-day 
activities if not controlled for potential confounders. For the studies measuring HRV in free liv-
ing conditions described in this thesis, special care was taken such as asking participants to 
avoid any strenuous physical activity as well as including sex as a fixed factor and physical ac-
tivity as a covariate in the statistical analysis. Other factors that influence HRV have been re-
ported in studies, including BMI (126), age (198,199), smoking (200,201), acute alcohol intake 
(202). For this reason, the design of the next studies excluded smokers and matched participants 
according to age and BMI, as well as asking participants to refrain from alcohol the day before 
HRV measurements took place. 
3.2 MARINA Study 
The MARINA (Modulation of Atherosclerosis Risk by Increasing dose of N-3 fatty 
Acids) study was a single-centre RCT to investigate the dose-response effect of fish oil 
supplementation (provided as purified triacylglycerol with an EPA:DHA ratio of 1.5:1 and 
supplied by Croda Chemicals Europe Ltd, Hull, Yorkshire, UK) at doses relevant to dietary 
intakes on cardiovascular risk factors, conducted at KCL between April 2008 and October 2010. 
The MARINA study collected Actiheart data on HRV as a secondary outcome. Detailed 
methods and primary outcomes have been reported previously (203). Sleep-time HRV data were 
previously analysed and results were published by Dr. Hall and colleagues (186), showing 
significant increases in SDANN, Ti and VLF power with LC n-3 PUFA supplementation, an 
effect which was not related to dose. However, the day-time data had not yet been analysed due 
to the time-consuming nature of data cleaning/processing raw data from a large trial. HRV 
analysis of the MARINA day-time IBI data therefore formed part of the HRV analysis training 
for the PhD candidate and is presented in the methods chapter as it contributed to further 
development of the methods used for Acitheart HRV analysis and the information gathered was 




The MARINA trial was a parallel design, double-blinded, RCT that compared the intake 
of 0.45, 0.9 and 1.8 g of EPA + DHA-rich triacylglycerols provided in 3 soft gel capsules 
(Croda Chemicals Europe Ltd, Hull, Yorkshire, UK) per day with matched placebo capsules 
containing an oleic acid-rich triacylglycerol consumed for 12 months. The EPA : DHA ratio 
was 1.5:1 and doses were chosen in order to be equivalent to eating 0 (placebo), 1, 2 or 4 
portions of oily fish a week. Ethical approval was obtained by the St Thomas’ Hospital NHS 
Research Ethics Committee (ref: 08/H0802/3) and was registered at www.controlled-trials.com 
(ref: ISRCTN66664610). Men and women, non-smokers, aged 45 to 70 years attended a 
screening visit and those with a medical history of CVD (including atrial fibrillation), type 1 
diabetes mellitus, uncontrolled type 2 diabetes (fasting plasma glucose > 7 mmol/L), cancer 
(excluding basal cell carcinoma) in the past 5 years, chronic renal, liver or inflammatory bowel 
disease, history of substance abuse or alcoholism, pregnancy, weight change > 3 kg in the 
preceding 2 months and BMI < 20 and > 35 kg/m2 were excluded. Potential eligible participants 
were asked to complete a 4 week run-in period taking placebo capsules and restricting oily fish 
intake. Once the run-in period was completed, participants were randomised to treatment by 
minimisation to balance age, gender and ethnicity. The day before each study visit, participants 
were instructed to follow standardised dietary advice, as well as to fast overnight for 12h and to 
refrain from any strenuous physical activity. Outcome measurements, including 24 h 
ambulatory HRV (using the Actiheart monitor), were taken at baseline (after completing the 
run-in period), after 6 and 12 months of the dietary intervention. Day-time data was analysed on 
an intention to treat basis based on the average values on treatment (mean of 6 and 12 months) 
using analysis of covariance (ANCOVA) adjusted for baseline values as well as for physical 
activity, age, gender, ethnicity and BMI. Recordings that presented < 6 h of good quality data 
were excluded. Data normality was determined using Shapiro-Wilk test and by visual inspection 
of the data distribution on the histogram and Q-Q plots. Non-normally distributed data were 
normalised by natural logarithm (LN) before analysis. This was a time-consuming analysis as 
there were 305 participants with 3 time points, which translates into 915 recordings to process. 
Depending on the quality of data, i. e. the amount of data needing manual editing and noisy data 
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that needed to be cut from the tachograms, the analysis of each recording took between 15 mins 
to over an hour to process, with an average of 40 mins per recording. The data processing took 
place between December 2012 and March 2014. 
3.2.2 Results 
Of 367 participants randomised to a treatment group, 305 participants completed the 
ambulatory 24 h HRV recordings and after processing the data, 257 participants presented 
usable day-time data for all three visits (mean 11:53 h; range 8:04, 15:11). Table 8 presents the 
subjects' characteristics of the participants included in the HRV analysis according to the 




  Table 8 - Subjects’ characteristics at baseline according to treatment group (n=257). 
 Placebo (n=57) 0.45 g/d (n=71) 0.9 g/d (n=64) 1.8 g/d (n=65) p value † 
Age (years)  55. 6 ± 7.1 55.0 ± 7.0 55.5 ± 6.4 55.0 ± 6.7 0.921 
Sex       
     Male 23 (40) 29 (41) 22 (34) 26 (40) 0.862 § 
     Female 34 (60) 42 (59) 42 (66) 39 (60)  
Ethnicity      
     White 50 (87.7) 56 (78.9) 53 (82.8) 57 (87.7) 0.244 § 
     Black 4 (7.0) 4 (5.6) 4 (6.3) 1 (1.5)  
     Asian 1 (1.8) 6 (8.5) 6 (9.4) 1 (1.5)  
     Far Eastern 0 (0) 2 (2.8) 0 (0) 3 (4.6)  
     Other 2 (3.5) 3 (4.2) 1 (1.6) 3 (4.6)  
BMI (kg/m2)  26.0 ± 3.6 25.4 ± 3.8 26.1 ± 4.0 25.2 ± 3.4 0.470 
Resting SBP (mmHg)  122 ± 17 120 ± 14 123 ± 14 120 ± 14 0.432 
Resting DBP (mmHg)  77 ±10 77 ± 10 78 ± 8 76 ± 9 0.480 
Erythrocyte EPA (%)a 1.26 (1.16, 1.37) 1.19 (1.10, 1.29) 1.29 (1.18, 1.42) 1.22 (1.12, 1.33) 0.542 
Erythrocyte DHA (%) 6.58 (6.24, 6.91) 6.47 (6.17, 6.76) 6.30 (5.89, 6.72) 6.55 (6.17, 6.93) 0.712 
Omega-3 index (%) 7.91 (7.48, 8.33) 7.73 (7.37, 8.09) 7.69 (7.19, 8.19) 7.85 (7.38, 8.31) 0.895 
BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid. 
Results are expressed as n (%) or mean ± SD or mean (95% CI), except a Geometric mean (95% CI). † comparison between treatment groups by 
one-way ANOVA, except § χ2 test.  
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Table 9 shows the HR, IBI and HRV parameters at baseline and the effect of following a 
dietary intervention with increasing doses of LC n-3 PUFA versus placebo. There was a 
significant treatment effect in SDANN and VLF after supplementation with LC n-3 PUFA. 
These results were not dose-dependent as the strongest effects were seen after supplementation 
with 0.9 g per day but not 0.45 g and 1.8 g of EPA + DHA per day. 
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Table 9 - HR, IBI and HRV parameters at baseline and following supplementation with increasing doses of LC n-3 PUFA. 
 HRV parameters  Placebo (n=57)  0.45 g/d (n=71)  0.9 g/d (n=64)  1.8 g/d (n=65)  p value  
HR (bpm) Baseline  86.1 (81.0, 91.2) 83.7 (79.8, 87.6) 81.8 (77.3, 86.3) 87.1 (82.1, 92.1)  
 Average on treatmenta  83.8 (80.8, 86.8) 81.2 (78.9, 83.6) 82.5 (79.9, 85.1) 81.9 (79.0, 84.8)  
 Treatment effect*  1.000 [reference]  0.970 (0.942, 0.997) 0.984 (0.953, 1.015) 0.977 (0.942, 1.012) 0.597 
IBI (ms)  Baseline  719 (675, 765)  738 (703, 775)  759 (718, 802)  706 (664, 751)   
 Average on treatmenta  741 (714, 769)  762 (741, 786)  745 (721, 770)  758 (731, 787)     
 Treatment effect*  1.000 [reference]  1.004 (1.000, 1.009)  1.001 (0.996, 1.006)  1.003 (0.998, 1.009)  0.550  
SDNN (ms) Baselinea  98.0 (85.1, 113.0)  98.1 (88.0, 109.4)  118.6 (104.6, 134.4)  100.6 (87.5, 115.6)   
 Average on treatmenta  110.1 (100.4, 120.6)  114.9 (106.9, 123.4)  100.1 (92.3, 108.5)  114.3 (104.5, 125.1)     
 Treatment effect*  1.000 [reference]  1.009 (0.994, 1.024)  0.980 (0.963, 0.997)  1.008 (0.989, 1.027)  0.064  
SDANN (ms)  Baselinea  82.0 (70.0, 96.2)  81.8 (72.3, 92.4)  105.3 (91.5, 121.2)  84.3 (72.0, 98.5)   
Average on treatmenta  94.4 (84.6, 105.3)  97.8 (89.8, 106.7)  83.6 (75.9, 92.2)  100.9 (90.6, 112.3)   
Treatment effect*  1.000 [reference]  1.008 (0.989, 1.027)  0.973 (0.952, 0.995)  1.015 (0.991, 1.038)  0.048  
RMSSD (ms) Baseline  14.6 (11.1, 19.3) 18.7 (15.1, 23.0) 21.4 (16.8, 27.3) 16.0 (12.2, 20.9)  
 Average on treatmenta  18.5 (15.6, 22.1) 18.5 (16.1, 21.2) 15.2 (13.0, 17.7) 18.2 (15.3, 21.7)  
 Treatment effect*  1.000 [reference]  0.999 (0.951, 1.046) 0.932 (0.878, 0.985) 0.994 (0.935, 1.053) 0.215 
pNN50 (%) Baseline  2.1 (1.1, 4.2) 3.2 (1.9, 5.5) 3.6 (2.0, 6.4) 2.8 (1.4, 5.4)  
 Average on treatmenta  3.8 (2.5, 5.9) 4.2 (3.0, 5.9) 2.4 (1.6, 3.6) 3.7 (2.4, 5.7)  
 Treatment effect*  1.000 [reference]  1.067 (0.810, 1.325) 0.658 (0.369, 0.948) 0.982 (0.660, 1.304) 0.185 
Ti Baseline  24.4 (20.9, 28.3) 25.2 (22.4, 28.3) 32.6 (28.6, 37.3) 27.1 (23.3, 31.4)  
 Average on treatmenta  30.1 (27.0, 33.6) 31.2 (28.7, 34.0) 26.4 (24.0, 29.1) 29.7 (26.7, 33.0)  
 Treatment effect*  1.000 [reference]  1.010 (0.985, 1.035) 0.962 (0.934, 0.990) 0.996 (0.965, 1.027) 0.080 
HF (ms2)  Baselinea  125 (78, 201)  142 (98, 204)  180 (117, 272)  169 (106, 270)   
Average on treatmenta  167 (118, 234)  198 (152, 259)  136 (100, 183)  176 (126, 246)     
Treatment effect*  1.000 [reference]  10.34 (0.982, 1.086) 0.960 (0.901, 1.019)  1.011 (0.945, 1.076)   0.317  
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LF (ms2) Baselinea  396 (286, 549) 412 (320, 529) 570 (427, 761) 521 (378, 718)  
 Average on treatmenta  489 (403, 594) 536 (460, 624) 437 (369, 519) 501 (414, 606)  
 Treatment effect*  1.000 [reference]  10.15 (0.990, 1.039) 0.982 (0.954, 1.010) 1.004 (0.973, 1.034) 0.377 
LF:HF ratio Baselinea  3.17 (2.19, 4.58) 2.90 (2.19, 3.85) 3.19 (2.31, 4.42) 3.08 (2.14, 4.42)  
 Average on treatmenta  3.06 (1.48, 3.77) 2.78 (2.35, 3.27) 3.41 (2.83, 4.10) 3.25 (2.65, 4.00)  
 Treatment effect*  1.000 [reference]  0.914 (0.767, 1.062) 1.098 (0.932, 1.263) 1.056 (0.872, 1.241) 0.395 
VLF (ms2) Baselinea  5973 (4476, 7972)  6229 (4990, 7776)  8911 (6902, 11492)  6542 (4926, 8690)   
 Average on treatmenta  8973 (7448, 10804)  8553 (7391, 9896)  6549 (5558, 7715)  8392 (6995, 10075)   
 Treatment effect*  1.000 [reference]  0.995 (0.979, 1.011) 0.965 (0.947, 0.983) 0.993 (0.973, 1.013) 0.042   
SD1:SD2 Baselinea  0.12 (0.09, 0.15) 0.13 (0.11, 0.15) 0.11 (0.09, 0.13) 0.12 (0.10, 0.15)  
(Poincaré ratio) Average on treatmenta  0.12 (0.10, 0.14) 0.12 (0.11, 0.14) 0.11 (0.10, 0.13) 0.11 (0.10, 0.13)  
 Treatment effect*  1.000 [reference]  0.990 (1.049, 0.932) 1.014 (1.080, 0.949) 1.018 (1.091, 0.945) 0.927 
HR, heart rate; IBI, interbeat interval; SDNN, standard deviation of all NN intervals; SDANN, standard deviation of the averaged NN intervals, calculated from 5 min epochs; 
RMSSD, the square root of the mean of the sum of squares of differences between adjacent NN intervals; pNN50, percentage of adjacent NN intervals that differ by greater than 50 
ms;  Ti, triangular index; HF, high frequency power; LF, low frequency power; LF:HF, ratio of LF to HF power; VLF, very low frequency power; SD1:SD2, the ratio of the SD of 
beat-to-beat IBI variability (SD1) against the SD of long-term IBI variability (SD2). Baseline results expressed as means (95% CI) and average on treatment represents the average of 
change at 6 and 12 months following each treatment based on estimated marginal means (adjusted for age, sex, ethnicity, BMI and baseline values), except a geometric means (95% 
CI) * Treatment effect versus placebo (Average on treatment divided by change on placebo at 6 and 12 months). 
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3.2.3 Discussion 
An increased LC n-3 PUFA consumption has been associated with higher HRV 
(105,107,204), suggesting that populations with low LC n-3 PUFA tissue status might be at 
greater risk of arrhythmic events or SCD. Increasing LC n-3 PUFA content in cardiomyocyte 
membranes in animals reduced intrinsic pacemaker rate by altering ion channel currents and 
reduced pacemaker current in sinoatrial node cells resulting in a decreased HR and increased 
HRV (9,84). In the day-time, beat to beat variation of the heart rate is constantly occurring as a 
response to the physiological demands arising from daily activities and events, and it would be 
expected that supplementation with LC n-3 PUFA would increase the variability of the shorter 
phase HRV parameters, such as RMSSD, pNN50 and HF. However, these parameters didn't 
significantly change after the fish oil supplementation. A potential explanation could be the fact 
that the population studied already had a good EPA and DHA tissue status so, although the 
intervention increased the proportions of EPA and DHA in erythrocyte membranes in a dose-
dependent manner compared to placebo, it might not have added an additional benefit in 
increasing short-term HRV indices that may be more related to membrane properties of cardiac 
myocytes. The significant treatment effect observed in SDANN and in VLF power in the day-
time analysis seems to derive from the group supplemented with 0.9 g with the other 
supplemented groups not presenting any significant changes, which makes these results likely to 
be a type I statistical error. The day-time analysis suggests that supplementation with LC n-3 
PUFA did not have an effect on HRV. Since this population appeared to be, on average, replete 
in LC n-3 PUFA from the start of the intervention, with their mean omega-3 index (O3I) near 
the 8% cut-off suggested for optimal cardioprotection (205), the logical next step is to assess 
HRV in a healthy population with a low LC n-3 PUFA status compared to a population with an 
adequate LC n-3 PUFA status. For this purpose, a cross sectional study using vegans as a model 
of a LC n-3 PUFA deficient population (the OM3GA study) was planned and will be presented 
in the next chapter. 
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Chapter 4 A comparison of heart rate variability, n-3 PUFA status 
and lipid mediator proﬁle in age- and BMI-matched middle-aged 
vegans and omnivores 
4.1 Introduction 
The major dietary source of LC n-3 PUFAs is seafood and they can also be found in lean 
red meat, in organ meat, such as liver, in eggs and in very small amounts in dairy products. 
Consequently, vegans who do not eat any animal-derived products have a diet naturally free 
from the LC n-3 PUFAs eicosapentaenoic acid (20 : 5 n-3, EPA) and docosahexaenoic acid (22 
: 6 n-3, DHA) (159). The main n-3 PUFA in vegan diets is α-linolenic acid (18 : 3 n-3, ALA), 
found in plant foods such as flaxseed, walnut, soybean, hempseed, chia seed and respective oils 
(206).  
Having a diet devoid of LC n-3 PUFA, vegans present blood lipid LC n-3 PUFA 
concentrations that are only a third of the level in omnivores (159). Although EPA and DHA 
can be endogenously synthesised from the downstream metabolism of ALA, the efficiency of 
this conversion is limited in humans (207). LC n-3 PUFA, especially DHA, is rapidly 
incorporated into a variety of cells, primarily into phospholipids of the plasma membrane, 
including the cardiac cells (cardiomyocytes). Dietary alterations of LC n-3 PUFA in 
cardiomyocyte membranes influence the function of membrane channels and receptors and, 
consequently, the cells’ contractile function (14,208,209). LC n-3 PUFA can also be oxygenated 
into numerous bioactive lipid mediators which act as precursors of the SPMs actively involved 
in the resolution of inflammation (210).  
It has been shown that LC n-3 PUFA are preferentially incorporated in cardiomyocytes 
and inhibit the synthesis of AA which may result in altered production of eicosanoids. The 
alteration in the type and amount of eicosanoids generated, which in turn will originate different 
lipid mediator profiles, has been suggested as an explanation for the anti-arrhythmic properties 
of LC n-3 PUFA via the effects of these changes on intercellular calcium release and Ca2+ 
channels (173). This may have further effects on the cardiac autonomic function of the heart and 
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we therefore hypothesise that this might be associated with lower HRV in vegans, as a result of 
lower LC n-3 PUFA status, compared to omnivores. Animal, epidemiological and clinical 
studies evaluating the effects of LC n-3 PUFA on CV health outcomes have been mainly 
positive (144). This poses a conundrum: vegan dietary patterns are associated with lower blood 
pressure, lipids and a lower body mass index (BMI), all important risk factors for CVD (211), 
yet vegans are depleted in LC n-3 PUFA fatty acids associated with a cardioprotective role. The 
Omega-3 index (O3I), which represents the EPA + DHA content of erythrocyte membranes 
(expressed as a percentage of total fatty acids), has been emerging as a risk factor for CVD 
(212). 
4.2 Hypothesis 
The primary hypothesis of the study is that vegans have higher HR/shorter IBI and lower 
HRV compared with omnivores.  
4.3 Aims 
This study aims to compare HRV between vegans and age/sex/BMI-matched omnivore 
controls, representing populations with low and high tissue LC n-3 PUFA status, respectively. 
The results of this study will provide cross-sectional data to determine the variability of the 
outcome measures in this population in order to calculate the sample size needed if there were 
enough evidence for a link to justify a RCT of LC n-3 PUFA supplementation. 
4.4 Study design, participants and recruitment 
4.4.1 Study design 
This is an observational cross-sectional pilot study being conducted at KCL. Recruitment 
onto the study was completed in two phases: the first phase ran between May and August 2013 
and the second phase ran between May and August 2014. 
4.4.2 Ethics and consent 
Ethical approval was obtained from KCL research ethics committee (BDM/12/13-84) and 
written informed consent was given by participants. 
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4.4.3 Participants  
Inclusion criteria: Healthy non-smoking men and women aged 40-70 y who report being 
vegan (for at least 2 y) or follow a mixed diet including meat, fish, eggs and dairy-containing 
foods (omnivore). Vegan subjects were matched with omnivore controls for sex, age (±5 y) and 
BMI (±2 kg/m2). 
Exclusion criteria: Reported history of CVD (myocardial infarction, angina, venous 
thrombosis, stroke, atrial fibrillation, pacemaker), type 1 diabetes mellitus or type 2 diabetes 
(fasting plasma glucose ≥ 7 mmol/L), cancer (excluding basal cell carcinoma) in the past five 
years, chronic renal, liver or inflammatory bowel disease, history of drug or alcohol abuse 
(previous weekly alcohol intake >60 units/men or 50 units/women), current self-reported 
weekly alcohol intake exceeding 28 units, current use of marine n-3 PUFA supplements, 
pregnancy, weight change of more than 3 kg in the previous 2 months, BMI <18.5 and >35 
kg/m2. 
4.4.4 Outcome measures 
The primary independent variable is erythrocyte EPA and DHA content as a % of total 
fatty acids. Total plasma fatty acid composition (which would reflect more recent dietary intake 
in healthy populations) will also be analysed for comparison between groups. The primary 
dependent variables are HR/IBI and time-domain parameters of different components of HRV: 
SDNN, the most commonly reported marker of HRV and an indication of overall HRV, mainly 
determined by day/night differences; and RMSSD, an indicator of beat-to-beat, respiration-
driven variability representing parasympathetic cardiac regulation.  
Secondary outcomes include other time- and frequency-domain and non-linear 
parameters of HRV, fasting blood lipid profile (total, low density lipoprotein (LDL) and high 
density lipoprotein (HDL) cholesterol and triacylglycerol concentrations), total fatty acid 
composition of plasma and erythrocyte membrane, plasma oxygenated lipid mediator profile, 
vitamin B12, fasting glucose concentrations, anthropometric measurements (weight, height, 
BMI, waist circumference, % body fat), HR, blood pressure, activity levels (in counts per 
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minute) and background diet (food frequency questionnaires) in order to compare risk factors 
for CVD in vegans and omnivores. 
4.4.5 Recruitment methodology 
Vegan participants were recruited through external advertising to the following vegan 
communities: the Vegan Society 3, London Vegans 4 and London Vegan Meetup 5. Omnivore 
participants were recruited through internal and external email circulars and posters among KCL 
students, staff and participants from the CRESSIDA study. The study was also promoted via 
Facebook, Gumtree and Twitter, flyer distribution to vegan restaurants and shops selling vegan 
foods and supplements throughout London, and through the participation in various food events, 
including the Big IF event (Hyde Park, 8th June 2013), the London Vegan Potluck dinner (3rd 
July 2013 and 4th June 2014) and the Vegan Drinks (15th May 2014). Volunteers who responded 
to advertisements were given more information about the study (Appendix 2), completed a 
recruitment questionnaire via telephone call or e-mail to establish their eligibility for the study 
and were sent a study information sheet. The eligible participants that were willing to participate 
attended a morning clinic visit at the MRU at Franklin-Wilkins building (King’s College 
London, Waterloo campus) booked according to participant’s availability. Recruitment 
methodology is summarised in Figure 15.  
                                                     
3 The Vegan Society, 47 Highlands Road, Leatherhead, Surrey. 
4 London Vegan Office, 7a Deansbrook Road, Edgware, Middlesex, HA8 9BE. 
5 www.meetup.com/londonvegan/ 
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Figure 15 – Diagram showing volunteer recruitment. 
4.5 Study days 
4.5.1 Study protocol 
The clinic visits took place in the morning (between 8.00 and 11.00 am) and lasted 
approximately 1 hour. Volunteers were instructed to fast for 12 h before the clinic visit and 
consume nothing but water until attending the clinic. On arrival, the study protocol was 
explained in detail and participants were given the opportunity to ask questions before signing 
the consent form. After a 10 minute rest, three measurements of seated blood pressure were 
taken using an A&D Medical UA-767Plus auto upper arm blood pressure monitor (A&D 
Instruments Limited, San Jose, USA), in accordance with guidelines from the BHS. Height, 
body weight and percentage body fat, and waist circumference were measured using a 
stadiometer, a Tanita weighing scale and a tape measure, respectively. Participants also 
completed a food frequency questionnaire (FFQ) that was checked for completeness and any 
missing data was verified directly with the participant. A fasting blood sample (20 ml equivalent 
to 4 tsp) was taken to check that lipids, haematology, liver function and glucose were within 
specified limits and a sample was set aside for plasma fatty acid and erythrocyte lipid analyses. 
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Volunteers were fitted with the Actiheart monitor and asked to wear it for 24 h. A diary was 
provided (Appendix 3) during the recording period to keep a register of all the daily activities 
(activities/exercise, meals or naps). After 24 h the devices were returned by courier. Participants 
were offered a light breakfast after completing the study visit. Screening blood samples were 
sent via courier to King’s College Hospital, Denmark Hill for analysis. Participants were 
provided with the results of the blood screening analysis and a letter to their general practitioner 
upon request detailing results and drawing attention if necessary to any out of range values. 
4.5.2 Anthropometric measurements 
Height was measured using a stadiometer to the nearest 1 cm while participants were 
barefoot, standing upright with heels and shoulders against the measuring rod and looking 
straight ahead. Waist circumference was measured using a metric measuring tape to the nearest 
0.1 cm in the standing position; waist circumference was measured at the midway point between 
the iliac crest and the lowest rib with the participant’s waist uncovered or with very light 
clothing. Readings were taken at the end of a normal exhalation. Weight was measured to the 
nearest 0.1 kg and percentage body fat was assessed by bioelectrical impedance analysis using a 
TANITA BC-418 segmental body composition analyser.  
4.5.3 Dietary assessment 
The EPIC-Norfolk FFQ (pages 2 to 10, Appendix 4) was used in this study to assess 
patients’ background diet over the past 12 months as well as to verify self-classification of 
dietary status of eligible volunteers. The FFQ consists of two parts: the first part asks about the 
frequency of consumption of 130 foods. Participants are asked to choose from nine frequency 
categories ranging from “never or less than once/month” to “6+ times per day”. The second part 
consists of additional questions to provide information about extra foods consumed frequently 
(more than once per week) that were not mentioned in the first part, type and amount of milk, 
breakfast cereals, cooking methods, type of fats used and supplements regularly taken. Data 
obtained from the completed FFQ was entered into an in-house customised Microsoft Access 
database and exported to Microsoft Excel for further processing. The daily nutrient intakes were 
estimated using food codes and portion size calculations. The average portion size for each 
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response was determined using a sliding scale of fractions of portions corresponding to those 
used in the EPIC study. The specific macronutrient, micronutrient and individual LC n-3 PUFA 
intake calculations were determined using the nutrient composition values from the McCance 
and Widdowson’s ‘The Composition of Foods Integrated Dataset’ 6 with additional data 
obtained from manufacturers and USDA values when required. 
4.5.4 Heart Rate Variability 
Heart rate variability was measured using the Actiheart monitoring equipment 
(CamNtech Ltd, Cambridge, UK). This is a small, light-weight (<10 g) waterproof device that 
records acceleration (counts per minute, cpm) as a measure of physical activity, HR, and all 
inter-beat intervals for approximately 24 h. Skin preparation took part including shaving of 
chest hair, use of alcohol wipes to clean and dry the skin and use of an abrasive pad (UnilectTM) 
to remove the top layer of skin cells. Two ECG electodes (SP-50, 50 mm round, Pulse Medical) 
were placed on the chest to fit the Actiheart monitor. A short signal test, involving around a 5 
minute walk with the participant, was performed before programming for the 24 h recording to 
confirm that the level of R wave signal being picked up by the Actiheart was adequate. Data 
processing of the 24 h HRV recordings was carried out using the Actiheart software (version 
4.0.91, CamNtech Ltd, Cambridge, UK) and Kubios HRV analysis software (Biosignal 
Analysis and Medical Imaging Group, Department of Physics, University of Kuopio, Finland). 
For more detailed information please refer to the general methods chapter (Chapter 2). HRV, 
HR/IBI and accelerometry data were analysed for the full length of recording time (minimum of 
18 h, up to 24 h). Further analysis was carried on a standardised day-time period of 8h and 
sleep-time period of 2 h to remove the inﬂuence of variability in recording duration on HRV 
parameters. The 8 h and 2 h time periods were selected as the first 8 h and 2 h of good quality 
data, respectively, from the start of day-time and sleep-time periods (excluding any noisy 
sections where signal was poor, and periods of awake time at night assessed by and increased 
heart rate matched with increased accelometry data).  
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4.5.5 Blood sample collection, handling and analysis  
Blood was drawn into vacutainer tubes. Blood for plasma glucose analysis was collected 
into 4 ml fluoride oxalate tubes. Blood for plasma lipids (triacylglycerol, total cholesterol, LDL- 
and HDL-cholesterol), liver function, vitamin B12 and 25-hydroxy vitamin D analysis was 
collected into 5 ml SSTTM serum tubes containing a gel for separation. Blood for the full blood 
count and IL-6 analysis was collected into 4 ml EDTA tubes. These bloods were sent by courier 
and analyses were carried out at the department of clinical biochemistry at King’s College 
Hospital (ViaPath). Glucose and lipids were analysed following enzymatic methods using 
reagents supplied by Bayer Diagnostics Europe Ltd (Bayer House) using an ADVIA 2400 
analyser (Siemans Healthcare Diagnostics); IL-6 was analysed using a high-sensitivity cytokine 
chip array assay (Human cytokine HS X biochip; Randox Laboratories Limited); and Serum 
vitamin D and B12 concentrations were analysed using the ADVIA Centaur total vitamin D and 
vitamin B12 immunoassays (Siemens Healthcare Diagnostics Ltd). Blood for the erythrocyte 
membrane phospholipid fatty acid and plasma fatty acid composition was collected into 6 ml 
EDTA tubes and analysed at the diabetes and nutritional sciences department at King's College 
London. Further details about the blood handling protocol can be found in Appendix 5.  
Following the blood collection, the 6ml EDTA tubes were centrifuged at 1500 g for 15 
minutes at 4 ºC. Plasma was aliquoted into cryovials and stored at -80 ºC until analysed. The 
remaining haematocrit was washed with isotonic saline 3 times to remove residual plasma and 
the buffy coat (white blood cells). A 0.5 ml aliquot of the washed cells was lysed with 
equivalent volume of deionised water. Following the erythrocyte lyses, 5.5 ml of isopropanol 
(containing butylated hydroxyl toluene, added as an antioxidant in the concentration of 50 
mg/L) was added to denature the proteinatious component of the cell membrane. This was 
followed by the addition of 3.5 ml chloroform to extract the lipids. The solution was vortexed 
and centrifuged to pelletize the cellular debris. The supernatant was then transferred to a glass 
tube with a cap and stored at -20 ºC until analysed. 
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4.5.6 Determination of the fatty acid composition of plasma and 
erythrocyte membrane lipids  
Plasma fatty acid composition was determined based on Lepage and Roy 1988 method, 
substituting toluene for benzene and using pentadecanoic acid as an internal standard. 
Erythrocyte membrane phospholipid fatty acid composition was determined as previously 
described (192). Proportions of fatty acids were expressed as weight % (Refer to chapter 2 – 
Methods, section 2.3, for further details). 
4.5.7 Extraction and determination of lipid mediators in plasma  
Lipid mediators are produced from the oxidation of PUFA through enzymatic or non-
enzymatic free radical mediated reactions. The three major enzymatic pathways are catalysed by 
COX, LOX and CYP monooxygenases. These lipidomic analyses were performed as a 
collaborative work with the laboratory of Prof. Anna Nicolaou at the University of Manchester. 
In this study the lipid mediators were extracted from plasma and analysed by liquid 
chromatography-electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS). This 
assay targets prostanoids and hydroxyl fatty acids derived from the main PUFA, including 
dihomo-gamma-linolenic acid (DGLA), LA, ALA, AA, EPA and DHA. The method has been 
previously described (210) Briefly, an ice-cold methanol solution (15% v/v) was added to the 
plasma samples to help extracting the lipid mediators and facilitate the denaturation and 
precipitation of proteins. After adding two deuterated internal standards to each sample (PGB2-
d4 for prostanoids and 12-HETE-d8 for hydroxyl fatty acids), the samples were centrifuged and 
any precipitate was removed. The clear supernatant was then acidified to pH 3 using a HCL 
solution (0.1 M). The acidified extract was then loaded onto a preconditioned solid phase 
extraction cartridge and washed three times, firstly with methanol solution (15% v/v), followed 
by deionised water and lastly hexane. Finally, the compounds of interest are eluted in methyl 
formate. The solvent is evaporated under nitrogen and the lipid residue is resuspended in a small 
volume of ethanol (70% v/v). After centrifuging, the samples were transferred to amber sample 
vials and stores at -20 ºC for LC/ESI-MS/MS analysis with the use of an Acquity UPLC system 
coupled to an electrospray triple quadrupole Xevo TQ-S mass spectrometer (Water, UK).  
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Calibration lines for all compounds of interest were generated during the assay using a 
cocktail of commercially-available lipid standards (Cayman) to accurately quantify each 
compound in plasma. Prostanoids and hydroxyl fatty acids were analysed through two separate 
LC/ESI-MS/MS runs using gradient methods. Each sample was analysed twice. The 
chromatographic analysis was performed on a C18 column (ACQUITY UPLC BEH, 1.7 µm, 
2.1 mm x 50 mm) and the analytes were separated at a flow rate of 0.6 ml/min. 
4.6 Statistical analysis 
A sample size of twenty-three in each group has 80% power to detect a difference 
between SDNN means of 25 ms and between RMSSD means of 15 ms with a significance level 
of 0.05 (two-tailed), based on SD of 30 and 18 ms, respectively, obtained from sleep-time HRV 
recordings in a previous cohort of middle-aged to older healthy men and women (186).  
Statistical analyses were performed using IBM SPSS Statistics 21.0 (Statistical Product 
and Service Solutions, IBM Corp). Chi-squared (χ2) tests for categorical variables and 
independent samples t-test for continuous variables were used to assess the differences between 
vegan and omnivore subjects’ characteristics, dietary intakes, erythrocyte and plasma fatty 
acids, and lipid mediators. Data normality was determined using Shapiro-Wilk test and by 
visual inspection of the data distribution on the histogram and Q-Q plots. Non-normally 
distributed data were normalised by natural logarithm (LN) (results shown as geometric means 
and 95% CI) before analysis by independent t test. If data was not normalised by LN 
transformation, a Mann–Whitney U test was applied to compare groups (results shown as 
medians with lower and upper quartiles). In the case of lipid mediators, results from non-
normally distributed data analysed by Mann–Whitney U test were shown as medians with 
minimum and maximum values due to the proportion of undetectable concentrations of LC n-3 
PUFA-derived mediators in omnivores and vegans. For HRV analysis, normally distributed raw 
data or LN transformed data were analysed by univariate ANCOVA, adjusted for sex, age, BMI 
and, in the case of day-time and 24 h data, for physical activity (accelerometry data). Results are 
expressed as estimated marginal means (95% CI), adjusted for sex, age, BMI and 24 h activity 
for 24 h HRV and sleep-time – day-time HRV, or sex, age, BMI and 8 h activity for 8 h day-
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time HRV, or adjusted for sex, age and BMI only for 2 h sleep-time. Estimated marginal means 
and 95% CI from data that were LN transformed before analysis by ANCOVA were back-
transformed and expressed as geometric means and 95% CI. Data that could not be normalised 
by LN transformation were analysed using Mann–Whitney U test and significance values are 
presented unadjusted, with results shown as medians (lower and upper quartiles).  
4.7 Results 
4.7.1 Subjects 
From the 127 subjects that responded to the adverts and completed the screening 
questionnaire, 62 were eligible and invited to take part in the study. Of these 49 attended the 
clinic visit and 47 completed the study (Figure 16).  
 
 
Figure 16 - Study consort diagram. 
4.7.2 Characteristics of study subjects  
The characteristics of the study subjects are presented in table 10. The study group was 
formed of a total of 23 vegan subjects (8 male, 15 female) with a mean age of 49 ± 8 y and a 
mean BMI of 23.5 ± 4.4 kg/m2 and 24 omnivores (12 male, 12 females) with a mean age of 54 ± 
9 y and a mean BMI of 23.3 ± 2.8 kg/m2. There were no significant differences in age or BMI, 
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or distribution of sex between groups, although the sex distributions were not fully balanced 
across groups. Furthermore, there were no significant differences in waist circumference and % 
body fat. Seated resting SBP was significantly lower in the vegan subjects while the seated 
resting HR was significantly lower in the omnivore group. There was no significant difference 
in DBP between groups. Biochemistry results for the vegan and omnivore subjects are reported 
in Table 11. Both fasting serum total and LDL-cholesterol were significantly lower in vegans, 
but there were no differences in fasting plasma glucose, serum triacylglycerol, serum HDL-
cholesterol, serum vitamin B12, serum 25-hydroxy vitamin D or IL-6 concentrations, nor blood 
haemoglobin concentrations, indicating that the vegan group did not differ in vitamin D status 
and were likely to be taking dietary vitamin D (65% taking supplements) and B12 supplements 
(61% taking supplements).  
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Table 10 – Characteristics of subjects who completed the study (n=47). 
 Omnivore (n=24) Vegan (n=23) P value† 
Sex     
   Male  12 (50) 8 (35) 0.292§ 
   Female  12 (50) 15 (65) 
Ethnicity    
   White  21 (88) 21 (91) 0.289§ 
   Black African/Caribbean 0 (0) 1 (5)  
   South Asian  2 (8) 0 (0)  
   Other  1 (4) 1 (5)  
Vitamin B12 supplement use  8 (33) 14 (61) 0.059§ 
Vitamin D supplement use  5 (21) 15 (65) 0.003§ 
Age (years)  54 ± 9.1 49 ± 7.9 0.081 
BMI (kg/m2)  23.3 ± 2.8 23.5 ± 4.4 0.896 
Waist circumference (cm)          
       Male   91.7 ± 6.5 97.2 ± 5.9 0.165 
       Female   88.8 ± 12.5 86.0 ± 14.8 0.617 
% body fat       
       Male   19.3 ± 7.9 21.1 ± 5.9 0.572 
       Female 30.6 ± 7.7 29.4 ± 9.9 0.751 
SBP (mmHg)  118 ± 9.8 111 ± 9.9 0.032 
DBP (mmHg)  75 ± 9.3 74 ± 8.2 0.703 
Heart Rate (bpm) 63 ± 10.8 70 ± 9.0 0.017 
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per 
minute. 
Results are expressed as number of subjects (%) or mean ± SD. † Using independent samples t-test, 
except § χ2 test. 
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Table 11 – Biochemistry results of subjects who completed the study (n=47). 
 Omnivore (n=24) Vegan (n=23) P value† 
Plasma fasting glucose (mmol/L)  5.2 ± 0.43 5.1 ± 0.40 0.616 
Serum triacylglycerol (mmol/L) a 0.77 (0.66, 0.92) 0.76 (0.64, 0.90) 0.849 
Serum total cholesterol (mmol/L) 4.9 ± 0.86 4.1 ± 0.66 0.001 
Serum LDL-C  (mmol/L) a 2.81 (2.49, 3.17) 2.16 (1.94, 2.41) 0.002 
Serum HDL-C (mmol/L)       
       Male 1.52 ± 0.35 1.29 ± 0.23 0.118 
       Female 1.71 ± 0.24 1.66 ± 0.42 0.725 
Haemoglobin (g/L)      
       Male 14.4 ± 0.6 14.4 ± 0.8 0.805 
       Female 13.2 ± 1.0 13.5 ± 1.0 0.460 
Serum vitamin B12 (ng/L) 442 ± 216 358 ± 117 0.108 
Serum 25-hydroxy vitamin D 
(nmol/L) 
54.3 ± 20.9 ** 55.6 ± 26.5 0.854 
Interleukin-6 (ng/L) b 0.93 (0.25, 1.54) ** 1.07 (0.23, 3.05) 0.701║ 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol 
Results are expressed as mean ± SD, a geometric mean (95% confidence intervals) or b median (upper and 
lower quartiles). † Using independent samples t-test, except ║Mann-Whitney U test ** n=23 due to sample 
loss. 
 
4.7.3 Dietary intake 
Dietary intakes (excluding supplements) are shown in table 12. Vegans and omnivores 
had comparable energy (kcal), total fat (%E) and monounsaturated fatty acids (MUFA, %E) 
intakes. Omnivores had significantly higher protein (%E), saturated fatty acids (SFA, %E) and 
food-derived vitamin B12 (µg) intakes and vegans had significantly higher carbohydrate (%E), 
PUFA (%E) and LA (g) intakes. As expected, vegans had no dietary intake of EPA and DHA, 
hence omnivores obtained significantly higher intake of these fatty acids. Dietary intake of 
vitamin B12 was below the lower reference nutrient intake (LRNI) in 30.4% of the vegan 
subjects. All omnivore subjects met the reference nutrient intake (RNI) of 1.5µg/day of vitamin 
B12 (through food intake) compared to 56.5% of vegan subjects.  
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Table 12 – Mean daily dietary intakes of vegans and omnivores assessed by food frequency 
questionnaire. 
 Omnivore (n=24) Vegan (n=23) P value† 
Energy (kcal) 1953 ± 478 1833 ± 662 0.477 
Protein (%E) 16.6 ± 2.2 13.3 ± 2.4 < 0.001 
Carbohydrates (%E) 49.2 ± 7.3 56.5 ± 11.6 0.013 
Total fat (%E) 33.8 ± 5.9 30.9 ± 9.5 0.216 
SFA (%E) 11.8 ± 2.6 6.3 ± 1.7 < 0.001 
MUFA (%E) b 13.5  (12.1, 15.0) 11.6 (9.3, 14.4) 0.136 ║ 
PUFA (%E) 6.0 ± 1.2 9.6 ± 3.1 < 0.001 
     18 : 2n-6, LA (g) b 7.6  (5.9, 10.2) 10.5 (7.3, 18.5) 0.025 ║ 
     18 : 3n-3, ALA (g) b 0.7  (0.5, 1.0) 0.8 (0.5, 1.2) 0.425 ║ 
     20 : 5n-3, EPA (g) b 0.14  (0.09, 0.24) 0.00 (0.00, 0.00) < 0.001 ║ 
     22 : 6n-3, DHA (g) b 0.45  (0.30, 0.81) 0.00 (0.00, 0.00) < 0.001 ║ 
Vitamin B12 (µg) 6.9 ± 2.7 2.3 ± 1.9 < 0.001 
ALA, α-linolenic acid; DHA, docosahexaenoic acid; %E, percentage energy; EPA, eicosapentaenoic acid; 
LA, linoleic acid; MUFA monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, 
saturated fatty acids. 
Results are expressed as mean ± SD, except b median (upper and lower quartiles). † Using independent 
samples t-test, except ║Using Mann-Whitney U test. 
 
4.7.4 Plasma and erythrocyte lipid fatty acid composition 
Plasma and erythrocyte membrane fatty acid composition are presented in Table 13. 
Vegans had a significantly higher proportion of plasma and erythrocyte LA and adrenic fatty 
acid (a metabolite of AA), plasma ALA and erythrocyte DGLA, compared to omnivores. Both 
plasma and erythrocyte membrane proportions of EPA and DHA, plasma palmitic acid, and 
erythrocyte docosapentaenoic acid (DPA) n-3 were significantly lower in vegans compared to 
omnivores. Vegans had a significantly lower O3I, with a geometric mean of 2.7% compared to 
5.4% in omnivores, although both groups would be considered below the proposed O3I cut-off 
of > 8% for optimal cardiovascular protection (205). Erythrocyte LA : ALA ratios were 
inversely moderately correlated with erythrocyte EPA contents in vegans (r = -0.541, P = 0.008, 
n = 23), but not DPA n-3 or DHA contents; with no significant correlations in the erythrocyte 
lipids of omnivores. In plasma, the ratio of LA : ALA was inversely moderately correlated with 
plasma DPA n-3 (r = -0. 576, P = 0.004, n = 23) and DHA (r = -0.498, P = 0.016, n = 23) in 
vegans and plasma DPA n-3 only in omnivores (r = -0.474, P = 0.019, n = 24).   
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Table 13 - Plasma and erythrocyte membrane fatty acid composition (weight %) of participants (n=47).  
Fatty acid  Omnivore (n=24) Vegan (n=23) Mean Δ (95% CI) P value† 
Plasma      
    16 : 0 (Palmitic) 20.8  (20.4, 21.3) 19.3  (18.6, 20.0) -1.49 (-2.31, -0.67) 0.001 
    16 : 1n-7 (Palmitoleic) 1.79 (1.48, 2.10) 1.11  (0.91, 1.32) -0.67 (-1.04, -0.31) 0.001 
    18 : 0 (Stearic) 7.62  (7.30, 7.94) 7.60  (7.15, 8.04) -0.02 (-0.55, 0.50) 0.931 
    18 : 1n-9 (Oleic) 18.5 (17.6, 19.3) 18.9  (17.9, 19.8) 0.37 (-0.89, 1.62) 0.559 
    18 : 2n-6 (LA) 27.1 (26.0, 28.2) 33.1  (31.9, 34.4) 6.06 (4.43, 7.68) < 0.001 
    18 : 3n-3 (ALA) a 0.53  (0.48, 0.59) 0.71  (0.59, 0.85) 1.34* (1.09, 1.64) 0.006 
    20 : 3n-6 (DGLA) 1.42 (1.28, 1.55) 1.42  (1.28, 1.57) 0.01 (-0.18, 0.20) 0.952 
    20 : 4n-6 (AA) 6.68 (6.12, 7.25) 6.55  (5.94, 7.16) -0.13 (-0.94, 0.68) 0.745 
    20 : 5n-3 (EPA) a 1.03  (0.79, 1.34) 0.47  (0.40, 0.55) 0.46* (0.34, 0.62) < 0.001 
    22 : 4n-6 (Adrenic) a 0.20 (0.19, 0.21) 0.23 (0.21, 0.25) 1.14* (1.01, 1.28) 0.036 
    22 : 5n-6 (DPA n-6) 0.26 (0.21, 0.30) 0.20 (0.15, 0.26) -0.05 (-0.12, 0.02) 0.146 
    22 : 5 n-3 (DPA n-3) 0.59 (0.53, 0.64) 0.51 (0.44, 0.59) -0.07 (-0.16, 0.02) 0.113 
    22 : 6  n-3 (DHA) a 2.23 (1.94, 2.57) 0.91 (0.80, 1.05) 0.41* (0.34, 0.49) < 0.001 
Erythrocyte membrane        
    16 : 0 (Palmitic)  16.8 (15.4, 18.2) 17.6 (16.7, 18.6) 0.81 (-0.87, 2.48) 0.337 
    16 : 1n-7 (Palmitoleic)b 0.41 (0.30, 1.57) 0.31 (0.21, 0.50) - - 0.016 ║ 
    18 : 0 (Stearic) a 15.6 (14.9, 16.3) 16.3 (15.6, 17.1) 1.05* (0.99, 1.14) 0.135 
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    18 : 1 n-9 (Oleic) 15.7 (15.1, 16.3) 15.4  (14.7, 16.2) -0.23 (-1.15, 0.68) 0.609 
    18 : 2 n-6 (LA) 11.7 (11.0, 12.3) 13.3 (12.5, 14.1) 1.64 (0.64, 2.64) 0.002 
    18 : 3 n-3 (ALA) a 0.34 (0.26, 0.45) 0.32 (0.27, 0.38)  0.92* (0.67, 1.27) 0.610 
    20 : 3 n-6 (DGLA) a 1.78 (1.64, 1.94) 2.02 (1.84, 2.22) 1.13* (1.01, 1.28) 0.042 
    20 : 4 n-6 (AA) 15.9 (14.9, 16.9) 15.6 (14.4, 16.9) -0.27 (-1.82, 1.27) 0.725 
    20 : 5 n-3 (EPA) 1.26 (1.07, 1.45) 0.67 (0.52, 0.81) -0.59 (-0.83, -0.36) < 0.001 
    22 : 4 n-6 (Adrenic) 2.75 (2.47, 3.03) 3.83 (3.50, 4.16) 1.08 (0.66, 1.50) < 0.001 
    22 : 5 n-6 (DPA n-6) 0.38 (0.27, 0.49) 0.52 (0.40, 0.64) 0.14 (-0.02, 0.30) 0.078 
    22 : 5 n-3 (DPA n-3) 2.62 (2.36, 2.88) 2.15 (1.94, 2.36) -0.47 (-0.80, -0.15) 0.005 
    22 : 6 n-3 (DHA) a 4.19 (3.63, 4.83) 2.07 (1.85, 2.32) 0.49* (0.41, 0.59) < 0.001 
    Omega 3 index a 5.42 (4.73, 6.20) 2.71 (2.40, 3.05) 0.50* (0.42, 0.60) 0.006 
AA, arachidonic acid; ALA, α-linolenic acid; DGLA, dihomo-gamma-linolenic acid; DHA, docosahexaenoic acid; DPA, docasapentaenoic acid; EPA, eicosapentaenoic acid; LA, 
linoleic acid. Results are expressed as mean (95% CI), except a Geometric mean (95% CI), b median (lower and upper quartile) † Using independent samples t-test, except ║ using 
Mann-Whitney U test. *Exponents of mean differences in LN values (the ratio of the geometric mean in vegans:that in omnivores, with 95% CI of the geometric mean ratios). Total 
plasma fatty acid concentrations were (geometric means with 95% CI): omnivores (1869 mg/L, 1660, 2104; n=24), vegans (1998 mg/L, 1755, 2274; n=23); there were no significant 
differences between groups. 
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4.7.5 Lipid mediators in plasma 
Figure 17 and Figure 18 show all the lipid mediators included in the analysis protocol, 
including those that were not detected in the plasma of this study population. Figure 17 presents 
the schematic outline of lipid mediators that derive from the n-6 PUFA fatty acids LA, DGLA 
and AA and Figure 18 presents the schematic outline of lipid mediators that derive from the n-3 
PUFA fatty acids ALA, EPA and DHA. Table 14 shows n-3 and n-6 PUFA-derived lipid 
mediators detected in the fasting plasma of the two study groups. Overall, the lipid mediators 
derived from n-6 PUFA (mainly DGLA and LA), and plant derived n-3 PUFA (ALA) were 
higher in vegans compared to omnivores, and the lipid mediators derived from EPA and DHA 
were lower in vegans compared to omnivores, showing a clear difference in the lipidomic 
profile between the groups. SPMs (resolvins, protectins and maresins) were not detectable in the 
fasting plasma samples. Notably, in vegans there were markedly lower fasting plasma 
concentrations of 18-hydroxyeicosapentaenoic acid (18-HEPE), an EPA-derived precursor 
marker for resolvin E1 (RvE1), and undetectable concentrations of 17-hydroxydocosahexaenoic 
acid (HDHA), a DHA-derived precursor marker for resolvin D1, resolvin D2, and PDX, an 
isomer of protectin D1. 14-HDHA, another mediator arising from DHA and a precursor marker 
for the macrophage-derived maresin 1, was also much lower in vegan fasting plasma compared 
to omnivores. In summary, these data show that vegans have increased blood concentrations of 
oxygenated metabolites of LA and ALA compared to omnivores, and very low or undetectable 
concentrations of LC n-3 PUFA-derived oxygenated metabolites. 




























Figure 17 – Schematic outline of n-6 PUFA-derived lipid mediators analysed in blood plasma of study participants. Red = higher in vegans, blue = higher in 
omnivores, purple = no difference, white = not detected or below the limit of detection. OxoODE, oxooctadecadienoic acid; HODE, hydroxyoctadecadienoic acid; 
EpOME, epoxyoctadecenoic acid; DiHOME, dihydroxyoctadecenoic acid; EKODE, epoxyketooctadecenoic acid; TX, thromboxane; HETE, 
hydroxyeicosatetraenoic acid; EET, epoxyeicosatetraenoic acid; DHET, dihydroeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid; 
DiHETE,dihydroxyeicosatetraenoic acid; LT, leukotriene; HX, hepoxilin. 






























Figure 18 – Schematic outline of n-3 PUFA-derived lipid mediators analysed in blood plasma of study participants. Red = higher in vegans, blue = higher in 
omnivores, purple = no difference, white = not detected or below the limit of detection. HOTrE, hydroxyoctadecatrienoic acid; TX, thromboxane; PG, prostaglandin; 
HEPE, hydroxyeicosapentaenoic acid; Rv, resolvin; HDHA, hydroxydocosahexaenoic acid; PD, protectin D; MaR, maresin; EpDPE, epoxydocosapentaenoic acid; 
DiHDPA,dihydroxydocosapentaenoic acid. 
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Table 14 – Plasma concentrations of n-3 and n-6 PUFA-derived lipid mediators in the study 
participants (n=47). 
  
Compound (ng/ml) Omnivore (n=24) Vegan (n=23) p value† 
n-6 PUFA-derived      
DGLA-derived       
15-HETrE 51.82 (36.94, 66.70) 53.87 (39.78, 67.96) 0.533 
13,14-dihydro-15-keto PGE1 a 17.45 (9.52, 31.99) 13.93 (7.82, 24.78) 0.519 
13,14-dihydro PGE1 b 0.000 (0.000, 4.332) 0.000 (0.000, 76.928) 0.001║ 
LA-derived       
9-HODE a 2433 (1982, 2988) 5045 (4067, 6260) <0.001 
9 OxoODE a 477 (398, 571) 994 (771, 1282) <0.001 
13-HODE a 3320 (2717, 4056) 6536 (5483, 7791) <0.001 
13 OxoODE 335 (291, 379) 537 (467, 606) <0.001 
12(13) EpOME 389 (326, 451) 769 (622, 917) <0.001 
12,13-DiHOME 2820 (2159, 3480)  5544 (4527, 6561) <0.001 
9,10-DiHOME a 3.20 (2.48, 4.12) 7.40 (5.91, 9.27) <0.001 
9(10) EpOME a 258 (220, 303) 426 (351, 518) <0.001 
Trans EKODE a 300 (248, 362) 560 (425, 738) <0.001 
AA-derived       
6-keto PGF1α b 8.20 (0.000, 59.14) 0.000 (0.000, 4.49) <0.001║ 
13,14-dihydro PGF2α a 48.4 (34.57, 67.91)  20.0 (14.82, 26.97) <0.001 
13,14-dihydro-15-keto PGF2α b 0.000 (0.000, 25.56) 0.000 (0.000, 12.79) 0.016 ║ 
13,14-dihydro-15-keto PGE2 a 3.67 (2.584, 5.217) 3.07 (2.172, 4.347) 0.459 
TXB2 a 10.3 (7.57, 14.14) 10.5 (6.08, 18.05) 0.968 
5-HETE a 124 (96.4, 160.4) 132 (103, 168) 0.738 
8-HETE 70.2 (56.77, 83.57) 74.5 (62.33, 86.60) 0.626 
9-HETE b 12.82 (0.00, 70.99) 0.000 (0.000, 70.99) 0.478 ║ 
11-HETE 62.3 (49.55, 75.13) 59.7 (49.68, 69.64) 0.736 
12-HETE b 146 (96.8, 1214.4) 144 (82.2, 1625.8) 0.580 ║ 
15-HETE 174 (145, 203) 186 (158, 214) 0.533 
20-HETE a 284 (232, 348) 290 (229, 367) 0.896 
5,6-DHET a 55.4 (47.09, 65.19) 52.0 (41.29, 65.37) 0.635 
8,9-DHET a 71.6 (62.75, 81.81) 82.1 (67.40, 99.95) 0.238 
11,12-DHET 204 (173, 235) 233 (207, 260) 0.147 
14,15-DHET 260 (231, 290) 312 (272, 352) 0.036 
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OxoODE, oxooctadecadienoic acid; HODE, hydroxyoctadecadienoic acid; EpOME, epoxyoctadecenoic 
acid; DiHOME, dihydroxyoctadecenoic acid; EKODE, epoxyketooctadecenoic acid; TX, thromboxane; 
HETE, hydroxyeicosatetraenoic acid; DHET, dihydroeicosatetraenoic acid; HETrE, 
hydroxyeicosatrienoic acid; HOTrE, hydroxyoctadecatrienoic acid; PG, prostaglandin; HEPE, 
hydroxyeicosapentaenoic acid; HDHA, hydroxydocosahexaenoic acid; MaR, maresin; 
DiHDPA,dihydroxydocosapentaenoic acid. 
Results are expressed as mean (95% CI), except a geometric mean (95% CI), b median (lower and upper 





Compound (ng/ml) Omnivore (n=24) Vegan (n=23) p value† 
n-3 PUFA-derived      
ALA-derived       
9 HOTrE a 139 (111, 173) 206 (170, 250) 0.007 
13 HOTrE a 150 (114, 198) 245 (201, 299) 0.005 
EPA-derived       
5-HEPE b 75.7 (0.000, 462.2) 21.4 (0.000, 107.5) <0.001 ║ 
8-HEPE b 15.2 (0.000, 219.0) 0.000 (0.000, 21.0) <0.001║ 
18-HEPE b 74.8 (0.000, 624.8) 0.000 (0.000, 150.2) <0.001 ║ 
DHA-derived       
4-HDHA b 75.8 (38.18, 413.41) 45.7 (0.000, 102.33) <0.001 ║ 
7-HDHA b 0.000 (0.000, 202.4) 0.000 (0.000, 125.8) 0.581 ║ 
10-HDHA b   20.5 (0.000, 197.11) 0.000 (0.000, 14.97) <0.001║ 
11-HDHA b   0.000 (0.000, 191.1) 0.000 (0.000, 0.000) 0.022 ║ 
13-HDHA b   19.3 (0.000, 87.86) 0.000 (0.000, 0.000) <0.001 ║ 
14-HDHA b   41.3 (0.000, 299.69) 0.000 (0.000, 57.82) <0.001 ║ 
17-HDHA b   0.000 (0.000, 364.5) 0.000 (0.000, 0.000) 0.001 ║ 
20-HDHA b   107.5 (44.09, 748.89) 25.4 (0.000, 105.46) <0.001║ 
19,20 DiHDPA a 1448 (1240, 1690)  1098 (878, 1374)  0.040 
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4.7.6 Heart rate and heart rate variability  
Twenty-four hour, day-time and sleep-time physical activity, heart rate and HRV are 
reported in Table 15. HRV parameters analysed from the data obtained from the Actiheart 
monitors are presented as IBI, time-domain, frequency-domain and non-linear parameters.  
The average recording time for the 24 h analysis was 21:02 (95% CI 20:11, 21:52) hours, 
for the day time analysis was 13:08 (95% CI 12:38, 13:38) hours and for the sleep time analysis 
was 5:56 (95% CI 5:25, 6:27) hours. Statistical significance was obtained for the following 
parameters over 24 h analysis: vegans had higher mean SDNN (172 vs. 145 ms), SDANN (155 
vs. 128 ms) and VLF (17980 vs. 12619 ms2). Differences in these parameters indicate greater 
variability in longer-phase cycles in the vegan group during the 24 h period, whereas beat-to-
beat (parasympathetically driven) variability (RMSSD, pNN50 and HF) and IBI/HR were not 
different between groups over the 24 h period. This is substantiated by much greater sleep-time 
minus day-time differences in mean IBI/HR, indicating that vegans experience a greater drop in 
HR from day to night compared to omnivores, due to having faster day-time HR.  
In contrast with the 24 h measurements, HRV was reduced in vegans in the day-time (8 h 
segment) compared to omnivores, even after adjusting for physical activity and other covariates. 
Vegans had significantly lower IBI (721 vs. 787 ms), SDNN (101 vs. 121 ms), RMSSD (25 vs. 
34 ms), pNN50 (2.7 vs. 6.6 ms), LF (628 vs. 908 ms2) and HF (135 vs. 260 ms2). Heart rate 
(reciprocal to IBI) was higher in vegans compared to omnivores but fell just short of statistical 
significance (p = 0.062). 
From the sleep-time analysis (2 h segments), no statistically significant differences were 
found between groups for any of the HRV parameters. The sleep-time minus day-time 
differences in HR/IBI were statistically significant, with the mean decrease in HR/increase in 
IBI from day-time to sleep-time being distinctly larger in vegans compared to omnivores. 
Vegans also presented with larger increases in beat-to-beat HRV parameters (RMSSD, HF, 
pNN50) during nocturnal sleep and smaller decreases in overall (SDNN) and longer-phase HRV 
(VLF).  
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Table 15 – Physical activity, heart rate and heart rate variability parameters of study participants over 24 h, day-time and sleep-time, with sleep-time – day-time 
differences (n=47). 
 Omnivore (n = 24)  Vegan (n = 22*) P § 
Twenty-four hour measurements   
Activity, IBI and HR    
  Physical activity (cpm)a†† 236 (196, 284) 285 (233, 348) 0.181 
  IBI (ms)††  845 (798, 892) 811 (760, 861) 0.336 
  HR (bpm)†† 75 (71, 79) 78 (74, 83) 0.210 
Time-domain HRV parameters    
  Ti 38 (33, 42) 41 (36, 46) 0.294 
  SDNN (ms)†† 145 (129, 162)   172 (154, 189) 0.039 
  SDANN (ms) 128 (114, 143) 155 (139, 170) 0.018 
  RMSSD (ms) a 35 (31, 40) 35 (30, 40) 0.905 
  pNN50 (%)a 8.9 (6.5, 12.2) 7.0 (5.0, 9.7) 0.299 
Frequency-domain HRV parameters    
  LF (ms2) a 971 (786, 1198) 761 (608, 953) 0.130 
  HF (ms2) a 350 (262, 467) 309 (227, 421) 0.567  
  VLF (ms2) a 12619 (10351, 15379) 17980 (14547, 22204) 0.022 
Non-linear methods    
  SD1:SD2 (Poincaré ratio)  0.13 (0.11, 0.14) 0.11 (0.10, 0.12) 0.051 
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 Omnivore (n = 24)  Vegan (n = 22*) P § 
Day-time (8 hours) measurement    
Activity, IBI and HR    
  Physical activity (cpm) a 437 (347, 552) 443 (345, 570) 0.935 
  IBI (ms) 787 (745, 830) 721 (675, 766) 0.039 
  HR (bpm) 80 (76, 84) 86 (81, 91) 0.062 
Time-domain HRV parameters    
  Ti 31 (28, 34) 27 (24, 31) 0.135 
  SDNN (ms) 121 (109, 132) 101 (89, 113) 0.021 
  SDANN (ms) 100 (89, 111) 84 (73, 96) 0.056 
  RMSSD (ms)  34 (30, 38) 25 (20, 30) 0.009 
  pNN50 (%) a 6.6 (4.6, 9.4) 2.7 (1.8, 3.9) 0.001 
Frequency-domain HRV parameters    
  LF (ms2)  908 (785, 1032) 628 (495, 761) 0.004 
  HF (ms2) a 260 (198, 342) 135 (100, 181) 0.002 
  VLF (ms2) a 8325 (6894, 10052) 6470 (5277, 7929) 0.078 
Non-linear methods    
  SD1:SD2 (Poincaré ratio)  0.15 (0.13, 0.16) 0.13 (0.11, 0.15) 0.125 
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 Omnivore (n = 24)  Vegan (n = 23) P § 
Sleep-time (2 hours) measurement    
IBI and HR    
  IBI (ms) 965 (903, 1026) 991 (925, 1056) 0.568 
  HR (bpm) 64 (61, 68) 62 (59, 66) 0.475 
Time-domain HRV parameters    
  Ti 19 (16, 22) 18 (16, 21) 0.762 
  SDNN (ms) 78 (68, 88) 85 (75, 96) 0.324 
  SDANN (ms) a 42 (36, 51) 44 (37, 54) 0.717 
  RMSSD (ms) a 38 (32, 45) 44 (37, 53) 0.214 
  pNN50 (%) a 10.9 (7.0, 16.9) 11.7 (7.3, 18.7) 0.826 
Frequency-domain HRV parameters    
  LF (ms2) a 882 (646, 1205) 902 (647, 1256) 0.925 
  HF (ms2) a 403 (280, 580) 464 (315, 684) 0.601 
  VLF (ms2) a 2881 (2215, 3744) 3519 (2661, 3744) 0.304 
Non-linear methods    
  SD1:SD2 (Poincaré ratio) a 0.27 (0.23, 0.32) 0.28 (0.24, 0.33) 0.740 
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 Omnivore (n = 24)  Vegan (n = 22*) P § 
Sleep-time – day-time differences    
IBI and HR    
  IBI (ms) 183 (139, 227) 270 (223, 317) 0.012 
  HR (bpm) -16 (-19, -13) -24 (-28, -20) 0.003 
Time-domain HRV parameters    
  Ti -12 (-15, -9) -9 (-12, -6) 0.185 
  SDNN -42 (-55, -29) -20 (-33, -6) 0.028 
  SDANN -52 (-65, -39) -39 (-53, -25) 0.184 
  RMSSD (ms)  8 (1, 14) 22 (15, 29) 0.006 
  pNN50 (%)  6.4 (0.9, 11.8) 14.2 (8.5, 20.1) 0.058 
Frequency-domain HRV parameters    
  LF (ms2) b 123 (-282, 461) 245 (5, 714) 0.235║ 
  HF (ms2) b 127 (-12, 417) 234 (84, 988) 0.095║ 
  VLF (ms2) -5836 (-7418, -4255) -3088 (-4746, -1431) 0.025 
Non-linear methods    
  SD1:SD2 (Poincaré ratio) 0.14 (0.10, 0.18) 0.16 (0.12, 0.20) 0.418 
Cpm, counts per minute; IBI, interbeat interval; bpm, beats per minute; HRV, heart rate variability; Ti, total number of all NN intervals divided by the height of the histogram of all 
NN intervals; SDNN, standard deviation of all NN intervals; ms, milliseconds; SDANN, standard deviation of the averaged NN intervals, calculated from 5 min epochs; RMSSD, the 
square root of the mean of the sum of squares of differences between adjacent NN intervals; PNN50, percentage of adjacent NN intervals that differed by more than 50ms; LF, low 
frequency power;  HF, high frequency power; VLF, very low frequency power; SD1:SD2,  the ratio of the SD of beat-to-beat IBI variability (SD1) against the SD of long-term IBI 
variability (SD2).  
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Results expressed as estimated marginal means (95% CI), adjusted for gender, age, BMI and 24 h activity for 24 h HRV and sleep-time – day-time HRV, or 8 h activity for 8 h day-
time, and adjusted for gender, age and BMI only for sleep-time. Sleep-time – day-time represents HR/IBI and beat-to-beat HRV during a standardized 2 h nocturnal sleep period 
minus a standardized 8 h day-time period, to indicate the difference between night and day. 
*Missing data from 1 subject due to unusable day-time HRV recording. 
§ P value obtained using analysis of covariance for normally distributed raw or LN transformed data (adjusted for gender, age, BMI and activity for 24 h, day-time and sleep-time – 
day-time differences, and adjusted for gender, age and BMI only for sleep-time), except for sleep-time – day-time differences in HF, where ║ denotes use of an unadjusted non-
parametric test, the Mann-Whitney U test, where data remained not normally distributed following LN transformation. a denotes geometric means (95% CI) and b denotes medians 
(lower and upper quartiles). 




It was hypothesised that LC n-3 PUFA status would be associated with parameters of 
cardiac autonomic regulation and to investigate this we compared HRV parameters and LC n-3 
PUFA status in vegans with an omnivore control group in a cross-sectional observational study. 
Vegans presented higher overall and longer-phase components of HRV over 24 h, but lower 
HRV, shorter IBI and higher HR in the day-time compared to omnivores. These results were 
substantiated by the fact that vegans had a greater sleep-time minus day-time differences in 
mean IBI/HR. 
4.8.1 Subject characteristic 
Vegan and omnivore subjects were successfully matched for age and BMI and there were 
no statistically significant differences in distribution of sex between groups, although the sex 
distribution wasn’t fully balanced. The anthropometry measurements - waist circumference and 
% body fat - didn't differ between groups. Seated DBP didn't differ between groups but seated 
SBP was significantly lower in vegans compared to omnivores. Two large studies directly 
compared blood pressure between vegans and omnivores: both the Adventist Health Study-2 
(AHS-2) and the EPIC-Oxford study reported lower SBP in vegans compared to omnivores 
(213,214). In contrast, vegans presented a higher resting HR as well as a significantly higher 
ambulatory daytime HR and, although not statistically significant, presented a higher 
ambulatory 24 h HR. Though there is no data published directly comparing vegan and omnivore 
subjects HR, there is evidence of increased concentrations of DHA in erythrocytes being 
associated with lower resting HR (215) and a meta-analysis of randomised, double-blind, 
placebo-controlled trials showed that consumption of fish oil reduced HR (216). The lower LC 
n-3 PUFA levels in vegan erythrocyte and plasma could be a possible explanation for their 
higher resting HR compared to omnivores.  
4.8.2 Plasma and erythrocyte membrane fatty acid composition 
Plasma and erythrocyte lipid fatty acid analysis were used as short- and long-term 
biomarkers of fatty acid intake, respectively, in order to assess adherence to a vegan diet. The 
vegan subjects have been on a vegan diet for at least 2 y which was also found to be the cut-off 
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considered for long-term vegans in other studies measuring the erythrocyte membrane fatty 
acids (217,218). There was a study in British vegans and vegetarians that didn’t show 
significant differences in the proportion of plasma LC n-3 PUFA according to duration of the 
diet between vegans and vegetarians that followed the diet from 1 y to 20 y (159). 
Plasma fatty acid analysis results showed a higher LA and ALA status in vegans 
compared to omnivores and erythrocyte fatty acid composition showed a higher LA status. 
Although the mean intake of ALA was greater in vegans compared to omnivores, the lack of a 
significant difference for erythrocyte ALA concentration may be explained by membrane 
saturation or by the greater LA intake of vegans resulting in a displacement of ALA (217). 
Vegan subjects showed significantly lower plasma and erythrocyte levels of DHA and EPA and 
a higher erythrocyte level of DPA n-3. These results were also shown by other published studies 
(159,218–220). The relatively lower intake of LA and the presence of preformed EPA and DHA 
in the diet of omnivores can explain the relatively higher proportion of EPA and DHA in the 
erythrocyte membrane and plasma compared with vegans. Because of the negligible intake of 
EPA and DHA, vegans are fully dependent on the endogenous synthesis of these fatty acids 
from ALA. The results show significantly higher levels of plasma ALA and LA in vegans 
compared to omnivores which suggest that the levels of EPA and DHA in plasma and 
erythrocytes found in vegans are derived from endogenous synthesis or, to some extent, from 
the triacylglycerols in adipose tissue, which has a half-life of 6 months to 2 years (221). There is 
evidence suggesting that humans can convert meaningful amounts of ALA to EPA and DHA 
when in the presence of a deficiency and this might explain the erythrocyte and plasma levels of 
EPA and DHA in vegans (157).  Also, the fact that the duration of the diet didn’t have an effect 
on the proportions of plasma EPA and DHA in a British vegan cohort, suggest that when 
excluding the foods with preformed EPA and DHA from the diet, the endogenous synthesis of 
EPA and DHA results in a low but stable plasma concentration of these fatty acids (159). The 
erythrocyte O3I in omnivores was double that in vegan (5.42 vs. 2.71 %). This index has been 
validated as a biomarker of tissue LC n-3 PUFA status (174). It has also been proposed as a 
marker for risk of death from coronary heart disease, with the greatest cardioprotection being 
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attributed to an O3I greater than 8% (205). The omnivore group in this study had an average 
O3I lower than 8%, and it was lower than the one reported in previous studies in UK 
populations (203,222,223). This could be attributable to a low overall fish-intake, as data from 
the latest National Diet and Nutrition Survey (NDNS) reported a mean oily fish consumption 
below the recommended amount in all age groups, with adults aged 19 to 64 consuming an 
average of 54 g per week (52 g for men and 54 g for women)7. An inverse relationship was 
observed between erythrocyte LA:ALA ratios and erythrocyte EPA content in vegans, 
supporting the existing evidence that higher dietary intakes of LA may inhibit the conversion of 
ALA to LC n-3 PUFA (224). 
4.8.3 HRV measurements 
It was hypothesised that vegans, who would have a lower LC n-3 PUFA status, would 
also display lower mean HRV. However, the observed differences between groups were more 
complex than hypothesised, mainly due to the divergence in night/day differences. Differences 
between groups in all primary outcome variables (HR/IBI, SDNN and RMSSD) were observed, 
but the inherent difference varied according to whether the analysis was performed over 24 h or 
only during day-time.  
4.8.3.1 24 h measurements 
Contrary to the hypothesis, vegans had higher overall (SDNN) and longer-phase 
components (SDANN and VLF) of HRV over 24 h, whereas IBI/HR and beat-to-beat variability 
(RMSSD, pNN50 and HF) were not different between groups over the 24 h period.  
Circadian changes are a key determinant of variability in HR over 24 h, measured as 
SDNN. Differences in mean nocturnal sleep-time and day-time IBI are a significant factor in the 
size of the SDNN value. Hence the higher overall variability being substantiated by a greater 
sleep-time minus day-time differences in mean IBI/HR, indicating that vegans experience a 
greater drop in HR from day to night compared with omnivores, due to having faster day-time 
HR.  
                                                     
7 National Diet and Nutrition Survey. Results from Years 1-4 (combined) of the Rolling Programme 
(2008/2009 – 2011/12) 
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The longer-phase components (SDANN and VLF) of 24 h HRV represent changes in HR 
in response to periodic fluctuations in neurohormonal and circadian physiology rather than beat-
to-beat variability. The higher 24 h SDANN and VLF presented by vegans may represent either 
more pronounced neurohormonal rhythms in vegans, or reflect the higher discrepancy in HR 
and HRV between sleep- and day-time in vegans or could be due to higher overall activity 
levels. Although activity levels between vegan and omnivores were not significantly different, 
vegans presented a trend towards higher activity levels over the 24 h recording. Overall, it has 
been shown that vegans tend to exercise regularly (225) which is not necessarily reflected by the 
activity level registered over only one 24 h recording. Healthy physically trained subjects have 
been shown to have enhanced circadian variation which is reflected in increased 
parasympathetic activity of the longer-phase components of the HRV (226), and hence could 
have impacted the results.  
4.8.3.2 Day- and sleep-time measurements 
In line with the hypothesis, vegans had higher HR and lower IBI, overall (SDNN) and 
beat-to-beat HRV (RMSSD, pNN50 and HF) during day-time. The lack of difference in sleep-
time HR between groups, together with observations of shorter IBI (and non-statistically 
significant greater HR) during the day in vegans, suggests that the larger night-day difference in 
vegans is a result of greater circadian fluctuations in sympathetic–parasympathetic balance. 
Sleep-time minus day-time HRV also reflects the degree of circadian modulation of autonomic 
regulation of HR in both vegans and omnivores. The larger increases in beat-to-beat HRV 
parameters (RMSSD, HF, pNN50) during nocturnal sleep may indicate a greater suppression of 
parasympathetic regulation during day-time waking hours in vegans when considered alongside 
the shorter mean day-time IBI in this group compared with omnivores. These observations 
might indicate that low LC n-3 PUFA status could lead to either a predominance of sympathetic 
regulation, a greater withdrawal of parasympathetic activity, or eventually, due to depletion of 
LC n-3 PUFA in the cardiomyocyte membranes, there could be a greater stimulation of 
pacemaker activity despite normal levels of sympathetic neural activity during waking hours 
(227). Nevertheless, there is the possibility that differences in HRV observed between vegans 
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and omnivores are unrelated to LC n-3 PUFA tissue status, although to test this possibility a 
dietary intervention trial would be required. In animal models the evidence suggests an effect of 
DHA in reducing HR via modulation of pacemaker activity rather than changes in cardiac 
autonomic regulation (84). 
To date, there has only been one published study assessing the effects of long-term 
vegetarian diets (> 2 y) on cardiac autonomic function, using frequency-domain HRV analysis, 
in healthy postmenopausal Chinese women (228). This study reported a higher day-time resting 
HF and LF power in vegetarians compared to non-vegetarians which is contrary to the results of 
this study. However, the HRV recording length of the postmenopausal Chinese women was 5 
minutes against 8 h in our day-time analysis.  
4.8.4 Lipid mediators and inflammatory markers 
The novel data derived from the lipidomic analysis allowed observation of different 
patterns of fasting plasma concentrations of lipid mediators in vegans and omnivores. Vegans, 
representing a population with no dietary intake of LC n-3 PUFA, presented lower or zero 
concentrations of DHA- and EPA-derived SPM precursor markers of resolvins (18-HEPE, 17-
HDHA), and maresins (14-HDHA), lower concentrations of markers of AA-derived prostanoid 
production (6-keto PGF1α – a marker of PGI2 synthesis, and 13,14-dihydro PGF2α/13,14-
dihydro-15-keto PGF2α – markers of PGF2α production) and greater concentrations of ALA- and 
LA-derived lipid mediators compared to omnivores. There were no differences between groups 
for a range of AA-derived LOX-catalysed mediators (HETE), suggesting that the lipid mediator 
profile of vegans may not necessarily be entirely pro-inflammatory relative to omnivores (227). 
17-HDHA (DHA-derived precursor marker of neuroprotection D1 – NPD1 – and RvD1) was 
not detected in the fasting plasma of any vegan subjects, whereas nine out of twenty-four 
omnivores had detectable concentrations. There were also marked differences in concentrations 
of 18-HEPE (EPA-derived precursor marker of RvE1) and 14-HDHA (DHA-derived precursor 
marker of MaR1). These same precursor markers concentrations were found to be increased 
following LC n-3 PUFA supplementation in healthy adults (229). The role of NPD1 in 
protecting the nervous system from inflammation-related injury shows that DHA-dependent 
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physiological mechanisms exist in synapses and neural circuits in order to sustain neuronal 
function (230,231). The higher levels of LA-derived lipid mediators in vegans is likely due to 
higher dietary intakes, which is supported by the FFQ estimates of dietary intake, proportions of 
total plasma fatty acids and incorporation into erythrocyte membrane lipids (232,233). Although 
plasma ALA proportions were higher in vegans, reported dietary intakes didn’t differ. However, 
FFQ estimates of dietary intakes are likely to underestimate true intakes due to incomplete food 
composition data. LA-derived lipid mediators, namely 9- and 13-HODE, and 9- and 13-
oxoODE have been implicated in a variety of diseases, including  CVD, and lowering dietary 
LA was shown to reduce the levels of these bioactive LA-derived metabolites (232). On the 
other hand, ALA-derived lipid mediators, including 13-HOTrE, have been shown to have 
cytoprotective effects in cell experiments (234).  
Although no differences were found in IL-6 concentrations, an inflammatory marker, 
between vegans and omnivores, this does not necessarily indicate that there are no differences 
between groups in their capacity to inhibit or resolve acute inflammatory events, since 
circulating cytokine concentrations have limited utility as biomarkers of inflammation that may 
be occurring in localised areas of tissue (227). Previous studies have shown that serum IL-6 
concentrations were inversely correlated with HRV in men with renal disease (93),  men with 
the metabolic syndrome (235) and young healthy subjects (88), although not all studies agree 
(89). Down-regulation of inflammatory cytokine gene expression plus increased production of 
pro-resolving lipid mediators are two potential mechanisms whereby cardiac function might 
possibly be modulated by increased EPA and DHA intakes, by reducing inflammatory tissue 
damage in the brain and autonomic nerves, and also in the heart tissue itself. 
4.8.5 Biochemistry profile and dietary intake  
The biochemistry profile of vegans presented significantly lower levels of total 
cholesterol and LDL cholesterol with no significant differences in the levels of glucose, 
triacylglycerol, HDL cholesterol or haemoglobin. A lower total and LDL-cholesterol levels 
have been previously reported in studies comparing vegans with omnivores (236–238). This 
could be associated with reported dietary intakes of SFA (%E) in vegans being almost half the 
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dietary intake of omnivores, in agreement with results reported in larger vegan populations 
(239), and correspondingly lower amounts of palmitic acid as a proportion of total plasma fatty 
acids. However, these differences are less likely to have a major influence on cardiac 
electrophysiology since animal studies have shown that PUFA feeding decreased vulnerability 
to arrhythmia compared with high SFA feeding without any reduction in the proportion of 
membrane SFA, and high-MUFA feeding did not reduce arrhythmia compared with high-SFA 
diets (240). This suggests that SFA membrane composition is not a major determinant of 
vulnerability to arrhythmias and addition of LC n-3 PUFA (replacing mainly oleic acid and n-6 
PUFA) might be the most important determinant. In fact, erythrocyte SFA proportions were not 
significantly different between groups and vegans presented lower daytime HRV, and therefore 
potentially a greater risk of arrhythmia if there was also coronary atherosclerosis present, 
despite lower SFA intake (227). There was one study in post-menopausal women that showed a 
significant moderate negative correlation between LDL and HRV (LF and HF power) measured 
over 5-min rest (53). However, the strength of correlations found between LDL and HRV 
parameters in the present study were weak (data not shown). 
The dietary intake of vegan subjects varied significantly from the omnivore subjects, with 
significantly lower intakes of protein, saturated fat, EPA and DHA and significantly higher 
intakes of carbohydrates, PUFA and LA, in accordance with other studies results (236,241,242). 
Although intake of vitamin B12 was significantly lower in vegan compared to the omnivore 
subjects, serum concentrations were not statistically significantly lower. This might be because 
supplements were not included in the FFQ analysis due to incomplete information provided 
about the type of some supplements. In this study, all subjects had serum concentrations of 
vitamin B12 within the normal ranges (180-1100 ng/L), as defined by the clinical biochemistry 
department at KCH, except for an omnivore participant that presented a concentration of 1168 
that could be explained by the intake of vitamin B12 rich supplements. Broad cut-off points for 
vitamin B12 deficiency have been reported by different authors which makes comparison of 
prevalence of vitamin B12 deficiency with other published studies difficult (243). Although the 
lower serum concentrations of vitamin B12 in vegans not obtaining a statistically significant 
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difference from omnivores, the results agree with previous studies showing a lower average 
serum concentration of vitamin B12 in vegans compared to omnivores (244). Vitamin D levels 
were not significantly different between groups, which is likely to be due to the significantly 
higher vitamin D supplement use in vegans compared to omnivores. Nevertheless, the nature of 
the study design doesn’t allow to exclude the influence of other dietary or lifestyle factors on 
HRV related with the vegan lifestyle. 
4.8.6 Strengths and limitations of the present study 
The strengths of this study include: 1) the distinctive type of population studied, since 
vegan diets are naturally free from EPA and DHA, representing a model of LC n-3 PUFA tissue 
deficiency; 2) measurement of plasma and erythrocyte membrane LC n-3 PUFA, which 
complements the data obtained from the FFQ as a biomarker of dietary intake; and 3) the 
novelty of measuring the lipid mediator profile in unsupplemented dietary n-3 PUFA free-living 
humans. 
The limitations of this study include the cross-sectional design, which limits the findings 
to being exploratory in nature and the associations between low LC n-3 PUFA status and 
reduced HRV requiring confirmation by a RCT of EPA + DHA supplementation in a population 
with a low O3I (<3%). On the other hand, the FFQ has only been previously validated in the 
general population and therefore not specific for the vegan diet, which might have over or 
underestimated certain nutrients intake. The FFQ presents limitations related to recall bias and 
measurement errors, including the errors derived from assuming a set portion size for each food 
group amongst others. However, from a subset of participants (12 omnivores and 8 vegans) that 
completed 4-day food diaries, the nutritional analysis obtained from these (data not shown) 
supported the data obtained with the FFQ. Although statistical power calculations were carried 
out for the primary HRV outcomes, the study may be underpowered to detect group differences 
in other variable outcomes such as beat-to-beat HRV. Multiple statistical testing was performed 
to explore group differences in short- and long-term, as well as time- and frequency-domain 
HRV, increasing the risk of generating false-positive results. There is no agreed upon method 
for correcting statistical analyses that involve the full set of HRV measures, but the data set 
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represents groupings of related outcomes rather than a large collection of disparate variables. 
The data presented here are consistent when comparing variables that represent similar 
physiological phenomenon. For example, there are two time-domain (RMSSD, pNN50) and one 
frequency-domain (HF) parameters of beat-to-beat variability. These are all vagally regulated 
and all show consistently that day-time beat-to-beat HRV is lower in vegans compared with 
omnivores. Therefore, although type I errors cannot be ruled out with complete certainty, it is 
reassuring that statistically significant differences between groups are supported by analogous 
parameters. Although there were no statistically significant differences in sex distribution 
between groups, matching for sex was not fully achieved. Nevertheless, any influence of this 
imbalance in sex distribution on HRV results was minimised by adjusting for sex in addition to 
age, BMI and activity levels for 24 h and day-time HRV. Technical problems in obtaining good 
quality sleep-time HRV data limited the standardised duration of sleep-time HRV to 2 h which 
may have led to effects on longer phase-HRV parameters being missed. 
  
In conclusion, this study shows differences in the cardiac autonomic regulation in vegans 
and omnivores with vegans presenting higher HRV over 24 h due to greater sleep-day 
differences compared to omnivores. This was mostly due to vegans presenting relatively lower 
HRV in the day-time rather than higher HRV at night, as no sleep-time differences were 
observed. This could indicate a greater predominance of sympathetic activity with reduced 
parasympathetic activity during waking hours due to an exaggerated response to various daily 
events and/or activities, or could be a direct effect of a low proportion of LC n-3 PUFA in the 




Chapter 5 Heart rate variability and long chain n-3 polyunsaturated 
fatty acids in chronic kidney disease patients on haemodialysis: a 
cross-sectional study 
5.1 Introduction 
Cardiovascular disease is particularly prevalent in CKD (44), and accounts for 43% of 
all-cause mortality among dialysis patients (45), compared to an estimated 11% of deaths in the 
general population (245). It has been observed that the risk of SCD is doubled when a patient 
with CKD stage 5 starts dialysis (46) and in haemodialysis, SCD accounts for two thirds of all 
cardiac deaths and one fourth of all-cause mortality (45). 
Haemodialysis patients have lower serum LC n-3 PUFA levels compared to control 
populations without CKD (246,247), and lower serum LC n-3 PUFA : AA ratios were 
predictive of CVD events (247). Fish consumption has been associated with reduced mortality 
in an observational study with incident dialysis patients (248), and Friedman et al suggested an 
inverse association between erythrocyte LC n-3 PUFA levels and mortality in haemodialysis 
patients  (249). Although evidence from RCT in end stage renal disease is essential before 
recommendations are made, preliminary observational data indicates that supplementation with 
LC n-3 PUFA (20:5n-3, EPA and 22:6n-3, DHA), may have the potential to offer a safe, side-
effect-free therapy to reduce SCD risk in patients initiating haemodialysis. Clinical trials that 
addressed SCD as a primary outcome in non-CKD populations are scarce due to low statistical 
power in most study populations. The “OMEGA” multicentre RCT defined SCD as a primary 
outcome but reported no reduction in risk in myocardial infarction survivors following LC n-3 
PUFA supplementation on top of modern guideline-adjusted medication, with low SCD rates of 
1.5% in both intervention and placebo groups, and post-hoc calculated statistical power at only 
44% (150,250). The earlier, pre-statin era GISSI-Prevenzione trial, in 11,323 myocardial 
infarction survivors, showed a significant reduction in SCD after just 4 months of treatment 
(0.88 g/d EPA+DHA) (251). The adequately-powered GISSI-Heart Failure trial demonstrated a 
non-significant relative risk of 0.93 in 6975 chronic congestive heart failure patients (average 
3.9 y follow-up, 0.88 g/d EPA+DHA) (141).  
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End-stage CKD patients are a population with low HRV indicating autonomic 
dysfunction (252) and low HRV has been reported to be independently associated with 
increased risk of all-cause mortality, SCD and all cardiac death in haemodialysis patients (253–
255). The pathogenesis of CVD in patients with CKD differs from the general population due to 
the prevalence of non-traditional risk factors, such as oxidative stress, inflammation, 
endothelium dysfunction and altered electrolyte balance (256) which results in lower 
effectiveness of the current treatments targeting traditional cardiovascular risk factors (such as 
statins, blood-pressure lowering and anti-platelet drug therapy) (257) and the need to explore 
other treatment options. LC n-3 PUFA presents as a good candidate for risk prevention in this 
population due to their potential anti-inflammatory, anti-oxidative and anti-arrhythmic effects 
on the cardiac myocytes (84,258,259). Mixed results have been obtained in previous 
investigations into the effect of LC n-3 PUFA on HRV in healthy subjects but there is stronger 
evidence in myocardial infarction survivors of benefits from fish oil supplementation (260). 
Few studies have investigated the relationship between LC n-3 PUFA and HRV in CKD 
patients. A pilot RCT in patients undergoing dialysis (n = 29) tried to assess the effects of fish 
oil supplementation on HRV but due to the high number of drop-outs (4 and 6 patients in the 
intervention and control groups, respectively), the two groups were not compared. Instead, the 
remaining patients with good quality Holter recordings (n = 17) were used to assess the 
relationship between SDNN and LC n-3 PUFA content in granulocytes. The findings showed a 
positive correlation between the content of EPA, DHA and total LC n-3 PUFA, and SDNN in 
these patients (106).  A subgroup (n = 30) of the chronic haemodialysis patient population used 
in a parallel design study on n-3 PUFA and cardiovascular events (261), was used to determine 
the effect of 1.7 g/d EPA+DHA on HRV after 3 months of intake (111). HRV parameters were 
found to be unaffected after 3 months supplementation, although this study was hampered by 
lack of statistical power, short duration, and the limited range of HRV parameters measured. 
Due to the equivocal findings and lack of studies investigating the relationship between LC n-3 
PUFA and HRV as a primary outcome, at present it is unclear whether low EPA+DHA tissue 
status (as indicated by the erythrocyte O3I) in end stage renal disease patients is associated with 
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HRV, and whether supplementation to increase EPA+DHA tissue status would be effective in 
improving autonomic function and cardiovascular outcomes. 
5.2 Hypothesis 
It is hypothesised that the proportion of EPA+DHA in the erythrocyte membrane – a 
biomarker of longer-term dietary intake – will be independently positively associated with HRV 
in patients with CKD stage 5 who have recently commenced haemodialysis.  
5.3 Aims 
This study aimed to test the feasibility of applying this cross-sectional study design on a 
larger scale by 1) establishing the viability of measuring erythrocyte membrane LC n-3 PUFA 
content as a biomarker of longer-term dietary intake, and 2) characterising the variability of LC 
n-3 PUFA status in patients who have recently commenced haemodialysis, since low variability 
in the population would preclude meaningful statistical tests of associations with HRV. The 
study also aimed to collect pilot data on relationships between erythrocyte membrane LC n-3 
PUFA status and HRV in these patients. 
5.4 Methods 
5.4.1 Study design 
This was a cross-sectional pilot study that characterised the tissue LC n-3 PUFA status of 
CKD patients who have recently started haemodialysis treatment and explored a potential 
relationship with HRV parameters.  
5.4.2 Ethics and consent 
Ethical approval was obtained from NRES Committee London – Camberwell St Giles 
(REC ref: 14/LO/0186). The study was registered on clinicaltrials.gov (NCT02014792) and 
conducted at King’s College Hospital (KCH) and Guy’s and St Thomas’ Trust (GSTT) and their 
respective satellite units. Figure 19 shows the locations visited for recruitment, taking consent 




Figure 19 – Location of the units included in the study. Legend: 
1 – Astley Cooper Dialysis unit, Guy’s hospital 2 – Borough Kidney Treatment Centre 
3 – Camberwell satellite dialysis unit  4 – Victor Parsons Haemodialysis Unit, KCH 
5 – Dulwich satellite dialysis unit & Dulwich mobile dialysis unit, Dulwich community hospital 
6 -  New Cross Gate Satellite Dialysis Unit  7 – Forest Hill Satellite Dialysis Unit 
8 – Sydenham Satellite Dialysis Unit  9 – King’s at Bromley Satellite Dialysis Unit  
10 – Woolwich Satellite Dialysis Unit, Queen Elizabeth Hospital 
5.4.3 Outcome measures 
The primary outcome of the study was the relationship between HR and HRV parameters 
during haemodialysis - more specifically 24 h SDNN and triangular index, which are reflective 
of overall HRV - and the proportion of EPA + DHA (O3I) in the erythrocyte membrane. The 
secondary outcomes include other time- and frequency-domain, and non-linear  HRV 
parameters, during 2 h dialysis, 24 h and sleep-time, plasma proportions of EPA, DPA and 
DHA, background diet (using food frequency questionnaires) and clinical risk factors, including 
history of sleep apnoea or suspected sleep apnoea (using Epworth Sleepiness Scale and Berlin 
Questionnaire, described in section 5.5.3), waist circumference, 12 month average SBP and 
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DBP and BP variability prior to starting haemodialysis, hs-CRP at start of dialysis session, 
serum creatinine, GFR, albumin, sodium, potassium, phosphate and calcium before and after the 
dialysis session; to assess the contribution of these risk factors to any relationships observed 
between HRV and erythrocyte membrane LC n-3 fatty acid composition. 
5.4.4 Inclusion and exclusion criteria 
The inclusion criteria were women and men with CKD stage 5 commencing haemodialy-
sis (6 to 10 weeks after the first session), aged 40-80 years and able to provide written informed 
consent. 
The exclusion criteria included unwilling to participate, history of chronic liver disease or 
neuropathy, infection or antibiotics within the last month and history of prior renal replacement 
therapy including transplantation. 
5.4.5 Participants and recruitment 
Potential participants were patients under the care of a Nephrologist. Only members of 
the clinical care team did the electronic search of patient records for suitable patients for the 
study and to check whether they met the inclusion criteria. The study team included members of 
the renal clinical team, who were associated with the study directly. Patients were identified 
through the course of usual clinical care, or via an efficient electronic database search conducted 
by Dr Helen MacLaughlin and Dr. Nicola Kumar (and Dr. Jasmine Lee while Dr. Kumar was 
on maternity leave) at King’s College Hospital and Guy’s and St Thomas’ Trust, respectively. 
Once a list of potential eligible patients was obtained, the nurses would approach the patient 
first asking if they were willing to talk to the PhD student, and then the student would approach 
each patient to give an explanation about the study and leave them with a patient information 
sheet (Appendix 6) before coming back another day to answer any questions the patient may 
have about the study and obtain written informed consent. Once consent was obtained, the study 
visits were scheduled for all the outcome measurements. Patients had haemodialysis treatment 
three times a week for a varied prescribed amount of time (usually 3 h to 4 h) and these oc-
curred in two different schedules, Monday, Wednesday and Fridays or Tuesday, Thursdays and 
Saturdays where the treatment could happen in the morning, afternoon or evening. The patients 
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would have to enrol in the study shortly after commencing haemodialysis treatments (and the 
study days were chosen in order to avoid the session right after the two consecutive days of in-
tradialytic period, also known as the "long gap" (Monday or Tuesday), when uraemia was in-
creased, and to maintain consistency throughout the study). Once the consent was obtained, the 
two study dates were agreed with the patients and then added to the patient’s medical diary so 
that the nurse in charge would be aware of when blood samples (pre- and post-dialysis) were 
needed.  
5.5 Study days 
An overall outline of the study days can be found in Figure 20. In both study visits, pre- 
and post-dialysis blood sample were taken by a nurse to measure electrolytes, including sodium, 
potassium, phosphate and calcium; and hs-CRP and to measure erythrocyte membrane and 
plasma fatty acid composition in pre-dialysis blood only. Waist circumference was taken on 
patient’s arrival on the first study visit before going on the dialysis machine. Immediately after 
the nurse started the patient on haemodialysis treatment, the PhD student would fit the monitor 
to record HR and HRV for a 24 h period. Patients were also asked to complete a FFQ and an 
Epworth sleepiness scale and Berlin questionnaire in the first study visit. Additional information 
was obtained from the medical records including patient's medical history, ethnicity, date of 
birth, pre- and post-dialysis weight and fluid removal in study days, current medication, any 
side effects or serious adverse events during the first 6 weeks of haemodialysis, and the 
previous 12 month average SBP and DBP (before starting haemodialysis). All patients 









5.5.1 HRV measurements 
Heart rate variability was measured using the Actiheart monitoring equipment 
(CamNtech Ltd, Cambridge, UK). Two ECG electrodes (SP-50, 50 mm round, Pulse Medical) 
were placed on the chest after skin preparation to fit the Actiheart monitor. A short signal test of 
around 5 minutes was performed before programming for the 24 h recording to confirm that the 
level of R wave signal being picked up by the Actiheart was adequate. Data processing of the 24 
h HRV recordings was carried out using the Actiheart software (version 4.0.91, CamNtech Ltd, 
Cambridge, UK) and Kubios HRV analysis software (Biosignal Analysis and Medical Imaging 
Group, Department of Physics, University of Kuopio, Finland). For more detailed information 
please refer to the general methods chapter (Chapter 2, section 2.1). Patients were given an 
activity and event diary (Appendix 7) to complete with information about the duration of 
dialysis, type of activities done, and nap and sleep times at night. HRV and HR/IBI data were 
analysed for a standardised 2 h of haemodialysis (from the moment the monitors were fitted), 
for the full length of recording time (minimum of 18 h, up to 24 h) and sleep time. 
5.5.2 Dietary assessment 
The EPIC-Norfolk FFQ (pages 2 to 10) was used in this study to assess patients’ 
background diet over the past 12 months. Further details about the questionnaire can be found in 
Chapter 4 (section 4.5.3).  
5.5.3 Epworth sleepiness scale and Berlin questionnaire 
The Epworth Sleepiness Scale (ESS, Appendix 8) is a validated method of assessing the 
likelihood of falling asleep in a variety of situations. The maximum score is 24 and can be used 
to clinically subdivide the patients into either the normal range (ESS˂11), mild subjective 
daytime sleepiness (ESS=11-14), moderate subjective daytime sleepiness (ESS=15-18) or 
severe subjective daytime sleepiness (ESS>18) (262).  
The Berlin Questionnaire (Appendix 8) asks about risk factors for sleep apnoea, namely 
snoring behaviour, wake time sleepiness or fatigue, and the presence of obesity or hypertension. 
Predetermination of high risk and lower risk for sleep apnoea was based on responses in three 
symptom categories. In category 1, high risk was defined as persistent symptoms (>3 to 4 times 
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/ week) in two or more questions about their snoring. In category 2, high risk was defined as 
persistent (>3 to 4 times / week) wake time sleepiness, drowsy driving, or both. In category 3, 
high risk was defined as a history of high blood pressure or a BMI more than 30 kg/m2. To be 
considered at high risk for sleep apnoea, a patient had to qualify for at least two symptom 
categories. 
5.5.4 Blood sample collection, handling and analysis  
Pre- and post-dialysis blood samples collected in SSTTM tubes were used to determine 
serum sodium, potassium, phosphate and calcium as well as albumin, creatinine and eGFR 
(estimated GFR according to CKD-EPI formula) before and after dialysis session and sCRP 
before dialysis. These analyses were performed by a clinical pathology accredited clinical 
biochemistry laboratory (ViaPath, Kings College Hospital). Pre-dialysis blood samples 
collected in EDTA tubes were used to determine erythrocyte membrane fatty acid composition 
(in percentage weight) and plasma fatty acid composition (concentration and percentage 
weight). These analyses took place at King's College London and were performed by the student 
with the help of technician Robert Gray. 
5.6 Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics 21.0 (Statistical Product 
and Service Solutions; IBM Corp.). Paired t-tests and Pearson correlations between first and 
second visits were performed for HR/IBI, HRV measurements and erythrocyte membrane and 
plasma fatty acid composition to test for intra-subject reproducibility. Subsequently the values 
were averaged in all subjects that had recordings for both visits for the final analysis. Pearson 
correlation coefficients were used to test the strength of correlations between variables in hae-
modialysis patients. Non-normally distributed data were normalised by natural logarithm (LN) 
before performing the correlations. Chi-square (χ 2) test and independent t-tests were used to 
compare categorical and continuous variables, respectively, between haemodialysis patients and 
a healthy cohort. Non-normally distributed data were normalised by LN transformation (results 
shown as geometric means and 95% CI) before analysis by independent t-test. If LN transfor-
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mation failed to yield a normal distribution, a Mann–Whitney U test was applied to compare 
groups (results shown as medians with lower and upper quartiles). 
5.7 Results 
Figure 21 shows the flow of participants through the study. Of the 49 patients consented, 
there were 3 withdrawals due to 2 patients not feeling well before the start of the first study day 
and 1 patient that was transferred out to a unit that was not associated with KCH or GSTT. One 
patient became ineligible due to start of peritoneal dialysis before the first study visit. Forty-five 
patients completed the first study visit and 31 completed both study visits. The reasons for pa-
tients not completing the second study visit were: unwilling to carry on the study, study visits 
rescheduling problems, patient transfers, and patients becoming unwell. Of the 45 patients, 39 
patients had good quality HRV recordings to be included in the 2 h dialysis period, 40 had good 
quality sleep-time HRV recordings (minimum 3 h period) and 35 had good quality 24 h record-
ings (minimum 18 h period). There was only one patient where it was not possible to obtain 
erythrocyte membrane fatty acid composition due to technical issues. 
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Figure 21 - Consort diagram. 
 
Characteristics of the patients enrolled in the study are presented in table 16. Data were 
not equally available for all patients either due to unwillingness to complete the questionnaires/ 
undergo certain measurements, because the data were not available electronically on the 
medical records, or due to issues taking a blood sample or transporting samples by medical 
courier. For this reason, the number of data points available for each variable are displayed on 
the table. Most patients presented hypertension and the second most common co-morbidity was 
type 2 diabetes. Nearly half the patients were taking statins, β-blockers and iron injections and 






Table 16 - Characterisation of the study population (n=45). 
Study population (n=45) 
 Mean SD N % 
Age (years) 58 9   
Sex     
     Male   25 55.6 
     Female   20 44.4 
Ethnicity     
     White   20 44.4 
     Black   19 42.2 
     Other   6 13.3 
Waist Circumference (cm)     
     Male 105.6 13.2 17  
     Female 97.1 19.4 12  
BMI (kg/m2) 27.8 7.0 45  
Average SBP (mmHg)* 141 16 33  
Average DBP (mmHg)* 76 9 33  
Fluid removal (L) 2.0 0.8 45  
Pre- and post-dialysis measurements 1 42  
    Pre-dialysis creatinine (μnol/L) 585 192   
    Post-dialysis creatinine (μnol/L) 228 100   
    Pre-dialysis albumin (g/L) b 38 (36, 40)   
    Post-dialysis albumin (g/L) b 40 (37, 44)   
    Pre-dialysis sodium (mmol/L) b 139.3 (137.6, 141.0)   
    Post-dialysis sodium (mmol/L) b 138.0 (137.0, 139.0)   
    Pre-dialysis calcium (mmol/L) 2.17 0.15   
    Post-dialysis calcium (mmol/L) 2.25 0.19   
    Pre-dialysis potassium (mmol/L) a 5.1 (4.9, 5.4)   
    Post-dialysis potassium (mmol/L) a 3.8 (3.6, 3.9)   
Co-morbidities 2     
     Hypertension   40 90.8 
     Coronary artery disease   5 11.4 
     Peripheral vascular disease   2 4.5 
     Heart failure   3 6.8 
     Cerebrovascular disease   3 6.8 
     Type 2 Diabetes    17 38.6 
     Hyperlipidaemia    9 20.5 
     Anaemia    5 11.4 
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 Mean SD N % 
Medications     
     ACE inhibitor   11 25.0 
     ARB   10 22.7 
     β-blocker   20 45.5 
     α-blocker   12 27.3 
     Diuretic   10 22.7 
     Statin   21 47.7 
     Insulin   11 25.0 
     Anti-diabetic   6 13.6 
     Anti-depressant  6 13.6 
     Vitamin D   25 56.8 
     Calcium-based phosphate binders  18 40.9 
     Iron injections  21 47.7 
Subjective daytime sleepiness  31  
     Normal  23 74.2 
     Mild   5 16.1 
     Moderate   1 3.2 
     Severe   2 6.5 
Risk of sleep apnoea   31  
     High  20 64.5 
     Low  11 35.5 
Fish and seafood intake (times/week)  35  
     All fish and seafood 2.4 2.3   
     Oily fish 0.6 0.6   
Nutritional intake   34  
     Energy (kcal) 1846 889   
     Protein (%E) 17.3 4.3   
     Carbohydrate (%E) 47.4 8.3   
     Total fat (%E) 34.4 6.8   
     SFA (%E) 12.7 3.1   
     MUFA (%E) 13.2 3.0   
     PUFA (%E) 5.9 1.7   
     20:5n-3, EPA (g) 0.14 0.11   
     22:6n-3, DHA (g) 0.44 0.34   
* 12 months prior to commencing HD aGeometric means (95%CI) b Median (IQR) 
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor antagonists; BMI, body mass index; 
DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; MUFA, 
monounsaturated fatty acids; %E, percentage of energy; PUFA, polyunsaturated fatty acids; SBP, systolic 
blood pressure; SFA, saturated fatty acids. 1 eGFR measures were not included in the table as these are 
not valid in haemodialysis patients. 2 Information taken from medical records with no further details on 
the approach used to diagnose. 
 
As expected, there were no significant differences between visit 1 and visit 2 for all HRV 
parameters during dialysis (n = 23), sleep time (n = 24) and 24h (n = 19), and also for erythro-
cyte membrane EPA, DHA and O3I (n = 26) and plasma EPA and DHA (n=31). All HRV pa-
rameters were significantly correlated with the same HRV parameters between the two study 
visits for dialysis (range of strength of correlations was moderate to strong: 0.578 < r < 0.880 
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and p values < 0.01), sleep-time (range of strength of correlations was moderate to strong: 0.468 
< r < 0.913 and p values < 0.05) and 24 h (range of strength of correlations was moderate to 
strong: 0.630 < r < 0.812 and p values < 0.01). Significant moderate to strong correlations were 
found between the two study visits measurements of erythrocyte membrane EPA (r = 0.687, p < 
0.001), DHA (r = 0.497, p = 0.010) and O3I (r = 0.538, p = 0.005) and plasma EPA (r = 0.729, p 
< 0.001), DPA(n-3) (r = 0.907, p < 0.001) and DHA (r = 0.885, p <0.001). 
Figure 22 shows the spread of average erythrocyte membrane LC n-3 PUFA and O3I in 
the study population. The mean O3I of this population was very low (below 4%), and only 2 
individuals had omega-3 indices greater than 5%. Variability in erythrocyte EPA (median [low-
er and upper quartile], 0.66 % [0.50, 0.89]) and DHA (mean ± SD, 2.6 % ± 0.94) was limited in 
this patient population, with 50% of omega-3 indices falling between 2.5% and 3.8%. and vari-
ability was lower in EPA content compared to DHA content as is observed in healthy popula-
tions, such as the MARINA study (EPA, median [lower and upper quartile], 1.16 % [1.00, 1.49] 
and DHA, mean ± SD, 6.6 % ± 1.42; refer to table 20). There was a strong significant correla-
tion between plasma EPA and erythrocyte membrane EPA (r = 0.704; p < 0.001), and between 
plasma DHA and erythrocyte membrane DHA (r = 0.608; p < 0.001), which was similar to the 
ones seen in the age- and sex-matched healthy cohort (erythrocyte EPA and plasma EPA: r = 
0.773 and p < 0.001; erythrocyte DHA and plasma DHA: r = 0.504 and p = 0.001). No correla-
tions were found between plasma or erythrocyte LC n-3 PUFA proportions and estimated 
PUFA, EPA, DHA or oily fish intake assessed by FFQ (Table 17). 
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Table 17 - Correlations between LC n-3 PUFA dietary intake and plasma and erythrocyte membrane LC n-3 PUFA in the study population (n = 35). 
Dietary intake Plasma EPA (%) a Plasma DHA (%) Erythrocyte EPA (%) a Erythrocyte DHA (%) Omega-3 index (%) 
 r p r p r p r p r p 
PUFA (%) 0.264 0.131 0.050 0.779 0.247 0.159 0.045 0.800 0.125 0.481 
PUFA (g) 0.083 0.642 0.018 0.918 0.038 0.831 0.045 0.802 0.023 0.897 
EPA (g) 0.159 0.369 0.048 0.788 -0.125 0.483 0.142 0.422 0.057 0.749 
DHA (g) 0.299 0.086 0.149 0.400 0.119 0.502 0.191 0.280 0.185 0.295 
Oily fish  
(times per week) 
0.261 0.130 0.118 0.499 0.196 0.258 0.159 0.360 0.201 0.247 
Total seafood  
(times per week) 
0.156 0.369 0.022 0.512 -0.115 0.512 0.068 0.699 0.019 0.912 




Figure 22 - Spread of erythrocyte membrane LC n-3 fatty acid composition in the study 
population. 
 
Results presented as median (interquartile range in lower and upper box borders, with 95% confidence 
interval t-bars). 
 
Figure 23 shows the correlations from the primary outcome variables, which assessed the 
relationship between O3I (erythrocyte membrane EPA + DHA) and 24 h SDNN and Ti. The 
relationship between 24 h HR and parameters reflecting vagal activity (RMSSD and HF) and 
O3I was also plotted. HF power correlated positively with the O3I, but no other statistically sig-
nificant correlations were observed. 
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Figure 23 - Scatter diagrams of the relationship between erythrocyte membrane EPA+DHA (Omega-3 index) and HR (r = -0.248; p = 0.150), SDNN (r = 0.130; p = 
0.456), Ti (r = 0.181; p = 0.298), RMSSD (r = 0.191; p = 0.272) and HF (r = 0.381; p = 0.024) in 24 h measurements in haemodialysis patients (n = 35). 
 
   Each figure presents linear regressions (fitted straight lines) with 95% confidence intervals (curve lines).  
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Table 18 further explored the relationship between HRV parameters and erythrocyte 
membrane O3I, as well as with EPA and DHA individually. Table 19 presents similar compara-
tive data for plasma EPA, DPA(n-3) and DHA, which were secondary outcomes of this study. 
Data was presented unadjusted and p values for 3 adjustment models were included, the first 
model adjusted for age alone, the second model adjusted for age, BMI and β-blocker usage 
(Yes/No), and the third model adjusted for age, BMI, β-blocker usage (Yes/No), diabetes 
(Yes/No) and hs-CRP.  
Erythrocyte membrane. During dialysis the only significant correlation found was an in-
verse relationship between HR and EPA which remained significant after adjusting for the age 
but presented only a trend after further adjustments for BMI and β-blocker usage were made, 
and lost significance once further adjustments for diabetes and hs-CRP were made. The only 
relationship between HRV and LC n-3 PUFA found during sleep-time was a positive correlation 
between HF power and O3I, which remained significant after adjustment for age but lost signif-
icance after further adjustments for BMI and β-blocker usage, diabetes and hs-CRP. In the 24 h 
period, EPA was positively correlated with Ti, SDNN, SDANN and VLF power but after full 
adjustments only Ti remained statistically significant; DHA and O3I were positively correlated 
with LF and HF power and this association remained significant after further adjustments only 
for the association between LF power and DHA and kept a trend for the association between 
DHA and HF power, and between O3I and LF power. 
Plasma. During dialysis the only significant correlation found was a positive relationship 
between DHA and Ti and VLF power, which remained statistically significant after full adjust-
ment for potential known confounders. In sleep-time no significant correlations were observed 
after full adjustments. The more interesting results were found over 24 h measurements where 
EPA significantly correlated with overall and longer phase components of HRV (SDANN, VLF 
power and trend for SDNN) and significantly negatively correlated with beat-to-beat variability 
(RMSSD, pNN50 and trend for HF power) after full adjustments. In line with the correlations 
between EPA and beat-to-beat variability, DPA(n-3) was also significantly negatively correlated 
with 24 h HF power, with a trend for RMSSD and pNN50.  
141  
Table 18 - Correlation between erythrocyte membrane LC n-3 PUFA and HRV parameters during dialysis, sleep time and 24h in study participants. 
 EPA a     DHA     Omega-3 Index    
 r p1 p2 p3 p4 r p1 p2 p3 p4 r p1 p2 p3 p4 
Dialysis 
(n=36) 
               
  HR (bpm) -0.339 0.035 0.050 0.086 0.108 -0.251 0.123 0.127 0.298 0.360 -0.344 0.032 0.038 0.124 0.159 
  IBI (ms) 0.204 0.212 0.237 0.582 0.677 0.187 0.253 0.260 0.302 0.527 0.230 0.160 0.172 0.255 0.482 
  Ti 0.229 0.160 0.351 0.582 0.682 0.231 0.157 0.137 0.056 0.126 0.263 0.106 0.126 0.060 0.158 
  SDNN (ms) 0.209 0.202 0.390 0.668 0.774 0.101 0.542 0.535 0.347 0.199 0.133 0.419 0.493 0.354 0.249 
  SDANN (ms) 0.157 0.339 0.497 0.656 0.563 0.143 0.387 0.388 0.339 0.306 0.166 0.313 0.357 0.329 0.287 
  pNN50 (%) a 0.079 0.631 0.624 0.984 0.996 0.090 0.584 0.589 0.430 0.202 0.100 0.546 0.550 0.445 0.243 
  RMSSD (ms) -0.101 0.541 0.519 0.333 0.479 -0.042 0.801 0.803 0.991 0.721 -0.080 0.626 0.625 0.775 0.931 
  LF (ms2) a 0.292 0.071 0.210 0.378 0.700 0.095 0.565 0.534 0.263 0.107 0.154 0.350 0.426 0.217 0.145 
  HF (ms2) a 0.062 0.708 0.815 0.713 0.694 0.129 0.433 0.439 0.186 0.128 0.120 0.466 0.498 0.271 0.231 
  logLF:HF 0.259 0.111 0.270 0.174 0.365 -0.092 0.579 0.539 0.528 0.617 -0.013 0.937 0.775 0.800 0.809 
  VLF (ms2) 0.265 0.103 0.234 0.439 0.562 0.137 0.404 0.388 0.279 0.183 0.189 0.249 0.299 0.236 0.188 
  SD1:SD2 a -0.190 0.246 0.355 0.284 0.459 -0.029 0.863 0.868 0.993 0.850 -0.085 0.608 0.666 0.766 0.975 
Sleep time (n=39)               
  HR (bpm) -0.270 0.097 0.091 0.154 0.221 -0.093 0.574 0.579 0.840 0.804 -0.169 0.304 0.310 0.522 0.840 
  IBI (ms) 0.258 0.113 0.113 0.182 0.292 0.081 0.625 0.631 0.850 0.804 0.154 0.349 0.360 0.532 0.869 
  Ti 0.297 0.067 0.091 0.429 0.638 0.059 0.722 0.732 0.701 0.933 0.173 0.293 0.327 0.879 0.976 
  SDNN (ms) 0.222 0.175 0.281 0.693 0.917 0.023 0.891 0.906 0.703 0.859 0.132 0.424 0.493 0.916 0.948 
  SDANN (ms) 0.145 0.377 0.409 0.680 0.961 -0.035 0.831 0.830 0.521 0.968 0.063 0.702 0.725 0.759 0.902 
  pNN50 (%) a 0.006 0.969 0.948 0.308 0.578 0.174 0.289 0.298 0.654 0.851 0.183 0.264 0.285 0.846 0.926 
  RMSSD (ms) -0.005 0.977 0.868 0.332 0.622 0.144 0.382 0.229 0.435 0.674 0.140 0.396 0.253 0.602 0.740 
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 EPA a     DHA     Omega-3 Index    
 r p1 p2 p3 p4 r p1 p2 p3 p4 r p1 p2 p3 p4 
Sleep time (continued)              
  LF (ms2) a 0.262 0.107 0.255 0.928 0.641 0.217 0.186 0.174 0.309 0.731 0.289 0.074 0.097 0.323 0.893 
  HF (ms2) a 0.181 0.271 0.395 0.644 0.815 0.288 0.075 0.077 0.207 0.547 0.350 0.029 0.0.37 0.247 0.544 
  logLF:HF 0.074 0.655 0.881 0.609 0.787 -0.118 0.474 0.460 0.674 0.648 -0.110 0.505 0.429 0.719 0.490 
  VLF (ms2) a 0.263 0.105 0.199 0.474 0.847 -0.050 0.763 0.740 0.421 0.613 0.073 0.659 0.764 0.663 0.770 
  SD1:SD2 a -0.171 0.299 0.351 0.194 0.568 0.209 0.202 0.204 0.267 0.513 0.127 0.440 0.415 0.515 0.659 
24 h (n=35)                
  HR (bpm) -0.210 0.225 0.219 0.436 0.370 -0.211 0.223 0.239 0.430 0.744 -0.248 0.150 0.154 0.308 0.532 
  IBI (ms) 0.246 0.154 0.165 0.316 0.256 0.209 0.228 0.253 0.414 0.622 0.256 0.137 0.152 0.256 0.362 
  Ti a 0.500 0.002 0.017 0.047 0.029 0.036 0.837 0.838 0.677 0.781 0.181 0.298 0.645 0.998 0.743 
  SDNN (ms) 0.381 0.024 0.123 0.336 0.313 0.000 1.000 0.666 0.342 0.833 0.130 0.456 0.886 0.484 0.871 
  SDANN (ms) 0.369 0.029 0.130 0.271 0.249 -0.041 0.815 0.502 0.255 0.624 0.084 0.631 0.906 0.390 0.935 
  pNN50 (%) -0.009 0.960 0.904 0.251 0.140 0.209 0.227 0.233 0.351 0.372 0.232 0.180 0.179 0.432 0.570 
  RMSSD (ms) -0.179 0.304 0.352 0.059 0.053 0.225 0.193 0.137 0.201 0.200 0.191 0.272 0.184 0.359 0.444 
  LF (ms2) a 0.268 0.119 0.664 0.331 0.452 0.313 0.067 0.105 0.145 0.038 0.387 0.022 0.072 0.222 0.070 
  HF (ms2) a 0.042 0.810 0.962 0.055 0.080 0.346 0.042 0.036 0.068 0.071 0.381 0.024 0.022 0.149 0.187 
  logLF:HF 0.281 0.102 0.635 0.305 0.205 0.017 0.923 0.572 0.786 0.840 0.069 0.692 0.553 0.918 0.609 
  VLF (ms2) 0.382 0.023 0.084 0.187 0.186 -0.025 0.886 0.632 0.377 0.846 0.102 0.561 0.913 0.588 0.776 
  SD1:SD2 a -0.310 0.070 0.214 0.099 0.073 0.202 0.244 0.110 0.102 0.189 0.108 0.539 0.227 0.197 0.433 
p1 - unadjusted; p2 adjusted for age; p3 adjusted for age, BMI and 𝛽-blockers; p4 adjusted for age, BMI, -blockers, diabetes and hs-CRP. 24h HRV analysis has activity level from 
accelerometery data (cpm) as an additional adjustment for p2, p3 and p4. 




Table 19 - Correlation between plasma LC n-3 PUFA and HRV parameters during dialysis, sleep time and 24h in study participants. 
 EPA a     DPA a     DHA     
 r p1 p2 p3 p4 r p1 p2 p3 p4 r p1 p2 p3 p4 
Dialysis 
(n=39) 
               
  HR (bpm) -0.173 0.292 0.328 0.614 0.761 0.125 0.448 0.400 0.433 0.253 -0.298 0.065 0.082 0.101 0.141 
  IBI (ms) 0.181 0.271 0.290 0.493 0.626 -0.106 0.522 0.500 0.589 0.383 0.239 0.143 0.158 0.128 0.203 
  Ti 0.232 0.156 0.200 0.167 0.181 0.029 0.862 0.946 0.988 0.870 0.328 0.042 0.065 0.022 0.042 
  SDNN (ms) 0.237 0.146 0.186 0.159 0.186 -0.003 0.983 0.814 0.879 0.671 0.252 0.122 0.178 0.081 0.100 
  SDANN (ms) 0.256 0.116 0.142 0.104 0.029 0.055 0.737 0.836 0.795 0.642 0.270 0.096 0.129 0.105 0.061 
  pNN50 (%) a 0.035 0.833 0.834 0.843 0.778 -0.090 0.584 0.588 0.637 0.564 0.056 0.737 0.737 0.567 0.530 
  RMSSD (ms) -0.150 0.363 0.363 0.236 0.438 -0.213 0.193 0.193 0.196 0.342 -0.120 0.468 0.463 0.605 0.923 
  LF (ms2) a 0.156 0.344 0.450 0.441 0.850 -0.051 0.758 0.490 0.496 0.085 0.239 0.142 0.223 0.076 0.233 
  HF (ms2) a 0.025 0.879 0.924 0.817 0.762 -0.133 0.419 0.384 0.376 0.317 0.120 0.468 0.519 0.254 0.256 
  logLF:HF 0.145 0.378 0.481 0.328 0.919 0.102 0.537 0.696 0.742 0.611 0.100 0.546 0.757 0.781 0.742 
  VLF (ms2) 0.314 0.051 0.066 0.050 0.070 0.084 0.609 0.764 0.667 0.932 0.332 0.039 0.060 0.027 0.042 
  SD1:SD2 a -0.252 0.121 0.146 0.074 0.192 -0.213 0.192 0.232 0.244 0.514 -0.202 0.218 0.272 0.337 0.625 
Sleep time (n=40)               
  HR (bpm) -0.173 0.285 0.251 0.318 0.552 0.099 0.545 0.576 0.673 0.357 -0.227 0.158 0.146 0.210 0.418 
  IBI (ms) 0.178 0.271 0.244 0.296 0.629 -0.077 0.636 0.661 0.778 0.356 0.216 0.180 0.170 0.218 0.502 
  Ti 0.250 0.119 0.161 0.282 0.447 -0.077 0.636 0.556 0.548 0.274 0.173 0.286 0.341 0.599 0.776 
  SDNN (ms) 0.190 0.239 0.325 0.473 0.866 0.056 0.730 0.832 0.810 0.543 0.083 0.609 0.709 0.970 0.509 
  SDANN (ms) 0.252 0.116 0.138 0.201 0.444 0.191 0.238 0.265 0.293 0.584 0.083 0.613 0.660 0.876 0.837 
  pNN50 (%) a -0.191 0.237 0.223 0.095 0.303 -0.356 0.024 0.023 0.023 0.088 -0.078 0.631 0.619 0.309 0.567 
  RMSSD (ms) -0.234 0.146 0.128 0.081 0.201 -0.306 0.055 0.052 0.063 0.168 -0.148 0.362 0.344 0.232 0.358 
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p1 - unadjusted; p2 adjusted for age; p3 adjusted for age, BMI and 𝛽-blockers; p4 adjusted for age, BMI, -blockers, diabetes and hs-CRP. 24h HRV analysis has activity level from 
accelerometery data (cpm) as an additional adjustment for p2, p3 and p4. 
a Correlations based on LN variables  
  
 EPA a     DPA a     DHA     
 r p1 p2 p3 p4 R p1 p2 p3 p4 r p1 p2 p3 p4 
Sleep time (continued)              
  LF (ms2) a 0.052 0.752 0.978 0.753 0.055 -0.100 0.538 0.410 0.440 0.020 0.107 0.511 0.637 0.823 0.336 
  HF (ms2) a -0.065 0.692 0.593 0.285 0.307 -0.218 0.176 0.149 0.133 0.146 0.040 0.808 0.877 0.765 0.719 
  logLF:HF 0.142 0.383 0.490 0.414 0.451 0.151 0.353 0.419 0.425 0.535 0.067 0.679 0.775 0.616 0.519 
  VLF (ms2) a 0.272 0.090 0.147 0.226 0.769 0.098 0.545 0.665 0.634 0.628 0.128 0.431 0.542 0.754 0.727 
  SD1:SD2 a -0.355 0.025 0.035 0.026 0.231 -0.372 0.018 0.024 0.033 0.242 -0.157 0.333 0.386 0.311 0.793 
24 h (n=35)                
  HR (bpm) -0.197 0.258 0.273 0.454 0.249 0.123 0.483 0.496 0.557 0.767 -0.294 0.086 0.088 0.170 0.172 
  IBI (ms) 0.259 0.133 0.154 0.251 0.146 -0.078 0.658 0.656 0.751 0.875 0.328 0.055 0.061 0.103 0.110 
  Ti a 0.369 0.029 0.077 0.112 0.114 -0.164 0.345 0.241 0.260 0.068 0.306 0.073 0.222 0.244 0.185 
  SDNN (ms) 0.483 0.003 0.010 0.025 0.089 0.036 0.836 0.946 0.893 0.416 0.274 0.112 0.309 0.506 0.530 
  SDANN (ms) 0.511 0.002 0.006 0.013 0.047 0.068 0.698 0.781 0.734 0.587 0.260 0.131 0.337 0.525 0.544 
  pNN50 (%) -0.317 0.064 0.058 0.019 0.037 -0.378 0.025 0.028 0.028 0.083 -0.028 0.873 0.833 0.636 0.654 
  RMSSD (ms) -0.395 0.019 0.023 0.009 0.015 -0.362 0.032 0.033 0.037 0.063 -0.082 0.639 0.732 0.573 0.621 
  LF (ms2) a 0.138 0.428 0.915 0.732 0.429 -0.055 0.755 0.508 0.525 0.184 0.259 0.132 0.462 0.574 0.602 
  HF (ms2) a -0.179 0.305 0.243 0.037 0.055 -0.293 0.088 0.073 0.045 0.048 0.098 0.575 0.655 0.986 0.918 
  logLF:HF 0.371 0.028 0.090 0.054 0.137 0.269 0.119 0.119 0.125 0.324 0.223 0.197 0.676 0.481 0.557 
  VLF (ms2) 0.503 0.002 0.006 0.013 0.043 0.038 0.827 0.912 0.850 0.536 0.262 0.129 0.285 0.422 0.445 
  SD1:SD2 a -0.574 <0.001 0.001 0.001 0.004 -0.363 0.032 0.038 0.045 0.168 -0.212 0.221 0.451 0.453 0.499 
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The low spread of LC n-3 PUFA erythrocyte levels in this study population prevented 
grouping the patients according to a low, medium and high O3I to further explore the relation-
ship between HRV and LC n-3 PUFA tissue status. For this reason, comparisons with matched 
healthy participants from the MARINA study (see Chapter 3, page 79 for study details) were 
made for sleep time HRV. Table 20 shows the comparison of haemodialysis patients with a 
subgroup of age- and sex-matched healthy participants from the MARINA study. Compared to 
the healthy cohort, haemodialysis patients showed significantly higher HR and lower HRV dur-
ing sleep as well as significantly lower proportions of erythrocyte membrane LC n-3 PUFA, 
while not reporting significantly different EPA and DHA dietary intakes.  
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Table 20 - Inflammatory marker, LC n-3 PUFA tissue status and HRV during sleep time in 
haemodialysis patients compared to age- and sex-matched healthy controls from the MARINA 
study. 
 Haemodialysis cohort  
(n = 42) 
Healthy cohort  
(n = 42) 
p value † 
Sex (M:F) 22 : 20  
Age (y) 57 ± 8  
Ethnicity (White:Black:Other) 19 : 18 : 5 32 : 7 : 3 0.013 § 
BMI (kg/m2) 27.6 ± 7.0 26.1 ± 3.4 0.231 
hs-CRP (mg/L) a 5.0 (3.3, 7.6) 0.6 (0.4, 0.9) <0.001 
EPA dietary intake (mg/day) 0.09 (0.06, 0.14) 0.10 (0.07, 0.13) 0.732 
DHA dietary intake (mg/day) 0.27 (0.16, 0.45) 0.18 (0.13, 0.25) 0.176 
Erythrocyte EPA (%) a 0.6 (0.54, 0.77) 1.2 (1.09, 1.35) <0.001 
Erythrocyte DPA (%) a 1.5 (1.37, 1.63) 3.3 (3.1, 3.5) <0.001 
Erythrocyte DHA (%) 2.6 ± 0.94 6.6 ± 1.42 <0.001 
Omega-3 index (%) 3.4 ± 1.17 7.9 ± 1.67 <0.001 
Plasma EPA (%) a 0.8 (0.63, 0.91) 1.0 (0.91, 1.18) 0.007 
Plasma DPA (%) a 0.44 (0.40, 0.47) 0.64 (0.60, 0.68) <0.001 
Plasma DHA (%) 1.8 ± 0.65 2.4 ± 0.63 <0.001 
HR and HRV parameters  
Sleep time 
N = 40 N = 40  
  HR (bpm) 77.4 ± 12.1 64.6 ± 9.7 <0.001 
  IBI (ms) 800 ± 133 962 ± 115 <0.001 
  Ti  12.2 ± 3.8 22.6 ± 6.3 <0.001 
  SDNN (ms) 53.1 ± 16.7 94.3 ± 25.9 <0.001 
  pNN50 (%) a 2.6 (1.7, 4.1) 6.2 (4.1, 9.5) 0.006 
  RMSSD (ms) a 23.5 (19.9, 27.8) 34.4 (29.4, 40.4) 0.001 
  LF (ms2)  a 104 (79, 137) 655 (504, 852) <0.001 
  HF (ms2)  a 106 (76, 148) 316 (231, 432) <0.001 
  logLF:HF -0.01 ± 0.82 2.64 ± 1.91 <0.001 
  VLF (ms2)  a 1514 (1257, 1824) 4932 (4132, 5888) <0.001 
  SD1:SD2 a 0.24 (0.21, 0.29) 0.20 (0.17, 0.23) 0.073 
BMI, body mass index; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; DPA, docosapentae-
noic acid; EPA, eicosapentaenoic acid; HR, heart rate; PUFA, polyunsaturated fatty acids; SBP, systolic 
blood pressure. Results expressed as a ratio or mean ± SD, except a Geometric means (95%CI) and † p 
value obtained by independent t-test, except § χ2 test. 
 
 
Figure 24 shows the correlations between the primary outcome variables during sleep-
time in the haemodialysis patients and the healthy cohort. There were no significant correlations 
within each group. There was only a trend for a positive relationship between O3I and HF in the 
haemodialysis group but after further adjustments there was no longer statistical significance.  
  
147  
Figure 24 - Scatter diagrams of the relationship between erythrocyte membrane EPA + DHA (Omega-3 index) and Ti (r = 226; p = 172 vs. r = 0.006; p = 0.969), 
SDNN (r = 0.199; p = 0.230 vs. r = -0.084; p = 0.595), HR (r = -0.118; p = 0.481 vs. r = -0.147; p = 0.352), RMSSD (r = 0.146; p = 0.383 vs. r = 0.111; p = 0.484) 
and HF (r = 0.313; p = 0.056 vs. r = 0.115; p = 0.469) during sleep-time in haemodialysis patients (n = 40) and age- and sex-match healthy cohort (n = 40) 
respectively.  
 
 Each figure presents linear regressions (fitted straight lines) for each group with respective 95% confidence intervals (curve lines).
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In order to assess how the HRV in this population of patients compares with similar pa-
tient populations reported previously, table 21 and table 22 show HRV during dialysis and 24h, 
respectively, in the current population (FISHH study, UK) with other published studies. Com-
pared to other studies measuring HRV during dialysis, the FISHH study presented HR values 
similar to the ones reported in the other UK study population during the first hour of dialysis 
(263) and similar to the group that presented ischaemic lesions in the French study population 
(264). Overall, the HRV across the studies was depressed, particularly the frequency-domain 
indices, compared to healthy populations. The FISHH study presented lower HRV during dialy-
sis, although better LF : HF ratio in both dialysis and 24 h, and lower IBI and overall HRV 
(SDNN and SDANN) but higher 24 h beat-to-beat variability (pNN50, RMSSD and HF power). 
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Table 21 - Comparison of the present study (FISHH study) with other published studies on HRV parameters measured during haemodialysis in stage 5 CKD 
patients. 










 N = 39 N = 35 N = 56 N = 76 N = 18 N = 14 
1st h on HD 
 






  HR (bpm) 77.2 ± 15.0   77 ± 11 80 ± 14 71 ± 10 75 ± 9 
  IBI (ms) 787 ± 131       
  Ti 11.0 ± 3.6       
  SDNN (ms) 45.8 ± 13.9 36.3 ± 10.6 88 ± 13     
  SDANN (ms) 32.7 ± 12.6  72 ± 14     
  pNN50 (%) 1.7 (1.0, 2.8) a 27.6 ± 2.3 9.2 ± 2.5   3.8 ± 5.2 2.6 ± 4.7 
  RMSSD (ms)  22.5 (18.4, 27.4) a 22.3 ± 6.2    24.5 ± 18 22.2 ± 15 
  LF (ms2)  89 (62, 128) a 53 ± 21 586 ± 108 x x 107 * 81 * 
  HF (ms2)   97 (67, 142) a 53 ± 11 312 ± 62 x x 48 * 38 * 
  LF:HF 0.98 (0.85, 1.13) a 1.02 ± 0.85 1.40 ± 0.08   3.40 ± 2.66 2.70 ± 2.25 
  logLF:HF -0.02 ± 0.43   0.39 ± 0.27 0.43 ± 0.33   
  VLF (ms2) 1338 ± 821       
  SD1:SD2  0.27 (0.23, 0.33) a       
Results expressed as mean ± SD, except a Geometric means (95% CI) x Values measured in Hz so these are not comparable. *Values were unlogged from the paper to allow for com-
parison, therefore SD is unobtainable.  
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Table 22 - Comparison of the present study (FISHH study) with other published studies on 24h HRV parameters in stage 5 CKD patients undergoing haemodialysis. 












China / Japan 
 Fukuta (253) 
Japan 
 
 N = 35 N = 15 N = 239 N = 237 N = 146 N = 99 N = 10 N = 11 










  HR (bpm) 83.0 ± 10.9 73.8 ± 8.5       
  IBI (ms) 747 ± 102 824 ± 102 812 ± 217 777 ± 97 775 ± 105 748 ± 98 718 ± 120 750 ± 57 
  Ti 19.7 (17.1, 22.8) a     25.4 ± 8.9 17.9 ± 6.2 30.2 ± 13.8 
  SDNN (ms) 84.1 ± 25.6 100 ± 45 79.1 ± 40.3 111 ± 33 85 ± 34 96.8 ± 32.3 77.5 ± 35.0 104.7 ± 48.1 
  SDANN (ms) 76.2 ± 25.6 90 ± 45  103 ± 32 80 ± 32    
  pNN50 (%) 4.8 ± 4.0   3.16 ± 5.96 2.19 ± 4.86    
  RMSSD (ms)  29.0 ± 11.7 21.2 ± 14.6  19 ± 11 17 ± 9    
  LF (ms2)  95 (68, 132) a  106 (48.0, 204) b 119 * 42 * 113 * 57 * 107 * 
  HF (ms2)   118 (88, 158) a  42.4 (29.4, 56.3) b 38 * 26 * 81 * 90 * 97 * 
  LF:HF 0.80 (0.61, 1.05) a  2.37 (1.43, 3.93) 1.33 ± 0.25 1.17 ± 0.29 1.82 ± 1.34 0.77 ± 0.44 1.60 ± 1.81 
  LogLF:HF -0.22 ± 0.79        
  VLF (ms2) 4844 ± 3218     503* 209* 469* 
  SD1:SD2  0.17 (0.14, 0.20) a        
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 N = 35 N = 29 N = 18 N = 14 




  HR (bpm) 83.0 ± 10.9  74 ± 11 77 ± 10 
  IBI (ms) 747 ± 102 752 ± 131   
  Ti 19.7 (17.1, 22.8) a    
  SDNN (ms) 84.1 ± 25.6 86 ± 31   
  SDANN (ms) 76.2 ± 25.6    
  pNN50 (%) 4.8 ± 4.0  4.5 ± 2.7 1.7 ± 1.4 
  RMSSD (ms)  29.0 ± 11.7  27.7 ± 13.4 19.7 ± 6.8 
  LF (ms2)  95 (68, 132) a  133 * 73 * 
  HF (ms2)   118 (88, 158) a  65 * 38 * 
  LF:HF 0.80 (0.61, 1.05) a  3.37 ± 2.61 2.85 ± 2.61 
  LogLF:HF -0.22 ± 0.79    
  VLF (ms2) 4844 ± 3218    
  SD1:SD2  0.17 (0.14, 0.20) a    
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Table 23 presents similar comparative data for erythrocyte and serum/plasma LC n-3 
PUFA composition. The present study (FISHH, UK), presents the lowest erythrocyte membrane 
DHA proportions, which translated in the lowest O3I, compared to the other studies that report-
ed comparable results in haemodialysis patients. The studies in Japanese and Korean popula-
tions presented particularly high proportions of EPA + DHA. Plasma proportions of EPA + 
DHA was more homogeneous across the studies, although the FISHH study had EPA and DHA 
proportions amongst the lowest compared to the other haemodialysis populations, except for the 
USA study populations. 
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Table 23 - Comparison of the present study (FISHH study) with other published studies on erythrocyte membrane and plasma/serum LC n-3 PUFA levels in stage 5 
CKD patients. 




N = 176 
Japan 
Hamazaki (269) 
N = 12 
Japan 
Oh (270) 









N = 14 
South Africa 
Erythrocyte membrane °       
  20:5n-3, EPA (%) 0.65 (0.54, 0.76) a 2.0 ± 1.0  1.98 ± 1.03 3.03 ± 1.92 0.23 ± 0.06 0.20 ± 0.07 
  22:6n-3, DHA (%) 2.51 (2.22, 2.83) a 7.7 ± 1.1  6.62 ± 2.20 10.03 ± 1.68 4.33 ± 0.83 3.74 ± 0.81 
  Omega-3 Index (%) 3.24 (2.90, 3.62) a   8.59 ± 2.98 13.07 ±3.02   
Serum / Plasma        
  20:5n-3, EPA (%) 0.75 (0.32, 0.91) a  1.2 ± 0.7   0.26 ± 0.14  
  22:6n-3, DHA (%) 1.78 ± 0.62  1.9 ± 0.6   3.00 ± 0.90  
Results expressed as mean ± SD, except a Geometric means (95% CI). ° N=44 due to technical issue with one sample 
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Table 23 (continued) - Comparison of this study (FISHH study) with other published studies on erythrocyte membrane and plasma/serum LC n-3 PUFA levels in 
stage 5 CKD patients. 
 FISHH study Saifullah (274) 














Erythrocyte membrane °       
  20:5n-3, EPA (%) 0.65 (0.54, 0.76) a 0.3 ± 0.2  0.29 ± 0.08   
  22:6n-3, DHA (%) 2.51 (2.22, 2.83) a 2.9 ± 2.0  4.65 ± 0.92   
  Omega-3 Index (%) 3.24 (2.90, 3.62) a   4.95 ± 0.95   
Serum / Plasma       
  20:5n-3, EPA (%) 0.75 (0.32, 0.91) a 0.5 ± 0.4 0.46 ± 0.45 0.35 ± 0.32 1.3 ± 0.6 1.58 ± 1.35 
  22:6n-3, DHA (%) 1.78 ± 0.62 1.7 ± 0.6 1.59 ± 0.55 1.33 ± 0.38 4.3 ± 0.8 4.07 ± 1.35 




This study is the first to characterise the variability of erythrocyte membrane LC n-3 
PUFA in patients who have recently commenced haemodialysis as well as exploring 
relationships with HRV parameters. Moreover, this is also the first known study to date to 
determine LC n-3 PUFA levels in haemodialysis patients in a UK-based population. 
Haemodialysis patients in other countries have been shown to have lower EPA, DHA, or both 
EPA + DHA, in erythrocyte membranes and / or plasma compared to healthy controls or healthy 
populations (246,272,275,277,278). Only one study by Friedman et al. showed a greater 
erythrocyte DHA and O3I, but lower plasma DHA, in haemodialysis patients (n=75) compared 
to a healthy control (n=25) (276). Compared to other haemodialysis cohorts, the mean levels of 
DHA and O3I in the present study population were amongst the lowest, and were markedly 
lower than an age- and sex-matched healthy cohort.  
Erythrocyte membrane fatty acid composition is considered to be a better marker of 
cardiovascular protection compared to plasma, as it has been shown to be more reflective of the 
cardiomyocytes fatty acid composition (174). None of the patients in this study presented an 
O3I above 8% which has been associated with the greatest cardio-protection and the mean 
O3Imega-3 index was below 4%, which has been associated with the least cardio-protection 
(205). This may reflect background diet to some degree, although this was not supported by 
food frequency questionnaire data on self-reported fish intake, or it may be due to the high level 
of uraemia presented right before dialysis as the uraemic nature of the blood samples posed an 
additional challenge to determine the erythrocyte membrane fatty acid composition. It is most 
likely that the major contributing factor to low LC n-3 PUFA content in erythrocytes is related 
to the pathology of kidney disease. Anaemia is prevalent in stage 5 CKD mainly due to low 
production of erythropoietin, a hormone produced by the kidney that regulates erythrocyte 
production from the bone marrow (necessitating erythropoietin therapy in most haemodialysis 
patients), and also as a result of uraemic inhibitors of erythrocyte production (279). Other 
factors include reduced lifespan of erythrocytes due to oxidative stress, inflammation and 
haemolysis, which may be a limitation in using erythrocyte membrane fatty acid composition as 
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a marker of general tissue membrane fatty acid status (cardiac myocytes, neurons, etc). Thus, 
although the utility of erythrocyte fatty acid composition as a biomarker of moderate-long term 
dietary intake has been established in other populations (280), the same relationships with 
dietary intake and tissue status cannot be assumed in populations in the advanced stages of 
CKD. These relationships are likely to be further disrupted in patients receiving haemodialysis 
due to haemodialysis-related factors such as chronic inflammation, oxidative stress and altered 
lipid metabolism/uptake into membranes. Our data show that variability in erythrocyte LC n-3 
PUFA contents is indeed limited to a small range, and it is unknown whether this is an accurate 
representation of general tissue status. 
The main findings from this study were that the primary HRV outcomes, 24 h SDNN and 
Ti, did not correlate with O3I and further analysis didn’t find any correlations between O3I and 
other HRV parameters in dialysis, sleep-time or 24 h. The only correlations that were still 
significant after all adjustments for potential confounders were between 24 h LF power and 
DHA, and between Ti and EPA which due to the amount of correlations performed could be a 
type I error. The lack of relationship between HRV and LC n-3 PUFA in this study could also 
be due to the limited variability of erythrocyte membrane EPA, DHA and O3I in this 
population. For this reason, it seems unlikely that the erythrocyte membrane O3I would be a 
good marker for LC n-3 PUFA content of other tissues relevant to cardiac autonomic function, 
such as the heart and neural tissue in patients on haemodialysis. Previously, there were no 
published studies correlating frequency-domain HRV parameters with LC n-3 PUFA. Only two 
published studies to date assessed the relationship between LC n-3 PUFA and time-domain 
HRV in stage 5 CKD patients on dialysis; Christensen et al found positive correlations between 
granulocyte EPA, DHA and total LC n-3 PUFA content and 24 h SDNN in 17 patients on 
haemodialysis or peritoneal dialysis after a fish-oil vs. olive oil dietary intervention (106), and 
Svensson et al measured LC n-3 PUFA in serum phospholipids in 30 patients and found no 
correlations with HRV measurements at baseline (111). Madsen et al. has conducted a RCT, 
placebo-controlled, double blind study investigating the effect of LC n-3 PUFA infusion on 
plasma and platelet phospholipids fatty acid composition and HRV but to date only the data on 
LC n-3 PUFA was published (281). Plasma EPA significantly positively correlated with overall 
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and longer phase components of HRV (SDANN, VLF power and trend for SDNN) and 
significantly negatively correlated with beat-to-beat variability (RMSSD, pNN50 and trend for 
HF power) over 24 h after full adjustment for main potential known confounders. As there were 
no correlations with 24 h DHA, the fact that increases in EPA significantly correlate with 
decreases in beat-to-beat variability may suggest that these patients could have a limit degree of 
conversion of EPA to DHA. Further analysis revealed that DPA(n-3), the next fatty acid in the 
interconversion cascade from EPA to DHA, was significantly negatively correlated with the 
same beat-to-beat HRV parameters (HF power and trend for pNN50 and RMSSD), but had no 
correlations with the longer-phase components. This indicates that a greater EPA (but not DPA 
or DHA) proportion in plasma, is associated with better overall and longer-phase autonomic 
regulation, generating the hypothesis that greater availability of EPA-derived lipid mediators 
may be involved in increased responsivity of HR to factors such as circadian fluctuations in 
hormone secretion and baroreflex. However, the beat-to-beat-regulation seems to be negatively 
affected by greater proportions of EPA, and the same trend for DPA, which suggests that a 
compromised conversion of DPA to DHA might reduce parasympathetic tone due to reduced 
availability of DHA in the membranes of cardiomyocytes and/or a reduction in DHA-derived 
lipid mediators involved in neuroprotective processes in this patient population. 
Patients in the FISHH study had SDNN measurements amongst the lowest in comparison 
to other HD cohorts. This could be partly explained by duration of HD treatments being that 
these were patients that recently started HD (measurements taken between 6 and 10 weeks of 
commencing treatment). Although commencing HD is associated with autonomic dysfunction, 
Tamura et al. reported the lowest SDNN levels in patients on HD for less than 30 months 
compared to those above 30 months (282). Moreover, after the start of HD treatments 
autonomic dysfunction of patients has been reported to improve or remain unaltered compared 
to patients with chronic renal failure before starting HD (283). Fukuta et al also showed that 
decreases in Ti independently predicted cardiac death (253) and Hayano et al. reported an 
independent prognostic value of Ti (<22) to predict both all-cause and sudden death (hazard 
ratio (95% CI); 8.1 (1.3, 48.6) and 12.6 (1.3, 126.4), respectively) (254). In the present study 22 
patients presented Ti < 22 ms which corresponds to 65% of those with valid 24h HRV readings. 
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Hayano et al also reported a 24 h SDNN below 50 ms to predict a greater risk of sudden death 
in 31 chronic haemodialysis patients with stage 5 CKD after 5 years of follow-up (254). 
Although only 2 patients presented SDNN under 50 ms in the present study, the mean 24 h 
SDNN of this study population was 84 ms which would be considered to be a moderately 
depressed HRV. This finding is consistent with other published studies reporting depressed 
HRV in haemodialysis patients (Table 22). In addition, effects of medication on HRV should be 
considered in this poly-medicated population. Treatment with β-blockers has been shown to 
increase HRV (284,285) and splitting the patients with valid 24 h HRV recordings into users 
(n=16) and non-users (n=18) of β-blockers showed that those taking β-blockers had a 
statistically significant lower HR (78 vs. 87, p = 0.017) and higher IBI (795 vs. 705, p = 0.009) 
and HF (161 vs. 81, p = 0.011). This agrees with a RCT in 13 patients with stage 5 CKD on 
haemodialysis where HF significantly increase after intravenous administration of propranolol 
(286). 
HRV is substantially reduced in haemodialysis patients compared to healthy controls as 
shown by previous studies comparing haemodialysis patients to age matched healthy controls 
and stage 5 CKD has been suggested to be an independent factor for a decreased HRV (287). 
This study confirms and extends these findings demonstrating consistently that time-domain and 
frequency-domain HRV parameters were significantly lower in haemodialysis patients 
compared to age- and sex-matched healthy controls from the MARINA study. Other studies 
reporting reduced HRV in stage 5 CKD patients compared to healthy participants (282) have 
not age- and sex-matched the healthy cohort and have not studied as extensively the different 
HRV parameters as the comparison done in this chapter. CRP has been previously positively 
associated with mortality in haemodialysis patients (288). The haemodialysis patients in this 
study presented significantly higher hs-CRP values compared to the healthy cohort, showing 
that inflammation could be a possible factor contributing for the lower LC n-3 PUFA and HRV 
levels compared to healthy individuals. There were no significant correlations between hs-CRP 
and HRV measurements in this study population after adjusting for age and BMI, which could 
be due to the small sample size. One study reported an inverse relationship between IL-6 and 
SDNN, SDANN and VLF in CKD patients but in dialysis patients in the same study, no 
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associations between HRV and inflammatory markers were found (93). Studies with a larger 
sample size showed independent associations between HRV and CRP in healthy and in patients 
with CHD (289) and a meta-analysis showed that CRP predicted CHD independent of 
traditional cardiovascular risk factors (290).  
This study presents several limitations, including multiple correlation tests because of the 
exploratory nature of the study, which might have generated significant associations that may 
have been type I errors. The sample size of 70 to 80 participants was not achieved due to 
multiple unforeseen challenges in the participant recruitment, compliance and retention of 
patients for the second visit. These unforeseen challenges related to obstacles faced by a non-
clinical researcher (working outside the NHS) recruiting at multiple NHS sites across London, 
(which is not feasible for a single researcher to work across 10 sites) relying on the goodwill of 
NHS employees to facilitate the study, and also the goodwill of patients who were already 
undergoing a highly invasive therapy and therefore may have been reluctant to undergo any 
additional procedures, however non-intrusive they may be. In addition, the patients enrolled in 
this study had different treatment schedules with patients dialysing at different times of the day 
(morning, afternoon or evening) which may have induced circadian differences in the readings. 
Another limitation of this study is the number of comorbidities presented by most patients 
which could have affected independently the HRV measurements not allowing the detection of 
potential associations with LC n-3 PUFA status.  
Patients with stage 5 CKD are at high risk of SCD and there are numerous mechanisms 
that could be involved in the electrophysiological instability that predispose these patients to 
malignant cardiac arrhythmias. These patients have a moderate to severe cardiac autonomic 
dysfunction and this may be a reason for the increased risk of cardiac events and death. This 
study population presented a particularly low HRV and LC n-3 PUFA levels compared to other 
haemodialysis patients and even more when compared to healthy cohorts together with levels of 
CRP indicative of a chronic low-grade inflammation. For this reason, this population would be a 
suitable candidate to test the cardiovascular benefits of LC n-3 PUFA supplementation. In order 
to justify such a clinical trial, data are needed showing associations between LC n-3 PUFA 
tissue status and HRV in patients in advanced stages of CKD. The main finding from the current 
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feasibility study is that erythrocyte LC n-3 PUFA are very low in patients who have recently 
commenced haemodialysis, and do not vary substantially within the group, which precludes any 
meaningful correlation analysis within this population. It can be concluded that the current 
study design should not be extended to a larger cross-sectional study of the same design, and 
that other tissue biomarkers of LC n-3 PUFA status should be explored in feasibility studies, 
such as platelets and mononuclear cells, which have been suggested as the most suitable 
biomarker of habitual LC n-3 PUFA intake (291). 
In summary, haemodialysis patients presented particularly low proportions of 
erythrocyte membrane EPA + DHA, which precluded any meaningful findings in the study 
primary outcome - the relationship between tissue LC n-3 PUFA status and HRV. However, 
plasma LC n-3 PUFA analysis revealed that there may be a compromised conversion of DPA to 
DHA in patients that recently started haemodialysis which is negatively impacting the vagally-
mediated regulation of cardiac autonomic function, and this could be a potential mechanism 




Chapter 6 Comparison of the effects of intermittent vs. continuous 
energy restriction diets on heart rate variability: a randomised 
controlled trial 
6.1 Introduction 
Obesity is a risk factor for the development of CVD and has been shown to alter ANS 
activity, presenting a higher risk of SCD. Chronic overactivation of the SNS, which is reflected 
by a low HRV, is thought to be a key factor in the pathogenesis of obesity-induced endothelial 
dysfunction and hypertension (292,293). A dysfunctional ANS carries consequences for obese 
subjects, namely reduced cardiovascular resilience and adaptability to daily activity demands 
and stress that increases their risk for cardiac events. 
Weight loss has been shown to improve HRV in obese subjects and carries cardio-
metabolic benefits (refer to Chapter 1, section 1.5.1.2). The traditional approach to weight loss 
is based on a continuous energy restriction (CER) which involves a reduced daily energy intake 
relative to total energy expenditure in order to promote a negative energy balance to achieve 
moderate weight loss. Intermittent energy restriction (IER) is an alternative weight loss 
approach that consists of a predefined period of time severely restricting energy intake, 
alternated with a period of greater energy intake (294). In animal models, imposing fasting 
periods has been shown to confer metabolic advantages over reducing daily energy intake (295) 
but seems to have comparable effects on improving ANS activity (296). Fasting may affect 
ANS activity via β-hydroxybutyrate antagonistic effects on FFA3 receptors, which regulate 
energy balance by modulating sympathetic activity. Under fasting conditions, β-
hydroxybutyrate inhibits FFA3 receptors in sympathetic ganglion, suppressing  sympathetic 
nerve activity (297). A previous pilot study (The LighterHeart Study, unpublished data)8 
comparing the short-term adherence (1 week) to a very low calorie diet (VLCD, 600 kcal per 
day) with a moderate energy restriction (MER) diet in obese subjects showed a significant 
increase in HF power after the VLCD compared to an overall decrease following a MER diet, 
indicating increased parasympathetic regulation. Since these results were obtained with minimal 
                                                     
8 Conference presentation, oral short communication, Glasgow, UKCO, 2016 
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weight loss, the increase in vagal tone might be only indirectly related to the weight loss itself. 
However, few human trials have studied the effects of IER directly comparing with an 
isoenergetic CER control group. Only a couple of published studies to date compared the two 
dietary approaches and showed that following an IER diet conferred additional metabolic 
benefits (increased insulin sensitivity) in overweight and obese women (298,299) but the effects 
of following an IER diet on HRV in humans is unknown. Increases in fat mass, particularly 
visceral fat, contribute to adipose tissue dysfunction and increased risk of cardio-metabolic 
disease through an underlying low grade chronic inflammation, resulting in altered adipokine 
production and insulin resistance (292). Abdominal visceral fat has been strongly associated 
with SNS activation (35) and high reactivity of the sympathetic vs. parasympathetic nervous 
system has been proposed as a link between central obesity and development of insulin 
resistance and type 2 diabetes (300). It has also been suggested that stress-induced sympathetic 
overactivity may promote visceral fat accumulation (301). 
Preliminary data from the LighterHeart Study showed that favourable changes in ANS 
function occur rapidly following onset of severe energy restriction (SER, within 1 week) 
compared to MER. Therefore, there is the possibility of some other mechanism, independent of 
weight loss, that might have additional benefits on the PNS/SNS activity but it is unknown 
whether there would be further changes over a longer period of time. The present research trial 
investigates the short-term effects (over 1 month) of an IER diet with two consecutive days of 
SER (600 kcal per day, considered a modified fasting) on HRV, insulin sensitivity and 
inflammation compared with an isoenergetic CER diet, aiming at the same amount of weight 
loss, in centrally obese but otherwise healthy adults. The mechanistic effects of any additional 
benefits for the cardiac autonomic control conferred by losing weight via an IER diet vs CER 
diet will also be explored.  
6.2 Hypothesis 
It is hypothesised that centrally obese adults will have greater reductions in HR and 
greater increase in HRV parameters following IER compared to CER. Furthermore, these 
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differences between groups will be associated with differences in markers of inflammation, 
insulin sensitivity, and blood pressure, and be independent of weight loss. 
6.3 Aims 
This study aims to assess the impact of an IER diet compared to an isoenergetic CER diet 
on HRV, insulin sensitivity, inflammatory markers, and blood pressure. 
6.4 Methods 
This study was funded by LighterLife® (UK) Ltd. 
6.4.1 Study design 
This was a 4‐week parallel arm RCT designed to compare the relative effects of 
short‐term IER and CER diets on cardio-metabolic risk factors in centrally obese men and 
women. Healthy adults, with waist circumference measurements exceeding ethnic group-
specific thresholds for substantially increased risk of cardio-metabolic disease were recruited 
and randomly allocated to 1 of 2 treatments. The control arm was a standard CER diet where 
subjects were provided with dietary advice aimed at reducing daily energy intake by 500 kcal 
relative to their estimated total energy expenditure; a weekly deficit of 3500 kcal. The energy-
matched experimental arm involved SER for 2 consecutive days (2-d SER) of the week (~600 
kcal per day) and the other 5 days of the week on a standard energy or MER diet calculated to 
be equivalent to a weekly deficit of 3500 kcal relative to estimated total energy requirements.  
6.4.2 Ethics and consent 
Ethical approval was obtained from KCL Research Ethics Committee (REC) (ref: 
HR‐15/16‐2179) and the study was registered at www.clinicaltrials.gov (ref: NCT02679989). 
The study was conducted in the MRU at Franklin-Wilkins Building, KCL between February 
and July 2016. Participants gave written informed consent before participation and received a 
small remuneration for taking part. 
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6.4.3 Outcome measures 
The primary clinical outcome of the Met-IER study was differences between treatments 
in R-QUICKI, an index of insulin sensitivity based on fasting blood concentrations of glucose, 
insulin and non-esterified fatty acids (NEFA). The primary mechanistic outcome for HRV was 
differences between treatments in HF power, RMSSD, and pNN50, indicators of 
parasympathetic activity (vagal tone). Reduced HRV has previously been associated with 
insulin resistance in non-diabetic individuals (302,303). 
Secondary outcomes include other indicators of ANS function, including time and 
frequency-domain and non-linear parameters of HRV, and additionally ABP, since the ANS is a 
significant contributor to the long-term regulation of blood pressure (304). Plasma 
catecholamine markers were also measured as indicators of sympathetic activity (metanephrine, 
a stable metabolite of epinephrine, and normetanephrine, a stable metabolite of norepinephrine); 
norepinephrine is continuously released into the circulation at low levels from synapses as 
“spillover” from sympathetic neurotransmission, therefore changes in normetanephrine might 
indicate changes in sympathetic nerve activity (305). Measurements of body composition (waist 
and hip circumference, BMI, percentage body fat) were made to monitor the impact of the 
energy restriction regimes on fat distribution. Full lipid profiles (total, LDL and HDL 
cholesterol, triglycerides, total cholesterol : HDL cholesterol ratio) were measured as an 
additional marker of CVD risk. Adiponectin and leptin were analysed to determine differential 
responses in adipose tissue function to CER and IER, and IL-6 was measured to indicate any 
differences in inflammatory status following the diets. Other secondary outcomes that were not 
included in the results of this doctoral research were digital volume pulse, eating 
behaviour/emotion/mood questionnaires (e.g. Three Factor Eating Questionnaire revised 18 
items version 2 (TFEQR18V2), COPE, Power of Food Scale), faecal sample (for microbial 
composition analysis) and cognitive function (Mnemonic Similarity Test). 
Body weight and β-hydroxybutyrate were outcome variables that indicated compliance to 
diet and fasting, respectively. 
165  
6.4.4 Power calculation, inclusion and exclusion criteria 
The power calculation for this study was based on previously published data (223) and 
performed for the primary outcome of this study (R-QUICKI). In order to detect a mean 
difference between groups of 0.060 (arbitrary units) with 80% power and an alpha of 0.05, 17 
participants per arm were required. The aim was to recruit 46 subjects in total to allow for 25% 
drop-out rates.  
Based on a previous study by our group (LighterHeart Study) that detected a difference of 
164 msec2 (SD 180) in HF power between a 1-week VLCD compared to a MER diet 
(unpublished data), a sample size of 17 participants in each group has 80% power to detect 
mean changes in HF power of 179 msec2 with an alpha of 0.05. 
The inclusion criteria were non‐smoking men and women aged between 35 and 75 years 
with a waist circumference above the cut‐off for high risk of cardio-metabolic disease (193): > 
102 cm and > 88 cm for men and women respectively (> 90 cm and > 80 cm, for men and 
women respectively, with South Asian or East Asian ethnic background). The exclusion criteria 
included reported kidney or cardiovascular diseases (myocardial infarction, angina, venous 
thrombosis, stroke, atrial fibrillation, pacemaker), cancer (excluding basal cell carcinoma) in the 
past 5 years, type 1 diabetes mellitus or type 2 diabetes (fasting plasma glucose ≥ 7 mmol/L), 
chronic liver disease; previous bariatric surgery or other major surgery (e.g. organ 
transplantation); significant psychiatric disorder or uncontrolled depression; participation in a 
weight management drug trial in the previous 3 months; uncontrolled epilepsy; taking 
medication likely to affect metabolic rate and/or weight (e.g. beta blockers, corticosteroids, 
diuretics); lactose intolerant; history of substance or alcohol abuse (previous weekly alcohol 
intake >60 units/men or 50 units/women). Women who were currently pregnant, lactating or 
planning pregnancy were also excluded.  
6.4.5 Recruitment methodology and randomization 
Participants were recruited through internal Research Ethics Office recruitment circular e-
mail and posters among KCL and through external advertising via two insertions in the 
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newspaper, one in metro and the other in the evening standard and via advertisement in 
LighterLife® website and customer’s database. The study was also promoted via Facebook, 
Gumtree and Twitter. Volunteers who responded to advertisements were given more 
information about the study, completed a recruitment questionnaire via telephone call or e-mail 
to establish their eligibility for the study and were sent a participant information sheet 
(Appendix 9). Potential participants gave written informed consent and attended a screening 
visit in the morning upon which anthropometric and blood pressure measurements were taken, 
and fasting blood sample was collected for assessment of lipid profile, glucose, liver function 
and haematology to confirm eligibility to take part in the study.  
Treatment was allocated using MinimPy 0.3 9, a computer online programme, by 
minimization for sex, BMI, ethnicity and waist circumference. The provision of stool samples 
for further trials was also considered as a factor in the minimization process. 
6.4.6 Screening visit 
Volunteers were instructed to fast for 12 h before the visit and consume nothing but water 
until attending the clinic. On arrival, the study protocol was explained in detail and participants 
were given the opportunity to ask questions before signing the consent form. Once written 
informed consent was obtained, seated blood pressure was measured in triplicate in the non-
dominant arm using an A&D Medical UA-767Plus upper arm automatic blood pressure monitor 
(A&D Instruments Limited), in accordance with guidelines from the BHS. Height, body weight 
and percentage body fat and waist circumference were measured using a stadiometer, a Tanita 
weighing scale (model: BC-418 MA; Tanita UK Ltd) and a tape measure, respectively. A 
fasting blood sample was taken followed by a light breakfast and the participants were given a 
7-day food diary and an International Physical Activity Questionnaire Short Form (IPAQ‐SF) to 
take home and instructed on how to complete it so they could bring it in before the first study 
appointment. Screening blood samples were sent the same day via courier to Clinical 
Biochemistry at King’s College Hospital, Denmark Hill for analysis. 
                                                     
9 https://sourceforge.net/projects/minimpy/ 
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6.4.7 Study visits 
Outcome measurements were made at baseline and twice at the endpoint (to account for 
differences at endpoint in the IER group depending on whether measurements were taken 
immediately after a 2‐day SER, or after a non‐SER period) after randomization to their 
respective diets. The CER group were matched to have identical end-point measurements. An 
overall outline of the study design is given in figure 25. 
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Figure 25 - Overall outline of the study design. 
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Before the first study visit, participants were instructed to have a standard low fat meal 
for dinner from a list of ready meals provided. Before all study visits participants were 
reminded to fast overnight for 12 h and to refrain from alcohol and avoid any strenuous physical 
activity 24 h before. Also, participants were sent a list of high nitrate foods to avoid eating and 
were asked to drink Buxton water (low-nitrate water) 24 h before each study visit. The study 
visits run in the morning, the first lasting around 3h15 and the endpoint visits lasting around 
2h30. On arrival participants were reminded of the study day outline and were given the 
opportunity to ask any questions.  
Anthropometric measurements – waist and hip circumferences, height, weight and 
percentage of body fat - were taken according to the standard operation procedures (refer to 
Chapter 2 - Methods, section 2.4). Body fat was estimated using bioelectrical impedance using 
a Tanita BC‐418 MA (Tanita, Arlington Heights, IL, USA). After taking these measurements 
participants had a 15 min supine rest where the eMotion Faros and ABP monitors were fitted 
and instructions were give on how to wear them as well as how to complete an activity diary 
including daily activities, meal and sleep times (Appendix 10). Three resting measurements of 
blood pressure were taken and 30 mins of resting HRV was recorded. While recording the 
resting HRV measurements, the resting metabolic rate (RMR) was determined using the 
FitMateTM (Cosmed, Rome, Italy). Also, while resting digital volume pulse measurements were 
taken. The mental stressor test (the Stroop colour-word test) was performed for 10 mins after 
the resting period and HRV was recorded during the test. Blood pressure was measured right 
after the test ended. Both ABP and eMotion Faros Monitors were programmed to record a 
further 24 h. A Mnemonic Similarity Task (MST) was performed after participants had the 
opportunity to have a glass of water and unwind from the Stroop test. The MST was included in 
this study for a collaboration with the Institute of Psychiatry at King’s College London 
(Denmark Hill campus). Data from the MST was analysed by the collaborators and the results 
will not be presented in this chapter. A blood sample was taken followed by a light healthy 
breakfast. The blood was processed according to the blood handling protocol (Appendix 11). 
The first study visit (baseline) was then followed by the dietary advice where participants were 
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revealed the treatment they were allocated to and were given personalised advice and set 
individual dietary and physical activity goals to follow throughout the intervention.   
6.4.8 Estimating total energy expenditure 
Total energy expenditure (TEE) was calculated using an adaptation of a previously 
published template spreadsheet, which identifies the fields needed for data entry by the 
researcher in the spreadsheet and uses in-build sex-specific algorithms (306). The present study 
used an adaptation of the template where RMR was measured by indirect calorimetry instead of 
being estimated through equations built into the template spreadsheet. The following variables 
were used to calculate TEE: age, weight (kg), RMR (kcal/d) and amount of time spent doing 
different levels of physical activities (min). The duration of the physical activity levels (walking 
slowly, walking briskly, moderate and vigorous physical activity) were estimated using an 
adaptation of the international physical activity questionnaire – short form (IPAQ‐SF, 
Appendix 12) which has 7 items and records the activity of four intensity levels: 1) vigorous-
intensity activity such as aerobics, 2) moderate-intensity activity such as leisure cycling, 3) 
walking, and 4) sitting. The participants were further enquired about their type of walking (slow 
vs. brisk) and of the type of activities practiced for each intensity level to ensure these were 
correctly labelled. Each activity level was given a metabolic equivalent (METs), which is a 
value representing the energy cost of physical activities as a multiple of the RMR (307). Based 
on the compendium of physical activities (308), slow walking was assigned 3.5 METs, walking 
briskly 4.3 METs, moderate activity 5 METs and vigorous activity 6.5 METs. 
The FitMate GSTM, a portable desktop indirect calorimeter with a canopy, was used for 
determining RMR by oxygen consumption. Participants breathed normally inside the canopy, a 
transparent hood, while in supine position. The canopy was connected to a blower that would 
provide the air flow inside the hood and the blower pumped in air at different flow rates that 
could be adjusted depending on participants’ weight. The calibration was always done before 
every measurement and before fitting the hood on the participant.  
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6.4.9 HRV and ABP measurements 
The eMotion Faros devices were used to record HRV in real time during resting and the 
stress test and on offline mode to record a further 24 h. Skin preparation, monitor fitting and the 
use of the Cardiscope software has been described elsewhere (Chapter 2 - Methods, section 
2.1) A&D TM-2430 ABP monitoring devices with appropriate cuff sizes were used to measure 
resting, immediately after stress test and 24 h SBP and DBP. The ABP monitor was 
programmed to take measurements every 30 minutes during the day (07:00 to 22:00) and hourly 
at night (22:00 to 07:00). On completion of the measurements, the eMotion Faros and the ABP 
devices were collected by courier and returned to KCL. The data were downloaded onto the 
Cardiscope software and the A&D software from the eMotion Faros and ABP devices, 
respectively. HRV outcomes were reported for the 24 h measurements, sleep-time and day-time. 
Sleep times were obtained from the physical activity diary and these entered onto the 24 h 
recordings in Cardiscope to allow differential analysis of the day/awake and sleep-time. Further 
analysis was carried on a standardised day-time period of 8 h and sleep-time period of 5 h to 
remove the influence of variability in recording duration on HRV parameters. 
6.4.10 Mental stressor test 
The Stroop colour word test was applied as a mental stressor, as it has been reported to 
experimentally induce stress and cause a shift towards greater sympathetic activity in response 
to the task (309). The test consisted of two tasks. In the first task, participants were asked to 
read colour words (red, green and blue) printed in black. Then, in the second task, participants 
were presented with a sample of colour words printed in coloured fonts, which were 
incongruent with respect to the colour word itself. They were asked to name the colour font of 
the printed words and not to read the printed words. Throughout the mental task, the subjects 
were given instructions by the examiner to work quickly but try not to make any mistakes. The 
total duration of the mental stress procedure was 10 min.  
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6.4.11 Blood biochemistry analysis 
Blood samples were collected into fluoride oxalate tubes for glucose analysis; SSTTM II 
tubes for full lipid profile (total, LDL and HDL cholesterol and triglycerides), insulin, NEFA, 
adiponectin, leptin and β-hydroxybutyrate; and EDTA tubes for IL-6 and catecholamines.  
Screening blood samples were centrifuged within a maximum of 1 h from collection and 
sent the same day (within a 5 h window) by a medical courier to the clinical biochemistry 
laboratory at King’s College Hospital. Spare plasma and serum samples were frozen at -40°C. 
Blood samples from the study visits were centrifuged within a maximum of 30 mins from 
collection and frozen at -40°C. These samples were sent by a medical courier once the study 
was completed so all the participants and timepoints were included in the same assay. Plasma 
glucose and serum lipids were analysed following enzymatic methods using reagents supplied 
by Bayer Diagnostics Europe Ltd (Bayer House) using an ADVIA 2400 analyser (Siemens 
Healthcare Diagnostics Ltd, Frimley, Surrey, UK). ELISAs were used to analyse insulin 
(Siemens Healthcare Diagnostics Ltd), adiponectin and leptin (Quantikine ELISA kits, R&D 
Systems, Abingdon, UK). β-Hydroxybutyric acid was analysed using an enzymatic assay 
supplied by Randox Laboratories Ltd (County Antrim, UK) for the ADVIA 2400 analyser. 
Inflammatory markers interleukin (IL)-6, IL-8, VEGF, IL-1b, IL-1RA, and MCP-1 were 
analysed using a high-sensitivity cytokine chip array assay (Human cytokine HS X biochip; 
Randox Laboratories Limited, County Antrim). Plasma free metanephrines (metanephrine (MN) 
and normetanephrine (NMN), the stable O-methylated metabolites of epinephrine and 
norepinephrine, respectively) were measured by liquid chromatography-tandem mass 
spectrometry using TurboFlowTM, an online sample preparation system. Insulin sensitivity was 
assessed by the revised quantitative insulin sensitivity check index (R-QUICKI: 1/(log glucose 
(mg/dL) + logInsulin (μU/mL) + logFFA (mmol/L))), and insulin resistance by the homeostatic 
model assessment (HOMA-IR: Glucose mM x Insulin mU/L / 22.5). 
6.4.12 Dietary and physical activity advice and group sessions 
Dietary advice was given in order to reduce the weekly energy intake by 3500 kcal, 
aiming at a weight loss of 2 kg over the 4-week intervention period. Participants allocated to the 
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CER diet were given dietary advice to reduce their daily energy intake by 500kcal based on a 
healthy balanced Mediterranean-type diet (Appendix 13). Those allocated to the IER diet were 
instructed to follow a VLCD on 2 consecutive days and to follow a healthy balanced 
Mediterranean-type diet on the other 5 days, prescribed according to the estimated requirements 
for an overall weekly deficit of 3500 kcal to match the CER group. Participants were provided 
with LighterLife® foodpacks (providing ~600 kcal/day and 100% of the RNI for vitamins and 
minerals) for the 2-d SER days. Each SER day consisted of 4 vegetarian foodpacks and 
participants were able to choose from a range of different options including milkshakes 
(chocolate, vanilla, strawberry, banana and caramel), porridge (original or apple and cinnamon), 
soups (vegetable or tomato and herbs), savoury dishes (curry or spaghetti Bolognese) and bars 
(chocolate raisin, nut fudge or double chocolate). The nutritional information of these foodpacks 
can be found in Appendix 14.  
Participants were given personalised dietary advice based on a 7-day food diary 
completed before attending the first study visit and set individualised dietary goals as well as 
one physical activity goal to keep throughout the intervention. The physical activity goal 
frequency and intensity was adjusted according to the current reported level of activity. For 
example, for a sedentary individual, physical activity frequency and intensity was gradually 
increased per week until reaching the UK physical activity guidelines for adults (150 min of 
moderate intensity activity per week in bouts of 10 minutes or more)10; in case of a participant 
that already followed the guidelines, he/she was requested to maintain the same level 
throughout the study. Another 7-day food diary was given to complete the week before the last 
follow-up visit in order to assess compliance to the dietary intervention by the change in energy 
intake. Mean daily energy intake was estimated using Nutritics dietary analysis software 
(Nutritics v3.06). 
To maximise compliance participants received motivational phone calls and were invited 
to attend a 1 h group session one to two weeks after the first study visit. These were dynamic 
sessions including information about portion sizes, weighing portions of different types of foods 
                                                     
10 https://www.gov.uk/government/publications/uk-physical-activity-guidelines 
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and comparing to recommendations, an interactive quiz and opportunity to discuss any 
difficulties or problems following the prescribed diets or share with other participants coping 
strategies or positive feelings.  
6.5 Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics 22.0 (Statistical Product 
and Service Solutions; IBM Corp.) on an intention-to-treat basis. Chi-square (χ2) tests for 
categorical variables and independent samples t-test for continuous variables were used to 
assess the differences between treatment groups’ subject characteristics. Non-normally 
distributed data were normalised by natural logarithm (LN) before analysis and results were 
back transformed and shown as geometric means (95% CI).  
For the study outcome variables, endpoint (END) was defined as the average of the 
measurements taken at the two follow-up visits for the CER group and the measurements taken 
at the follow-up visit after normal eating (at least two consecutive days of normal eating/only 
MER) for the IER. The SER endpoint is defined as the measurements taken at the follow-up 
visit after two consecutive days of SER (600 kcal/d).  
Baseline results are expressed as means (95% CI) or geometric means. For END analysis, 
between-group differences of normally distributed data or LN transformed data were tested 
using univariate ANCOVA, adjusted for baseline values and, for non-anthropometric variables, 
percentage of weight loss. Day-time and 24 h HRV analysis were also adjusted for physical 
activity (accelerometry data). The endpoint (END) results are expressed as estimated marginal 
means (95% CI). Data that could not be normalised by LN transformation were analysed using 
Mann-Whitney U test and significance values are presented unadjusted, with results shown as 
medians (lower and upper limits of the interquartile range).  
To explore the acute effects of SER on HRV parameters, ABP and biochemistry markers, 
changes between END and SER were assessed in the IER group using paired t-test. Data that 
could not be normalised by LN transformation were analysed using Wilcoxon signed-rank test. 
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To assess compliance to the dietary intervention, changes in weight, waist circumference 
and energy intake were assessed using paired t-test at baseline and END. To assess compliance 
with SER, changes in β-hydroxybutyrate in the IER group were assessed using paired t-test at 
END and SER. 
6.6 Results 
6.6.1 Subjects 
Of the 172 participants that responded to the adverts, 56 potential eligible participants 
attended a screening visit and 45 were eligible and randomised to a treatment group (Figure 
26). In total, 2 participants from the IER group withdrew from the study (4%) after the baseline 
visit due to change in availability and the remaining 43 participants completed the study.  
Subject characteristics of the 43 participants that completed the study are reported in 
table 24. The CER group was formed of 22 subjects (6 male, 16 female) with a mean age of 56 
± 8 years and the IER group was formed of 21 subjects (6 male, 15 female) with a mean age of 
50 ± 12 years. There were no significant differences in mean age, waist circumference or BMI 
between groups, or distributions of ethnicity and sex between groups. There were also no 
significant differences in seated resting DBP, SBP and HR between groups or biochemistry 
measurements (plasma glucose, serum triacylglycerides, serum total-cholesterol, LDL-
cholesterol and HDL-cholesterol). 
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Table 24 – Subject characteristics at screening visit. 
 CER (N=22)  IER (N=21)  p value † 
 n % n %  
Sex      
     Male 6 27 6 28 1.000 § 
     Female 16 73 15 72  
Ethnicity      
     White 15 68 14 67 0.570 § 
     Black 
African/Caribbean 
3 14 1 5  
     South Asian 3 14 3 14  
     Other 1 5 3 14  
 Mean SD Mean SD  
Age (years) 56 8 50 12 0.097 
Waist circumference 
(cm) a 
     
     Male 120 (110, 131)  113 (106, 120)  0.158 
     Female 108 (100, 116)  105 (99, 110)  0.532 
BMI (kg/m2) 31.1 5.7 31.8 4.5 0.638 
% body fat       
     Male 31.2 4.2 33.6 6.7 0.476 
     Female 40.6  5.7 43.1 4.1 0.173 
SBP (mmHg) 132 16 127 14 0.325 
DBP (mmHg) 88 12 86 8 0.491 
HR (bpm) 64.1 7.1 67.0 7.5 0.201 
Plasma glucose 
 (mmol/L) 
5.4 0.5 5.3 0.4 0.431 
Serum TAG (mmol/L) a 1.08 (0.88, 1.33)  1.17 (0.96, 1.43)  0.560 
Serum total cholesterol 
(mmol/L) 
5.6 0.9 5.4 1.2 0.544 
Serum LDL-cholesterol 
(mmol/L) 
3.4 0.7 3.3 1.0 0.719 
Serum HDL-cholesterol 
(mmol/L)  
     
     Male 1.31 0.24 1.35 0.33 0.768 
     Female 1.80 0.38 1.61 0.42 0.190 
BMI, body mass index; DBP, diastolic blood pressure; HDL, high density lipoprotein; HR, heart rate; 
LDL, low density lipoprotein; SBP, systolic blood pressure; TAG, triacylglycerides  
a Results expressed as n (%), mean ± SD, except a geometric mean (95% CI) and † p value obtained using 




6.6.2 Compliance to dietary intervention 
Changes in weight, waist circumference and energy intake were used to assess 
compliance to the dietary intervention and β-hydroxybutyrate was used to assess compliance 
with SER in the IER group (Table 25). Additional anthropometric measurements that indicate 
compliance to the dietary intervention are also shown in Table 25. Both groups significantly 
reduced weight, waist circumference, BMI, %BF and energy intake, demonstrating satisfactory 
compliance to the dietary intervention. The percentage of weight loss was -2.6 ± 1.7 and -2.9 ± 
1.6 in the CER and IER groups, respectively. Compliance to SER in the IER group was also 
achieved as shown by the significant increase in serum β-hydroxybutyrate after the SER 
endpoint compared to baseline and in agreement with the non-significant difference observed at 
endpoint in the CER group compared to baseline. However, the CER group presented a 
significantly higher serum β-hydroxybutyrate at the end of the intervention compared to the IER 
group (after at least 2 consecutive days of eating normally/MER). 
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Table 25 – Compliance to dietary intervention, compliance to severe energy restriction and other anthropometry measurements. 
















Overall compliance  Baseline END  p value 1 Baseline END  p value 2 2-d SER p value 2 p value 3 
Weight (kg) 89.2 (80.1, 98.2) 86.2 (85.5, 86.9) <0.001 87.7 (80.2, 95.2) 85.9 (85.2, 86.6) <0.001 84.7 (77.5, 91.9) 0.003 0.464 
Waist circumference 
(cm) a  
111 (104, 118) 105 (103, 106) <0.001 107 (103, 111) 104 (103, 106) <0.001 103 (98, 108) 0.432 0.535 
Energy intake (kcal) 2140 (1833, 2446) 1233 (1068, 1398) <0.001 2032 (1839, 2224) 1478 (1313, 1643) <0.001 N/A N/A 0.042 
β-hydroxybutyrate 
(mmol/L) a 
0.09 (0.07, 0.12) 0.12 (0.09, 0.16) 0.164 0.07 (0.04, 0.11) 0.06 (0.05, 0.09) 0.748 0.20 (0.13, 0.31) 0.001 0.004 
Other anthropometry measurements          
BMI (kg/m2) 31.0 (28.4, 33.5) 30.6 (30.4, 30.9) <0.001 31.9 (29.7, 34.0) 30.5 (30.2, 30.7) <0.001 30.8 (28.7, 32.9) 0.017 0.340 
% BF 37.4 (34.1, 40.6) 36.3 (34.8, 37.8) 0.028 40.0 (37.2, 42.9) 37.5 (35.9, 39.0) <0.001 38.7 (35.8, 41.5) 0.524 0.357 
% BF, percentage of body fat; BMI, body mass index; CER, continuous energy restriction; IER, intermittent energy restriction; 2-d SER, measurements taken following 2-d severe 
energy restriction; END, measurements at endpoint (not following 2-d SER in case of IER group); BF, body fat; BMI, body mass index; 1 comparison within CER group by paired t-
test; 2 comparison within IER group by paired t-test; 3 comparison between groups at END by ANCOVA adjusted for baseline values and, for non-anthropometric outcomes, 
percentage weight loss. Baseline results expressed as mean (95% CI) and END results expressed as estimated marginal means (95% CI) adjusted for baseline values and, for non-
anthropometric outcomes, percentage weight loss, except a Geometric means (95% CI).  
 
180  
6.6.3 Resting measurements and mental stress-induced changes in HR and 
HRV parameters 
There were no significant differences between treatments at endpoint on resting HRV 
measurements, during the mental stressor test, nor in the response to the mental stressor test 
relative to resting (Table 26), except for resting LF power which was significantly higher in the 
IER group compared to the CER group. 
However, the overall effect of both dietary interventions on HRV parameters, 
independent of the type of treatment followed, produced significant changes in the following 
resting measurements (mean change [95% CI]): increased IBI (39 [13, 65]) and min IBI (32 [5, 
59]) and corresponding decreases in HR (-2.8 [-4.5, -1.0]) and min HR (-1.9 [-3.8, -0.1]).  
The following significant changes occurred when the whole cohort was analysed during 
the mental stressor test at endpoint compared to baseline (mean change in Ln values [95%CI]): 
increased IBI (mean change [95% CI]; 54 [27, 81]), RMSSD (1.18 [1.03, 1.36]), pNN50 (1.59 
[1.14, 2.22]) and HF (1.34 [1.04, 1.72]). 
When inspecting relative changes from rest to stress in HR and HRV, assessed by 
analysing HRV at rest minus Stroop test (10 min recordings), the IER diet at endpoint 
significantly produced a lower rise in HR in response to stress compared with the CER diet. 
Although IBI (reciprocal to HR) didn't reach statistical significance between groups at endpoint, 
only the IER group presented a significantly lower decrease in IBI after treatment. There were 
no other statistically significant treatment effects noted between groups. When analysing the 
effect of the weight loss dietary intervention in the whole cohort, the overall intervention 
significantly attenuated the stress-induced changes on IBI, HR, minHR, LF and HF.  
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Table 26 –Heart rate variability parameters at rest and during Stroop test measurements at baseline and endpoint. 
















 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Resting measurements (30 min)        
IBI and HR        
  IBI (ms) 958 (921, 996) 974 (942, 1007) 0.099 917 (866, 967) 980 (947, 1013) 0.018 0.808 0.004 
  Min IBI (ms) 705 (664, 747) 736 (703, 769) 0.082 692 (650, 734) 718 (684, 752) 0.147 0.457 0.022 
  HR (bpm) 63.1 (60.4, 65.9) 62.3 (60.2, 64.4) 0.101 66.2 (62.7, 69.8) 61.5 (59.3, 63.6) 0.013 0.591 0.003 
  Min HR (bpm) 50.7 (47.7, 53.7) 50.3 (47.7, 52.9) 0.444 52.8 (50.2, 55.3) 48.8 (46.1, 51.5) 0.053 0.410 0.040 
Time-domain HRV parameters        
  Ti a 13.8 (11.8, 16.1) 14.0 (12.3, 15.9) 0.374 12.8 (11.1, 14.8) 13.7 (12.0, 15.6) 0.805 0.841 0.559 
  RMSSD (ms) a 35.1 (27.5, 44.8) 32.4 (26.6, 39.5) 0.811 29.5 (24.3, 35.9) 38.0 (30.9, 46.6) 0.117 0.272 0.209 
  pNN50 (%) a 8.9 (4.7, 16.7) 7.5 (5.0, 11.3) 0.877 4.9 (2.9, 8.3) 9.5 (6.2, 14.6) 0.056 0.415 0.113 
Frequency-domain HRV parameters       
  LF (ms2) a 843 (594, 1195) 657 (524, 823)  0.204 598 (413, 868) 956 (759, 1205) 0.073 0.025 0.390 
  HF (ms2) a 390 (227, 670) 356 (255, 498) 0.951 291 (199, 427) 441 (312, 623) 0.104 0.380 0.184 
  logLF:HF 0.33 (0.15, 0.52) 0.29 (0.18, 0.40) 0.401 0.31 (0.20, 0.43) 0.33 (0.22, 0.44) 0.639 0.598 0.345 
Non-linear methods        
  SD1:SD2 (Poincaré ratio) 0.32 (0.27, 0.37) 0.29 (0.25, 0.32) 0.374 0.29 (0.25, 0.32) 0.32 (0.29, 0.36) 0.094 0.197 0.763 
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 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Stroop test (10 min)         
IBI and HR        
  IBI (ms) 883 (842, 925) 926 (888, 965) 0.012 861 (809, 913) 922 (882, 962) 0.011 0.878 <0.001 
  Min IBI (ms) 708 (670, 746) 745 (708, 783) 0.049 713 (679, 747) 714 (675, 752) 0.543 0.883 0.055 
  HR (bpm) 68.7 (65.3, 72.0) 65.5 (62.4, 68.5) 0.010 70.6 (66.6, 74.7) 64.9 (61.7, 68.0 0.005 0.779 <0.001 
  Min HR (bpm) 55.9 (52.8, 59.1) 54.1 (51.0, 57.2) 0.100 57.8 (53.8, 61.8) 53.1 (49.9, 56.4) 0.031 0.668 0.006 
Time-domain HRV parameters        
  Ti a 10.6 (9.0, 12.5) 11.3 (9.8, 13.1) 0.455 10.5 (8.5, 12.8) 11.5 (9.8, 13.4) 0.293 0.910 0.191 
  RMSSD (ms) a 28.0 (22.8, 34.4) 32.1 (26.0, 39.5) 0.094 26.5 (20.4, 34.4) 34.1 (27.4, 42.3) 0.093 0.686 0.017 
  pNN50 (%) a 5.5 (3.5, 8.5) 6.7 (4.1, 11.0) 0.048 3.4 (1.7, 6.9) 7.7 (4.7, 12.9) 0.074 0.694 0.007 
Frequency-domain HRV parameters       
  LF (ms2) a 639 (479, 852) 830 (644, 1068) 0.080 709 (431, 1165) 767 (590, 997) 0.485 0.667 0.088 
  HF (ms2) a 218 (135, 352) 314 (214, 459) 0.050 213 (124, 366) 286 (193, 425) 0.228 0.738 0.024 
  logLF:HF 0.47 (0.33, 0.61) 0.44 (0.35, 0.53) 0.328 0.52 (0.41, 0.63) 0.44 (0.34, 0.53) 0.159 1.000 0.092 
Non-linear methods        
  SD1:SD2 (Poincaré ratio) 0.29 (0.23, 0.35) 0.30 (0.25, 0.34) 0.586 0.28 (0.24, 0.32) 0.29 (0.25, 0.33) 0.896 0.800 0.585 
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 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Resting – Stroop differences        
IBI and HR        
  IBI (ms) 79 (41, 117) 58 (39, 78) 0.145 75 (58, 93) 39 (17, 61) 0.014 0.186 0.006 
  Min IBI (ms) 98 (57, 138) 85 (58, 113) 0.578 83 (63, 104) 83 (53, 114) 0.817 0.932 0.563 
  HR (bpm) -5.8 (-8.5, -3.1) -3.8 (-5.0, -2.6) 0.063 -5.8 (-7.3, -4.2) -1.4 (-2.8, 0.7) <0.001 0.013 <0.001 
  Min HR (bpm) -2.5 (-4.9, -0.2) -0.8 (-2.4, 0.8) 0.227 -1.7 (-4.2, 0.8) 0.8 (-0.9, 2.6) 0.071 0.171 0.034 
Time-domain HRV parameters        
  Ti 0.5 (-1.4, 2.4) -0.9 (-2.3, 0.5) 0.333 -1.8 (-3.5, -0.1) -1.2 (-2.8, 0.4) 0.662 0.760 0.519 
  RMSSD (ms) c 1.05 (0.85, 1.29) 1.01 (0.92, 1.10) 0.910 0.89 (0.78, 1.02) 1.00 (0.90, 1.10) 0.127 0. 858 0.600 
  pNN50 (%) 9.4 (2.7, 16.1) 3.3 (-1.0, 7.6) 0.076 0.8 (-2.5, 4.2) 1.0 (-3.8, 5.8) 0.707 0.487 0.109 
Frequency-domain HRV parameters       
  LF (ms2) c 1.05 (0.74, 1.50) 0.74 (0.60, 0.90) 0.074 0.65 (0.48, 0.88) 0.66 (0.52, 0.82) 0.343 0.448 0.042 
  HF (ms2) c 1.90 (1.41, 2.56) 1.30 (1.02, 1.64) 0.038 1.39 (0.94, 2.05) 1.25 (0.96, 1.63) 0.436 0.845 0.038 
  logLF:HF -0.26 (-0.41, -0.11) -0.23 (-0.34, -0.13) 0.685 -0.33 (-0.45, -0.20) -0.30 (-0.42, -0.18) 0.842 0.401 0.655 
Non-linear methods        
  SD1:SD2 (Poincaré ratio) 0.11 (0.04, 0.19) 0.09 (0.03, 0.15) 0.501 0.08 (0.05, 0.12) 0.12 (0.05, 0.18) 0.442 0.604 0.920 
CER, continuous energy restriction; IER, intermittent energy restriction; END, measurements at endpoint (not following 2-d SER in case of IER group); IBI, interbeat interval; bpm, 
beats per minute; HR, heart rate; HRV, heart rate variability; Ti, triangular index; RMSSD, the square root of the mean of the sum of squares of differences between adjacent NN 
intervals; pNN50, percentage of adjacent NN intervals that differed by more than 50 ms; LF, low frequency power; HF, high frequency power; SD1:SD2, the ratio of the SD of beat-
to beat IBI variability (SD1) against the SD of long-term IBI variability (SD2).  
1 comparison within CER group by paired t-test; 2 comparison within IER group by paired t-test; 3 comparison between groups at END by ANCOVA adjusted for baseline values and 
percentage weight loss; 4 comparison within the whole cohort by paired t-test. 
Baseline results expressed as mean (95% CI) and END results expressed as estimated marginal means (95% CI), adjusted for baseline values and percentage weight loss, except a 
Geometric means (95% CI), c exponents of mean differences in Ln values (the ratio of the geometric mean in resting:that in stroop test, with 95% CI of the geometric mean ratios). 
Resting – Stroop represents HR/IBI and beat-to-beat HRV during a standardized 10min resting period minus a standardized 10min stress test (Stroop) period, to indicate the 
difference between rest and stress.  
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6.6.4 Ambulatory HR and HRV measurements  
The ambulatory HR and HRV results are reported for 24 h, day-time (8 h segments) and 
sleep-time (5 h segments) in table 27. There were no significant differences between treatments 
at endpoint except for SDANN that was significantly higher on the CER group in the sleep-time 
analysis.  
The overall effect of both weight loss dietary interventions combined on HRV 
parameters, independent of the type of treatment followed, produced significant changes in the 
following 24h measurements (mean change [95% CI]): increased IBI (20 [0, 40]), SDANN (9.7 
[0.5, 19.0]) and VLF (exponent of mean change in Ln values [95% CI]; 1.13 [1.02, 1.25]). HR 
(reciprocal of IBI) decreased after weight loss, but fell short of significance. 
The overall effect of both weight loss dietary interventions on HRV parameters produced 
significant changes in the following day-time measurements (mean change [95% CI]): increased 
Ti (3.6 [1.3, 6.0] and VLF (exponent of mean change in Ln values [95% CI]; 1.21 [1.06, 1.39]). 
Sleep-time analysis showed a statistically significant increase in pNN50 (exponent of 
mean change in Ln values [95% CI]; 1.46 [1.06, 2.03]) when analysing the effect of weight loss 
in the whole cohort. Sleep-time minus day-time differences didn’t produce any significant 
changes when looking at the cohort altogether. 
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Table 27 – Ambulatory 24 h, day-time and sleep-time HRV measurements at baseline and endpoint. 
















 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
24 h measurements         
Activity, IBI and HR          
  Activity level (cpm) 79 (72, 87) 81 (75, 87) 0.923 87 (75, 100) 82 (75, 88) 0.443 0.847 0.631 
  IBI (ms) 817 (780, 855) 823 (798, 849) 0.122 789 (755, 824) 828 (798, 859) 0.200 0.805 0.048 
  Min IBI (ms) 350 (320, 380) 358 (333, 383) 0.570 366 (331, 402) 381 (352, 410) 0.484 0.230 0.358 
  HR (bpm) 74.2 (70.6, 77.8) 73.7 (71.4, 76.0) 0.141 76.5 (73.2, 79.8) 73.2 (70.5, 75.8) 0.218 0.756 0.062 
  Min HR (bpm) 42.5 (39.9, 45.2) 40.4 (38.0, 42.8) 0.187 42.5 (39.7, 45.3) 42.4 (39.6, 45.3) 0.899 0.273 0.214 
Time-domain HRV parameters        
  Ti 36.5 (32.6, 40.4) 40.2 (36.1, 44.2) 0.029 36.5 (31.4, 41.6) 39.0 (34.3, 43.8) 0.492 0.719 0.068 
  SDNN (ms)  137 (123, 151) 145 (132, 158) 0.069 137 (122, 152) 145 (129, 160) 0.438 0.938 0.123 
  SDANN (ms) 114 (101, 128) 129 (115, 142) 0.006 116 (100, 131) 112 (96, 129) 0.509 0.134 0.039 
  RMSSD (ms) 37.6 (28.1, 47.1) 40.4 (33.5, 47.3) 0.562 41.7 (28.4, 55.0) 43.7 (35.6, 51.8) 0.570 0.537 0.156 
  pNN50 (%) 12.9 (7.1, 18.7) 14.2 (10.1, 18.3) 0.583 14.1 (6.7, 21.4) 16.4 (11.6, 21.2) 0.443 0.482 0.063 
Frequency-domain HRV parameters        
  LF (ms2) a 763 (557, 1046) 852 (725, 1000) 0.400 934 (570, 1532) 932 (771, 1125) 0.621 0.472 0.398 
  HF (ms2) a 336 (216, 523) 430 (326, 567) 0.158 412 (241, 705)  454 (328, 628) 0.451 0.800 0.127 
  logLF:HF 0.36 (0.24, 0.47) 0.31 (0.22, 0.40) 0.222 0.36 (0.24, 0.48) 0.32 (0.21, 0.42) 0.498 0.908 0.171 
  VLF (ms2) a 1634 (1376, 1942) 1727 (1520, 1962) 0.170 1556 (1146, 2112) 1910 (1645, 2119) 0.078 0.307 0.024 
Non-linear methods         
  SD1:SD2 (Poincaré ratio)  0.12 (0.10, 0.15) a 0.15 (0.12, 0.17) 0.474 0.14 (0.10, 0.18) a 0.16 (0.13, 0.19) 0.604 0.551 0.376 
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 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Day-time measurements (8h)         
Activity, IBI and HR         
  Activity level (cpm) 113 (96, 130) 118 (107, 132) 0.501 114 (98, 130) 117 (105, 130) 0.626 0.916 0.399 
  IBI (ms) 774 (738, 809) 760 (738, 781) 0.812 733 (697, 769) 774 (750, 799) 0.115 0.368 0.242 
  Min IBI (ms) 395 (359, 430) 377 (352, 402) 0.238 384 (352, 416) 394 (365, 422) 0.689 0.382 0.609 
  HR (bpm) 78.4 (74.7, 82.0) 79.9 (77.7, 82.0) 0.763 82.6 (78.5, 86.7) 78.1 (75.6, 80.6) 0.103 0.289 0.223 
  Min HR (bpm) 49.2 (46.5, 51.8) 48.1 (46.1, 50.1) 0.529 47.4 (43.9, 51.0) 47.3 (45.0, 50.0) 0.577 0.665850 0.401 
Time-domain HRV parameters        
  Ti  28.8 (25.4, 32.3) 30.9 (27.8, 34.0) 0.039 25.5 (21.2, 29.7) 31.2 (27.6, 34.7) 0.044 0.907 0.003 
  SDNN (ms)  112 (100, 125) 113 (103, 123) 0.252 103 (86, 119) 118 (107, 129) 0.100 0.520 0.077 
  SDANN (ms)  87 (77, 96) 91 (81, 100) 0.127 79 (62, 96) 91 (80, 102) 0.219 0.990 0.058 
  RMSSD (ms) 33.7 (24.5, 43.0) 35.6 (29.2, 41.9) 0.619 34.8 (23.7, 45.8) 39.0 (31.7, 46.2) 0.395 0.480 0.115 
  pNN50 (%)  6.3 (3.8, 10.5) a 11.4 (7.5, 15.2) 0.063 5.9 (3.0, 11.8) a 14.5 (10.1, 18.9) 0.454 0.292 0.089 
Frequency-domain HRV parameters        
  LF (ms2) a 667 (497, 894) 752 (631, 897) 0.192 761 (452, 1282) 790 (647, 964) 0.548 0.715 0.257 
  HF (ms2)  264 (168, 416) a 403 (293, 513) 0.117 278 (153, 506) a 515 (389, 640) 0.230 0.182 0.052 
  logLF:HF 0.45 (0.30, 0.59) 0.41 (0.29, 0.52) 0.354 0.47 (0.33, 0.62) 0.36 (0.23, 0.49) 0.240 0.612 0.127 
  VLF (ms2) a 1483 (1238, 1778) 1476 (1297, 1681) 0.086 1276 (894, 1822) 1746 (1505, 2023) 0.010 0.096 0.002 
Non-linear methods         
  SD1:SD2 (Poincaré ratio) a 0.13 (0.11, 0.15) 0.15 (0.13, 0.18) 0.276 0.15 (0.11, 0.19) 0.15 (0.12, 0.18) 0.994 0.760 0.452 
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 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Sleep-time measurements (5h)        
IBI and HR          
  IBI (ms) 920 (852, 987) 965 (916, 1015) 0.102 949 (884, 1013) 956 (898, 1014) 0.508 0.801 0.125 
  Min IBI (ms) 578 (513, 643) 549 (514, 583) 0.285 558 (496, 621) 571 (531, 612) 0.423 0.398 0.977 
  HR (bpm) 66.9 (61.9, 71.9) 63.5 (60.1, 66.9) 0.139 64.0 (59.3, 68.8) 64.0 (60.1, 68.0) 0.649 0.833 0.229 
  Min HR (bpm) 45.6 (42.3, 49.0) 43.3 (39.9, 46.8) 0.502 43.1 (40.0, 46.3) 44.4 (40.4, 48.4) 0.982 0.695 0.546 
Time-domain HRV parameters        
  Ti  18.4 (15.3, 22.0) 21.5 (19.4, 23.6) 0.117 21.1 (17.7, 25.0) 17.8 (15.4, 20.3) 0.212 0.026 0.927 
  SDNN (ms)  76 (67, 87) a 90 (81, 100) 0.028 82 (69, 98) a 78 (67, 89) 0.473 0.106 0.393 
  SDANN (ms) 43.8 (37.0, 50.5) 54.8 (47.6, 62.1) 0.041 49.2 (42.7, 55.7) 41.0 (32.6, 49.5) 0.135 0.017 0.438 
  RMSSD (ms) 31.8 (23.0, 43.9) 47.7 (37.6, 57.9) 0.224 42.3 (31.0, 57.7) 48.4 (36.6, 60.2) 0.836 0.934 0.110 
  pNN50 (%) a 8.2 (4.4, 15.0) 14.5 (10.1, 20.7) 0.015 11.2 (5.7, 22.1) 12.6 (8.3, 19.1) 0.447 0.606 0.023 
Frequency-domain HRV parameters        
  LF (ms2) a 815 (534, 1244) 911 (708, 1170) 0.373 998 (576, 1729) 951 (709, 1274) 0.980 0.822 0.743 
  HF (ms2) a 400 (234, 683) 624 (456, 853) 0.024 579 (331, 1015) 553 (384, 797) 0.765 0.613 0.091 
  logLF:HF 0.38 (0.21, 0.54) 0.18 (0.07, 0.29) 0.029 0.24 (0.08, 0.40) 0.24 (0.11, 0.36) 0.626 0.502 0.068 
  VLF (ms2) a 1773 (1407, 2234) 1858 (1566, 2203) 0.463 1715 (1181, 2490) 1799 (1475, 2196) 0.804 0.807 0.495 
Non-linear methods         
  SD1:SD2 (Poincaré ratio) 0.22 (0.18, 0.28) 0.29 (0.23, 0.34) 0.316 0.26 (0.21, 0.32) 0.31 (0.26, 0.37) 0.165 0.448 0.084 
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 Baseline END p value 1 Baseline END p value 2 p value 3 p value 4 
Sleep-time – day-time differences        
IBI and HR          
  IBI (ms) 169 (121, 217) 211 (172, 251) 0.022 187 (149, 225) 183 (137, 229) 0.862 0.345 0.119 
  HR (bpm) -13.7 (-17.4, -10.0) -16.9 (-19.6, -14.2) 0.050 -16.4 (-19.7, -13.0) -14.5 (-17.7, 11.3) 0.721 0.256 0.332 
Time-domain HRV parameters        
  Ti  -9.1 (-13.0, -5.3) -9.1 (-11.9, -6.4) 0.927 -4.7 (-8.8, -0.7) -11.3 (-14.5, -8.1) 0.053 0.315 0.087 
  SDNN (ms)  -31.1 (-40.9, -21.2) -22.3 (-32.3, -12.3) 0.150 -13.5 (-30.2, 3.2)  -34.8 (-46.6, -23.1) 0.070 0.118 0.484 
  SDANN (ms) -39.7 (-48.7, -30.7) -33.5 (-42.9, -24.1) 0.322 -26.0 (-40.4, -11.5) -46.9 (-58.0, -35.9) 0.036 0.075 0.283 
  RMSSD (ms) 10.1 (0.6, 19.7) 13.7 (5.5, 21.9) 0.470 13.2 (2.7, 23.7) 7.8 (-0.8, 16.4) 0.662 0.323 0.975 
  pNN50 (%)  6.8 (0.6, 12.9) 9.9 (4.3, 15.6) 0.212 6.9 (0.6, 12.9) 2.7 (-3.2, 8.7) 0.718 0.085 0.678 
Frequency-domain HRV parameters        
  LF (ms2) c 1.21 (0.87, 1.69) 1.26 (1.00, 1.59) 0.736 1.32 (0.98, 1.78) 1.29 (0.98, 1.69) 0.997 0.910 0.880 
  HF (ms2) c 1.75 (1.12, 2.73) 1.99 (1.54, 2.57) 0.626 2.35 (1.44, 3.83) 1.72 (1.28, 2.32) 0.318 0.462 0.626 
  VLF (ms2)  396 (-5, 797) 500 (107, 892) 0.757 698 (151, 1244) 143 (-315, -602) 0.146 0.241 0.317 
Non-linear methods         
  SD1:SD2 (Poincaré ratio) 0.11 (0.08, 0.15) 0.11 (0.08, 0.16) 0.910 0.10 (0.06, 0.14) 0.15 (0.11, 0.19) 0.072 0.407 0.154 
CER, continuous energy restriction; IER, intermittent energy restriction; END, measurements at endpoint (not following 2-d SER in case of IER group); IBI, interbeat interval; bpm, 
beats per minute; cpm, counts per minute; min IBI, minimum IBI; HR, heart rate; HRV, heart rate variability; Ti, triangular index; RMSSD, the square root of the mean of the sum of 
squares of differences between adjacent NN intervals; pNN50, percentage of adjacent NN intervals that differed by more than 50 ms; LF, low frequency power; HF, high frequency 
power; SD1:SD2, the ratio of the SD of beat-to beat IBI variability (SD1) against the SD of long-term IBI variability (SD2); SDNN, standard deviation of all NN intervals; ms, 
milliseconds; SDANN, standard deviation of the averaged NN intervals, calculated from 5 min epochs; VLF, very low frequency power.  
1 comparison within CER group by paired t-test; 2 comparison within IER group by paired t-test; 3 comparison between groups at END by ANCOVA adjusted for baseline values, 
percentage weight loss and 24 h or day-time activity for 24 h and day-time measurements, respectively, and adjusted for baseline and percentage weight loss for sleep-time 
measurements; 4 comparison within the whole cohort by paired t-test. 
Baseline results expressed as mean (95% CI) and END results expressed as estimated marginal means (95% CI), adjusted for baseline and percentage weight loss, and 24 h or day-
time activity for 24 h and day-time measurements, respectively, and adjusted for baseline and percentage weight loss for sleep-time measurements, except a geometric means (95% 
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CI); and c Results expressed as exponents of mean differences in Ln values (the ratio of the geometric mean in sleep:that in day, with 95% CI of the geometric mean ratios). Sleep-





6.6.5 Acute effects of severe energy restriction on HR and HRV 
measurements  
The acute effects of SER on HR and HRV parameters are shown in table 28. Statistically 
significant acute effects of 2-d SER were observed in the measurements taken during the mental 
stressor test where significantly lower HR, Ti and HF were observed after 2-d SER compared to 
non-SER endpoint. IBI (reciprocal of HR) has increased but fell short of significance. However, 
no differences were found in relative changes from rest to stress after 2-d SER compared to non-
SER endpoint, as assessed by resting minus stroop analysis. 
No significant differences were found in the IER group between the resting, 24 h and 
day-time measurements taken after the endpoint visit following 2 consecutive SER days 
compared to the non-SER endpoint (at least 2 days after the last SER day). The only sleep-time 
measurement showing a significant change was SDANN which was higher after the SER 
endpoint compared to endpoint.  
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Table 28 – Heart rate variability parameters at rest, during Stroop test, and ambulatory 
measurements over 24 h, day-time and sleep-time: acute response to 2 days SER compared to at 
least 2 days of normal eating/MER (END) following 4-week intermittent energy restriction 
dietary intervention. 
 END 2-d SER Δ difference  
END – 2-d SER 
p value1 
Resting measurements (N=19)    
IBI and HR     
IBI (ms) 974 (938, 1010) 982 (937, 1028) -8.2 (-39.6, 23.2) 0.590 
Min IBI (ms) 722 (689, 756) 730 (694, 767) -8.0 (-34.3, 18.3) 0.531 
HR (bpm) 61.9 (59.6, 64.2) 61.6 (58.7, 64.5) 0.3 (-1.5, 2.1) 0.723 
Min HR (bpm) 49.5 (46.1, 53.0) 49.3 (45.8, 52.9) 0.2 (-1.2, 1.6) 0.748 
Time-domain HRV parameters    
Ti a 13.1 (11.1, 15.4) 13.8 (11.7, 16.3) 0.95 (0.85, 1.05) 0.297 
RMSSD (ms) a 36.0 (27.3, 47.3) 38.0 (28.4, 51.0) 0.95 (0.85, 1.05) 0.293 
pNN50 (%) a 7.7 (4.4, 13.4) 8.1 (4.1, 16.3) 0.94 (0.63, 1.40) 0.753 
Frequency-domain HRV parameters    
LF (ms2) a 767 (489, 1202) 815 (488, 1363) 0.94 (0.72, 1.24) 0.641 
HF (ms2) a 396 (250, 628) 458 (260, 807) 0.87 (0.70, 1.08) 0.182 
logLF:HF 0.29 (0.16, 0.41) 0.25 (0.15, 0.36) 0.04 (-0.05, 0.12) 0.404 
Non-linear methods     
SD1:SD2  
(Poincaré ratio)  
0.31 (0.27, 0.35) 0.31 (0.28, 0.35) 0.00 (-0.03, 0.02) 0.729 
Stroop measurements (N=19)    
IBI and HR     
IBI (ms) 921 (872, 969) 945 (902, 988) -24.5 (-56.1, 7.0) 0.120 
Min IBI (ms) 726 (684, 768) 720 (676, 765) 5.2 (-34.2, 44.6) 0.784 
HR (bpm) 64.6 (60.7, 68.5) 61.6 (58.8, 64.5) 3.0 (0.2, 5.7) 0.035 
Min HR (bpm) 53.7 (49.2, 58.2) 53.1 (49.2, 57.0) 0.6 (-2.0, 3.1) 0.644 
Time-domain HRV parameters    
Ti a 11.4 (9.6, 13.5) 13.5 (11.4, 16.0) 0.84 (0.75,0.95) 0.009 
RMSSD (ms)a 33.0 (24.6, 44.2) 36.9 (27.0, 50.5) 0.89 (0.79, 1.01) 0.068 
pNN50 (%)a 6.2 (3.2, 11.9) 8.2 (4.2, 15.9) 0.76 (0.48, 1.20) 0.221 
Frequency-domain HRV parameters    
LF (ms2) a 807 (467, 1395) 915 (531, 1576) 0.88 (0.67, 1.17) 0.358 
HF (ms2) a 283 (155, 515) 399 (212, 749) 0.71 (0.53, 0.94) 0.020 
logLF:HF 0.46 (0.36, 0.56) 0.36 (0.25, 0.47) 0.10 (-0.02, 0.21) 0.092 
Non-linear methods     
SD1:SD2  
(Poincaré ratio)  
0.29 (0.24, 0.33) 0.30 (0.26, 0.34) -0.01 (-0.05, 0.03) 0.488 
Resting – Stroop measurements (N=18)    
IBI and HR     
IBI (ms) a 39 (12, 66) 46 (17, 75) 1.00 (0.95, 1.04) 0.821 
Min IBI (ms) 83 (46, 120) 110 (71, 149) -27.0 (-72.0, 18.0) 0.222 
HR (bpm) -1.3 (-2.6, 0.0) -0.3 (-0.8, 0.1) -1.0 (-2.5, 0.5) 0.195 
Min HR (bpm) 1.3 (-0.8, 3.4) -0.9 (-0.4, 7.6) 2.4 (0.0, 4.7) 0.053 
Time-domain HRV parameters    
Ti -1.5 (-3.1, 0.1) -3.0 (-4.7, -1.3) 1.6 (-0.3, 3.4) 0.089 
RMSSD (ms)a -5.0 (-13.0, 3.0) -3.9 (-8.3, 0.6) 1.00 (0.90, 1.12) 0.981 
pNN50 (%)a -0.8 (-4.8, 3.1) -0.2 (-3.3, 2.8) 1.14 (0.75, 1.73) 0.520 
Frequency-domain HRV parameters    
LF (ms2) a -804 (-1599, -9) -763 (-1788, 261) 1.00 (0.69, 1.47) 0.984 
HF (ms2) a -152 (-529, 225) -78 (-227, 71) 1.09 (0.86, 1.37) 0.456 
logLF:HF -0.31 (-0.44, -0.18) -0.28 (-0.40, -0.15) -0.03 (-0.22, 0.16) 0.720 
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 END 2-d SER Δ difference  
END – 2-d SER 
p value1 
Resting – Stroop measurements (continued)    
Non-linear methods    
SD1:SD2 a  
(Poincaré ratio)  
0.12 (0.04, 0.19) 0.12 (0.07, 0.17) 1.00 (0.81, 1.24) 0.997 
24 h measurements (N=17)    
Activity, IBI and HR     
Activity level (cpm) 82 (75, 89) 76 (68, 85) 5.6 (-1.9, 13.2) 0.133 
IBI (ms) 814 (779, 849) 831 (799, 864) -16.9 (-47.2, 13.4) 0.255 
HR (bpm) 74.2 (71.3, 77.2) 72.5 (69.8, 75.1) 1.7 (-0.8, 4.3) 0.166 
Time-domain HRV parameters    
Ti 39.0 (34.0, 44.0) 41.4 (36.5, 46.3) -2.4 (-9.4, 4.6) 0.476 
SDNN (ms) 146 (125, 167) 152 (135, 170) 6.5 (-13.6, 26.6) 0.396 
SDANN (ms) 124 (102, 147) 132 (116, 148) -7.4 (-28.1, 13.2) 0.458 
RMSSD (ms) 44.0 (32.2, 55.7) 46.4 (33.5, 59.2) -2.4 (-12.4, 7.6) 0.617 
pNN50 (%)a 10.0 (5.5, 18.1) 11.0 (6.2, 19.7) 0.90 (0.47, 1.73) 0.748 
Frequency-domain HRV parameters    
LF (ms2) a 1004 (690, 1459) 989 (637, 1537) 1.01 (0.81, 1.26) 0.892 
HF (ms2) a 472 (292, 762) 494 (295, 826) 0.96 (0.62, 1.48) 0.830 
logLF:HF 0.33 (0.19, 0.46) 0.30 (0.17, 0.44) 0.03 (-0.12, 0.17) 0.703 
VLF (ms2) a 1886 (1449, 2454) 1894 (1424, 2519) 1.00 (0.85, 1.17) 0.956 
Non-linear methods     
SD1:SD2  
(Poincaré ratio)  
0.16 (0.11, 0.21) 0.16 (0.12, 0.20) 0.00 (-0.04, 0.04) 0.877 
Day-time measurements (8h, N=18)    
Activity, IBI and HR     
Activity level (cpm) 117 (101, 132) 115 (101, 130) -1.0 (-17.3, 15.3) 0.900 
IBI (ms) 762 (724, 800) 757 (720, 794) 6.5 (-21.8, 34.8) 0.636 
HR (bpm) 79.4 (75.5, 83.3) 80.0 (76.1, 83.8) -0.7 (-3.6, 2.3) 0.634 
Time-domain HRV parameters    
Ti a 28.7 (25.2, 32.7) 28.3 (25.1, 32.0) 1.03 (0.91, 1.16) 0.642 
SDNN (ms)  112 (95, 129) 116 (98, 133) -4.5 (-20.8, 11.7) 0.562 
SDANN (ms) 86 (71.3, 100) 89 (75, 103) -3.5 (-19.0, 12.1) 0.643 
RMSSD (ms)  38.0 (26.7, 49.4) 40.2 (27.9, 52.4) -2.3 (-11.4, 6.8) 0.598 
pNN50 (%) a 6.6 (3.0, 14.5) 7.9 (3.8, 16.2) 0.83 (0.37, 1.83) 0.622 
Frequency-domain HRV parameters    
LF (ms2) a 790 (512, 1220) 755 (472, 1207) 1.03 (0.86, 1.23) 0.718 
HF (ms2) a 323 (190, 551) 347 (203, 593) 0.93 (0.60, 1.44) 0.719 
logLF:HF 0.39 (0.23, 0.55) 0.34 (0.16, 0.51) 0.05 (-0.10, 0.20) 0.521 
VLF (ms2) a 1628 (1200, 2210) 1503 (1053, 2145) 1.07 (0.92, 1.25) 0.342 
Non-linear methods     
SD1:SD2 a  
(Poincaré ratio) 
0.15 (0.12, 0.20) 0.16 (0.12, 0.21) 0.97 (0.72, 1.31) 0.833 
Sleep-time measurements (5h, N=16)    
IBI and HR     
IBI (ms) 958 (897, 1019) 983 (933, 1032) -24.4 (-86.2, 37.3) 0.413 
HR (bpm) 63.5 (59.4, 67.5) 61.6 (58.6, 64.5) 1.9 (-2.3, 6.1) 0.354 
Time-domain HRV parameters    
Ti a 18.2 (15.8, 20.6) 22.0 (17.5, 26.3) -3.8 (-7.8, 0.2) 0.059 
SDNN (ms) a 79.8 (67.9, 93.7) 87.9 (72.8, 106.1) 0.91 (0.79, 1.05) 0.167 
SDANN (ms) 42.0 (35.2, 48.8) 53.9 (40.3, 67.4) -11.9 (-23.8, 0.0) 0.050 
RMSSD (ms)  53.1 (37.6, 68.5) 55.1 (36.2, 74.1) -2.0 (-15.5, 11.4) 0.749 
pNN50 (%) a 14.9 (9.1, 24.2) 13.8 (7.1, 26.7) 1.08 (0.61, 1.91) 0.781 
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 END 2-d SER Δ difference  
END – 2-d SER 
p value1 
Sleep-time measurements (continued)    
Frequency-domain HRV parameters    
LF (ms2) a 1191 (774, 1832) 1061 (639, 1761) 1.12 (0.80, 1.58) 0.482 
HF (ms2) a 691 (432, 1107) 645 (354, 1177) 1.07 (0.68, 1.68) 0.750 
logLF:HF 0.24 (0.09, 0.38) 0.22 (0.07, 0.36) 0.02 (-0.13, 0.17) 0.771 
VLF (ms2) a 1974 (1441, 2705) 2153 (1529, 3031) 0.92 (0.69, 1.22) 0.533 
Non-linear methods     
SD1:SD2  
(Poincaré ratio) 
0.33 (0.27, 0.39) 0.31 (0.23, 0.39) 0.02 (-0.05, 0.09) 0.597 
IER group only. IBI, interbeat interval; bpm, beats per minute; cpm, counts per minute; min IBI, 
minimum IBI; HR, heart rate; HRV, heart rate variability; Ti, triangular index; RMSSD, the square root 
of the mean of the sum of squares of differences between adjacent NN intervals; pNN50, percentage of 
adjacent NN intervals that differed by more than 50 ms; LF, low frequency power; HF, high frequency 
power; SD1:SD2, the ratio of the SD of beat-to beat IBI variability (SD1) against the SD of long-term IBI 
variability (SD2); SDNN, standard deviation of all NN intervals; ms, milliseconds; SDANN, standard 
deviation of the averaged NN intervals, calculated from 5 min epochs; VLF, very low frequency power.  
Results expressed as mean (95% CI), except a geometric means (95% CI) 1 comparison within IER group 
using paired t-test, END vs. 2-d SER. 
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6.6.6 Resting and ambulatory blood pressure 
The resting and ambulatory blood pressure results are shown in table 29. The ABP 
results are reported as 24 h, day-time and sleep-time. There were no significant differences in 
resting SBP or DBP at endpoint between treatment groups although there was an overall 
decrease in BP following both dietary intervention treatments combined which was statistically 
significant for resting SBP (p = 0.032). Twenty four hour, day-time and sleep-time systolic and 
diastolic ABP did not differ between groups at endpoint. When analysing the effect of weight 
loss in the whole cohort, there was a statistically significant decrease in 24 h (p < 0.001), day-
time (p = 0.001) and sleep-time DBP (p = 0.011) although no statistical significance was found 
in SBP. 
The IER produced significant acute reductions (after 2-d SER) in resting DBP and 




Table 29 – Resting and ambulatory blood pressure measurements. 
















 Baseline END  p value 1 Baseline END  p value 2 2-d SER p value 2 p value 3 
Resting a         
  SBP 130 (123, 138) 123 (119, 127) 0.011 124 (117, 130) 123 (119, 127) 0.477 116 (111, 122) 0.051 0.889 
  DBP 79 (75, 84) 77 (74, 79) 0.248 77 (72, 82) 77 (74, 79) 0.677 73 (69, 76) 0.014 0.916 
Ambulatory Blood Pressure         
24 h measurements b         
  SBP 124 (119, 128) 121 (117, 124) 0.248 121 (116, 126) 119 (116, 123) 0.216 117 (113, 121) 0.257 0.741 
  DBP 75 (72, 78) 72 (70, 74) 0.024 75 (72, 78) 71 (69, 74) 0.005 72 (70, 74) 0.435 0.674 
Day-time / awake measurements         
  SBP 127 (123, 131) 125 (121, 129) 0.521 126 (120, 131) 123 (119, 127) 0.228 120 (1155, 125) 0.344 0.438 
  DBP 78 (75, 81) 75 (73, 78) 0.069 79 (75, 82) 74 (72, 76) 0.003 74 (71, 76) 0.819 0.448 
Sleep-time measurements         
  SBP 110 (104, 115) 104 (100, 108) 0.089 106 (99, 112) 105 (100, 109) 0.545 105 (99, 110) 0.739 0.928 
  DBP 65 (62, 69) 61 (58, 63) 0.026 61 (58, 65) 60 (57, 63) 0.202 61 (58, 64) 0.664 0.796 
DBP, diastolic blood pressure; SBP, systolic blood pressure; 2-d SER, measurements taken following 2-d severe energy restriction; END, measurements at endpoint (not following 
2-d SER in case of IER group). 1 comparison within CER group by paired t-test; 2 comparison within IER group by paired t-test; 3 comparison between groups at END by ANCOVA 
adjusted for baseline values and percentage weight loss. Baseline results expressed as mean (95% CI) and END results expressed as estimated marginal means (95% CI) adjusted for 
baseline values and percentage weight loss. a One missing resting BP measurement in the CER group due to an error that occurred while downloading the data to the computer. b 2 
missing participants from each group for ABP due to technical problems with the monitor.  
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6.6.7 Serum and plasma biochemistry markers 
Plasma IL-6 and catecholamines (normetanephrine); serum triglycerides, total cholesterol 
: HDL ratio, leptin and adiponectin; and insulin sensitivity (R-QUICKI) values are presented in 
table 30. There were no significant differences in these markers at endpoint between treatments. 
The overall effect of weight loss, by analysing the whole cohort together, produced a significant 
increase in R-QUICKI (mean change [95% CI]: 0.02 [0.01, 0.04]), and significant decreases in 
triglycerides (exponent of mean change in Ln values [95%CI]; 0.96 [0.93, 0.99]),  total 
cholesterol : HDL ratio (exponent of mean change in Ln values [95%CI]; 0.81 [0.74, 0.88]),  
leptin (exponent of mean change in Ln values [95%CI]; 0.77 [0.68, 0.86]), adiponectin (mean 
change [95% CI]: -0.7 [-1.14, -0.18]) and leptin : adiponectin ratio (exponent of mean change 
[95% CI]: 0.83 [0.74, 0.92]). The IER produced additional significant acute reductions (after 2-
d SER) in triglycerides, leptin and the leptin : adiponectin ratio compared to endpoint. 
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Table 30 – Biochemistry measurements: IL-6, catecholamines, insulin sensitivity, leptin and adiponectin. 
















 Baseline END  p value 1 Baseline c END c  p value 2 2-d SERd p value 2 p value 3 
Plasma IL-6 (ng/L) b 0.63 (0.36, 0.88) 0.65 (0.49, 0.96) 0.903 e 1.02 (0.60, 1.55) 0.77 (0.63, 1.12) 0.147 e 0.88 (0.73, 1.19) 0.354 e 0.224 f 
Plasma Normetanephrine 
(pmol/L)  
489 (380, 597) 563 (428, 699) 0.406 491 (392, 590) 573 (426, 719) 0.255 538 (407, 670) 0.719 0.928 
R-QUICKI 0.39 (0.38, 0.41) 0.41 (0.40, 0.43) 0.013 0.39 (0.37, 0.42) 0.42 (0.40, 0.44) 0.006 0.41 (0.39, 0.44) a 0575 0.590 
Triglycerides (mmol/L) a 1.12 (0.90, 1.39) 0.96 (0.86, 1.06) <0.001 1.38 (1.09, 1.75) 1.04 (0.93, 1.17) 0.018 0.98 (0.83, 1.14) 0.031 0.270 
Total cholesterol: HDL 
cholesterol ratio a 
3.52 (3.17, 3.92) 3.44 (3.29, 3.60) 0.028 3.36 (3.01, 3.75) 3.51 (3.34, 3.68) 0.262 3.71 (3.40, 4.06) 0.171 0.558 
Serum Leptin (µg/L) a 18.0 (13.1, 24.7) 15.1 (13.5, 17.0) 0.009 23.5 (16.7, 33.0) 16.2 (14.3, 18.3) 0.001 14.4 (9.9, 20.9) <0.001 0.448 
Serum Adiponectin (mg/L) 8.45 (6.62, 10.34) 7.76 (7.21, 8.32) 0.187 7.91 (5.89, 9.92) 7.31 (6.71, 7.90) 0.015 7.41 (5.56, 9.27) 0.613 0.267 
leptin : adiponectin ratio a 2.40 (1.65, 3.49) 2.23 (1.96, 2.53) 0.020 3.53 (2.48, 5.02) 2.56 (2.23, 2.94) 0.024 2.34 (1.56, 3.52) <0.001 0.152 
CER, continuous energy restriction; IER, intermittent energy restriction; IL, interleukin; 2-d SER, measurements taken following 2-d severe energy restriction; END, measurements 
at endpoint (not following 2-d SER in case of IER group). 1 comparison within CER group by paired t-test; 2 comparison within IER group by paired t-test; 3 comparison between 
groups at END by ANCOVA adjusted for baseline values and percentage weight loss. Baseline results expressed as mean (95% CI) and END results expressed as estimated marginal 
means (95% CI) adjusted for baseline values and percentage weight loss, except a geometric mean (95% CI) and b median (lower and upper IQR); c 2 missing samples in IER group, 
n=19; d 1 missing value, IER n=20; e p value obtained using related samples Wilcoxon Signed Rank Test; f p value obtained by Mann-Whitney U test.  
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6.7 Discussion 
This is the first RCT assessing the effects of intermittent fasting on HRV that recruited 
healthy centrally obese men and women based on waist circumference ethnicity specific cut-offs 
for high risk of cardio-metabolic disease. The IER intervention group was compared with an 
isoenergetic CER control group in a parallel design. Both treatments achieved comparable 
weight loss and waist circumference reductions which was the aim of the trial so that changes in 
the outcome variables could be attributed to the type of energy restriction diet followed as 
opposed to weight loss alone. 
In otherwise healthy individuals, obesity has been shown to decrease HRV (310) and that 
losing weight can improve HRV in obese and normal weight individuals as well as diseased 
states (hypertension, type 2 diabetes; please refer to Chapter 1, section 1.5.1.2). However, 
preliminary data from the LighterHeart Study in our group showed that favourable changes in 
ANS function occur rapidly following onset of SER (within 1 week) and these could be through 
a weight-loss independent mechanism. Therefore, this study tested whether an IER approach for 
weight loss would confer any additional cardiometabolic benefits compared to a CER approach 
in centrally obese individuals, independent of weight loss. It was therefore hypothesised that 
losing weight via an IER approach would have superior benefits for the cardiac autonomic 
system (assessed by HRV), compared to a CER approach. However, this study showed no 
superior effects of following an IER diet compared to a CER diet on HRV at rest, during a 
mental stress inducing test, or in ambulatory measurements. Any observed improvements in 
HRV were due to overall weight loss. Analysis of the acute effects of SER in the IER group 
showed lower stress-induced changes in HRV after two consecutive days of SER. 
6.7.1 Resting and stress-induced changes in heart rate variability 
measurements  
In a controlled setting, resting measurements were recorded followed by a mental stressor 
test to record stress-induced changes in HRV. These changes recorded in a controlled setting 
explored the effects of a mild stressor on autonomic changes with minimal potential 
confounders as opposed to a free-living situation. From the measurements taken under 
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controlled conditions, there were no significant differences at endpoint between treatments, 
except for resting LF power which was significantly higher in the IER group compared to the 
CER group; and HR increase in response to stress was significantly attenuated in the IER group 
compared to the CER group. The studies assessing HRV in intermittent fasting are limited and 
come from rodent experiments. Mager et al measured 24 h HRV in rats maintained on an 
intermittent fasting diet (every other day feeding) or energy restricted diet (40% energy 
reduction) and showed an increase in LF and HF power of HRV (with a stable LF:HF ratio) that 
was comparable between the two diets, and maximal effects achieved after 4 to 5 weeks (296). 
The greater LF power in the IER group was not accompanied by a significant increase in HF but 
preserved the LF:HF ratio. Although there were no differences between groups in IBI 
(reciprocal to HR) stress-induced decrease, within the IER group the stress induced decrease in 
IBI was significantly reduced. This effect of intermittent fasting on cardiovascular adaptation to 
stress has been previously described in rats subjected to stress (immobilization and cold-water 
swim) where the rats on intermittent fasting had a lower stress-induced increase in HR 
compared to a control ad libitum diet (311). Acutely, SER further reduced the stress-induced 
increase in HR and attenuated the stress-induced decrease in overall HRV, as shown by a 
significantly lower stress-induced decrease in Ti after SER compared to non-SER endpoint, and 
by preserving better the vagal tone, shown by a lower stress-induced decrease in HF. A potential 
mechanistic explanation for this finding in the IER group could involve the enhanced activity of 
brainstem cholinergic cardiac vagal neurons - which increase parasympathetic tone - by the 
brain-derived neurotrophic factor (BDNF) (312). BDNF expression and signalling have been 
shown to increase in response to physical activity and intermittent fasting (313) and Wan et al 
were able to provide evidence for the first time in mice of its role in the regulation of HR by 
enhancing the activity of cardiovagal neurons in the nucleus ambiguus of the brainstem, which 
in turn send their axons through the vagus nerve to the heart releasing acetylcholine that has a 
HR lowering effect (314).  
The overall weight loss effect, independent of the type of diet followed, resulted in 
statistically significant increases in resting IBI and minIBI, and decreases in HR and min HR. 
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The IBI and HR changes were consistently greater after following the IER diet compared to the 
CER diet. The overall weight loss effect also resulted in attenuated stress-induced changes 
during the stressor test in HR/IBI and beat-to-beat HRV (pNN50, RMSSD and HF - 
representing parasympathetic tone). Further analysis showed that the IBI/HR stress induced 
changes were more attenuated in the IER group whereas the stress-induced beat-to-beat HRV 
changes were more attenuated in the CER group. These observed changes in the response to the 
stress test after the intervention could be the effect of weight loss or could also be habituation to 
the mental stress test. The greater perseverance of the parasympathetic tone observed in 
response to the mental stress test confers a more flexible autonomic regulation which in turn 
represents a better cardiovascular resilience and adaptation to mild stress following weight loss. 
6.7.2 Ambulatory heart rate variability measurements 
From the ambulatory measurements, there were no significant differences between 
treatment groups at endpoint, except for nocturnal SDANN, a measure of longer-phase 
variability, which was significantly lower in the IER group compared to the CER group. 
However, this finding may be a multiple testing type I error as VLF, the other HRV parameter 
reflecting longer-phase variability, did not show any significant differences between groups.  
The overall effects of weight loss show statistically significant increase in 24 h IBI, and a 
trend towards a decrease in HR, that are comparable to the results observed after a 12-week 
continuous energy restriction weight-loss programme in overweight women, that were 
otherwise healthy (103). This study also observed a significant increase in SDNN after weight 
loss, which was not observed in our findings, except for a trend towards an increase in SDNN in 
the day-time. However, our findings showed a statistically significant increase in 24 h and day-
time SDANN (borderline significance in day-time) and VLF after weight loss, which represent 
the longer-phase variability arising from hormonal changes, including the renin-angiotensin-
aldosterone system and thermoregulation. An increase in 18 h VLF power was observed in a 
study with severely obese normotensive subjects after a 3 week dietary and high intensity 
aerobic physical activity intervention, along improvements in vagally-mediated parameters 
(RMSSD, pNN50 and HF) (100). Another small study (n = 8) in severely obese subjects (≥ 40 
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kg/m2) showed an increase in 24 h and day-time IBI, SDANN and VLF after 3 months on a 
weight loss program (varying between 1000 – 1500 kcal / day provided with foodpacks – 
percentage of energy restriction was not mentioned) (99). In our study, a statistically significant 
increase in Ti after weight loss was seen in the day-time, and a trend of an increase in 24 h 
period. The only study showing an increase in Ti after weight loss comes from a study in 
women with bariatric surgery-induced weight loss, over 24 h measurements (127). 
6.7.3 Resting and ambulatory blood pressure 
No differences at endpoint were seen between groups in resting or ambulatory BP. The 
only other published RCT in humans that compared directly the effects of a CER and IER diets 
in metabolic disease risk with the same protocol used in this study (2 consecutive days of a 
VLCD per week) was done in healthy overweight women with an increased risk of breast 
cancer (299). This study measured resting BP and found small reductions in systolic and 
diastolic BP that were not different between groups at endpoint which is consistent with the 
resting BP results in this study. A study comparing alternate-day fasting (25% energy needs on 
fast days and 125% energy needs on alternating “feast days”) with CER (25% daily energy 
restriction) also reported no differences in resting HR, systolic and diastolic BP between 
treatment groups after 6 months of intervention (315). An 8-week intermittent fasting study with 
30% energy restriction (6 days energy restricted + 1 day fasting - 120 kcal juice powder for 24 
h) where one group (IFCR-L) had liquid meal replacements for breakfast and lunch and a food 
based dinner on energy restricted days and the other group (IFCR-F) had all three meals food 
based on energy restricted days. Both groups had a non-significant reduction in resting SBP but 
only the IFCR-L group additionally presented a non-significant reduction in resting DBP which 
is in line with the results obtained in both groups in this study. The IFCR-L group achieved a 
greater energy restriction that was reflected in a significantly higher weight loss which is more 
comparable to the energy restriction achieved by this study’s cohort (316).  
6.7.4 Biochemistry measurements 
In the present study serum leptin significantly decreased in both groups after the dietary 
intervention and had further significant reductions in the IER group when measured after the 
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two consecutive days of SER. The significant decrease in leptin concentrations observed in both 
groups is likely to be related to the comparable reduction in fat mass by both groups (317). 
Klempel et al also measured adiponectin and leptin which showed both significant decreases 
within each group (316). There is strong evidence showing an increase in leptin, with the 
activation of the brain melanocortin system, linking obesity with overactivation of sympathetic 
renal activity and elevated blood pressure (318). A decrease in leptin may be one of the 
mechanisms responsible for the blood pressure lowering-effects of weight lost in central obesity 
and the fact that the IER regime presented further significant reductions in leptin after 2-d SER 
could be associated with the greater reductions seen in 24 h and day-time systolic and diastolic 
BP following 2-d SER. Although both treatments resulted in decreases in adiponectin, only the 
IER produced significant decreases within group. It’s been shown that adiponectin acutely 
decreases in response to the first 8-12 weeks of energy restriction and tends to increase once a 
10% of weight loss has been achieved (319). 
The significant increase in ketone bodies after two consecutive days of SER, measured by 
an increase in serum β-hydroxybutyrate, indicates a switch in metabolic mode from 
glycogenolysis to beta-oxidation of fatty acids. β-hydroxybutyrate has been shown to inhibit 
SNS activity at the level of sympathetic ganglion in mice as an antagonist for GPR41 and may 
also have a direct inhibitory effect on the heart rate (132). This could be a potential mechanism 
for the beneficial acute effects of fasting in preserving HR and HRV under stress conditions.  
6.7.5 Other considerations 
In rodents, the cardiovascular system response to IER (reduced resting HR and BP) is 
reversed within 1 to 2 weeks of going back to an ad libitum diet indicating that the 
cardioprotective benefits are not sustained in the long-term once the IER is discontinued (296). 
Studies on weight-maintenance in intermittent fasting are scarce and the few that have been 
performed have shown the reductions in weight to be maintained in both groups, although this 
was assessed one month after the termination of the intervention (299), or showed better weight-
maintenance for the alternate-day fasting group 6 months after the intervention (320). Whether 
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the effects of intermittent fasting are sustained in the weight-maintenance phase should be 
addressed in the future. 
6.7.6 Strengths and limitations 
This study has a few strengths, namely the fact that ambulatory measurements were taken 
for blood pressure, HR and HRV so there is no influence of the white-coat hypertension (321), 
and the IER diet was directly compared to the CER diet. This study also has a few limitations, 
namely the short duration of the dietary intervention (4 weeks), although this was a mechanistic 
study based on a 1-week acute pilot study (the LighterHeart study) that didn't provide a 
justification for a longer intervention. This study lacked a control group where participants 
weight was stable, hence the overall weight loss effects presented needs further confirmation by 
another study in order to rule out a habituation effect of wearing the monitors. The acute effect 
of ambulatory measurements is actually a carry-over effect as the ambulatory measurements 
started while participants were fasted but recorded further 24 h when the participants would 
have started the non-SER eating days. Physical activity was measured for 24 h while wearing 
the heart monitor (which had an incorporated accelerometer where physical activity data was 
obtained from) and the ABP monitor which may not represent the overall physical activity 
levels taken throughout the intervention. Another limitation is the fact that HRV and ABP 
measurements were done simultaneously and due to some volunteers having their sleep 
interrupted while the blood pressure monitor was taking a reading, this could have interfered 
with the HRV measurements. 
 
In summary, this study showed no superior effects of weight loss achieved through an 
IER diet compared to a CER diet on HRV at rest, during a mental stress inducing test, or in 
ambulatory measurements. The improvements in HRV observed were due to overall weight loss 
effect and there was no evidence of an independent effect of energy restriction pattern. Analysis 
of the acute effects of SER in the IER group showed lower stress-induced changes in HRV after 
two consecutive days of SER. An IER approach to weight loss appears to be an alternative to a 
CER approaches with comparable weight loss and body composition changes. IER could 
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potentially be used as part of a healthy lifestyle for weight-maintenance if this regime suits best 
certain individuals' lifestyle. Further RCTs are needed with longer durations and assessment of 
cardio-metabolic outcomes in a weight-maintenance phase to assess whether the changes 
observed could potentially be sustained in the long term. 
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Chapter 7 Discussion 
This thesis broadly explored diet as a determinant of cardiac autonomic function by 
investigating relationships between HRV and aspects of diet / nutritional status that could 
influence sympathetic and parasympathetic activity in healthy and diseased states. 
Cardiac autonomic function is a neglected aspect of the pathophysiology of CVD in the 
field of nutritional sciences, and there is relatively little published literature on how whole diets 
or dietary components may influence this important CVD risk factor, compared to other risk 
factors such as blood lipids, insulin resistance and blood pressure. The overall aim of the thesis 
was to explore the associations and impacts of some of the main dietary candidates that may 
influence HRV: LC n-3 PUFA and energy intake restriction. 
7.1 Method development for assessing HRV in nutritional sciences 
research 
In nutritional sciences research, the use of low-burden HRV measuring devices is 
advantageous as participants are required to wear them in the free-living state. In contrast to the 
widely used Holter monitors, the Actiheart and eFaros devices are small, chest worn devices 
with incorporated accelerometers that, when used in free-living populations, do not interfere 
with subjects' daily activities, hence not altering their usual routine. Throughout the doctoral 
work, two different methods for measuring HRV were used. The first method used Actiheart 
devices which only stored IBI data and required a substantial amount of manual editing of data 
to remove artefacts and quite a few recordings had to be excluded due to too much unusable 
data either derived from loss of signal or too much noise. This method was further improved by 
testing new ECG pads in the reproducibility study and using those that produced an overall 
better signal to noise ratio in the Om3ga and FISHH studies, although the amount of editing was 
still substantial and very subjective. The second method used for assessing HRV was greatly 
improved due to the acquisition of a new recording device (eFaros) that had just become 
available for the last study, the Met-IER. This method substantially reduced the subjectivity of 
the manual component of HRV data processing through improvement in software analysis, 
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while still allowing for visual inspection of the raw ECG data and manual edits if/where needed. 
This method was suitable for measurement of acute changes, for example during a mental stress 
test, as well as ambulatory 24 h monitoring, it demonstrated detection of increases in mean IBI 
and longer-phase HRV in response to weight loss across the study population, and could be 
appropriate for use in further dietary intervention studies. Limitations to the application of this 
approach for assessing cardiac autonomic function in future dietary intervention studies include 
the large number of parameters generated, rendering the interpretation of such sizable dataset 
complex and vulnerable to type I errors. Further work is required to identify the most clinically 
meaningful and sensitive parameters for use in detecting the subtle physiological effects 
expected from dietary interventions. 
7.2 LC n-3 PUFA and HRV 
Initially, HRV data collected from the MARINA trial, a RCT assessing the effect of fish 
oil supplementation equivalent to eating 0, 1, 2 or 4 portions of fish per week, was analysed for 
the day-time period, showing that there may be a treatment effect of an increase in longer-phase 
HRV similar to that previously shown and published for the sleep-time period (186). However, 
the population studied appeared to be replete in LC n-3 PUFA from the start of intervention, and 
therefore unlikely to respond in the same way as populations that have low LC n-3 PUFA status. 
This led on to the first observational study (the Om3ga study) comparing HRV in vegans with 
age/sex/BMI-matched omnivore controls, representing populations with low and high tissue LC 
n-3 PUFA status, respectively. It was hypothesised that vegans would display lower mean HRV, 
however, the observed differences between groups were more complex, with vegans presenting 
higher 24 h overall HRV due to greater sleep-day differences compared to omnivores, and lower 
beat-to-beat HRV in the day-time. Vegans also presented lower availability of LC n-3 PUFA 
lipid mediators that may influence anti-inflammatory capacity, especially in populations with 
underlying chronic low-grade inflammation that present low tissue LC n-3 PUFA status. This 
led to a feasibility study to characterise the variability of LC n-3 PUFA status in a sample of 
stage 5 CKD patients commencing haemodialysis, which is a population with a high burden of 
inflammation and CVD compared to the general population, with the aim of establishing a 
207  
potential relationship with HRV. Haemodialysis patients in this study had particularly low 
proportions relative to total fatty acid content and a narrow degree of variability of erythrocyte 
membrane EPA + DHA, which precluded any meaningful findings in the relationship between 
tissue LC n-3 PUFA status and HRV. Nevertheless, analysis of the plasma LC n-3 PUFA, a 
biomarker of short-term LC n-3 PUFA intake, showed that EPA (but not DPA or DHA) 
proportions in plasma, was associated with better overall and longer-phase autonomic 
regulation. However, EPA was associated with reduced beat-to-beat regulation, which presented 
the same trend for DPA, which suggests that a compromised conversion of DPA to DHA might 
be a potential mechanism whereby these patients have depressed parasympathetic tone, either 
due to the reduced availability and incorporation of DHA into the cardiomyocytes membranes 
and/or due to a reduction in DHA-derived lipid mediators involved in neuroprotective processes 
in this patient population. The Om3ga study showed that vegans - as a model of a population 
with low LC n-3 PUFA tissue levels - had reduced availability of precursor markers for pro-
resolving lipid mediators. As a healthy population, this might not necessarily have a significant 
impact on cardiovascular events or SCD but in populations at higher risk of cardiovascular 
disease and SCD such as CKD, having low LC n-3 PUFA tissue levels as it was observed in the 
FISHH study (median O3I 3.26%) may have severe repercussions. In addition, the plasma DHA 
in this haemodialysis population was lower than the one found in the omnivore subjects from 
the Om3ga study, although the estimated DHA dietary intake was comparable, which indicates 
a compromised metabolism and/or incorporation of the LC n-3 PUFA in tissue, which is likely 
to be at the level of interconversion from DPA to DHA, suggested by the FISHH study results.  
The pathophysiology of CVD observed in patients with stage 5 CKD is characterised by 
atherosclerosis caused by excess LDL-cholesterol and vascular inflammation (322). The fact 
that the FISHH study population presented very low erythrocyte and plasma proportions of 
DHA and EPA, and potential compromised interconversion of DPA to DHA, indicates reduced 
availability of lipid mediator precursors involved in the resolution of inflammation. Reduced 
availability of SPM precursors would be likely to potentiate vascular inflammation and is 
implicated as one of the potential mechanisms in the accelerated atherosclerosis observed in this 
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population (323). A RCT in stage 3 and 4 CKD patients showed that n-3 PUFA 
supplementation reduced plasma 20-HETE (324), an AA-derived lipid mediator previously 
shown to enhance vascular inflammation in animal models of diabetes and 
ischaemia/reperfusion (325). The same trial has also shown that supplementation with n-3 
PUFA significantly increased RvD1, and precursors of the E- and D-series resolvins 18-HEPE 
and 17-HDHA, respectively, which are involved in actively promoting the resolution of 
inflammation (326). Therefore, it could be argued that a fish oil supplementation study to 
increase EPA and DHA tissue levels in haemodialysis patients is clinically justified in order to 
reduce risk of cardiac mortality/events. The cardiovascular effects of LC n-3 PUFAs in 
haemodialysis patients have not been extensively explored, as discussed in the introduction of 
Chapter 6 (section 6.1), and studies relating LC n-3 PUFAs tissue status to HRV are scarce 
(106,111), which warrants further studies in CKD patients to assess the relationship between 
HRV and LC n-3 PUFA tissue status using other potential biomarkers of intake, such as 
mononuclear cells and adipose tissue. Adipose tissue fatty acid composition is reflective of long 
term dietary intake with an estimated average t1/2 of 6-9 months of intake, and has been 
considered the gold standard measurement for dietary fatty acid status (221). Exploring the use 
of adipose tissue for n-3 PUFA status in patients that recently started haemodialysis may inform 
of their longer-term status and using this method to measure LC n-3 PUFA status wouldn't be 
affected by the uraemic conditions. Mononuclear cells have more recently been suggested as the 
most suitable biomarker for long-term oily fish intake within the range likely to be consumed by 
the UK population (1-4 portions/week) (291). This biomarker has not been used previously in a 
haemodialysis cohort to assess LC n-3 PUFA status and may be explored as an alternative to 
erythrocyte membrane, as the analysis of the latter biomarker presented challenges in this 
population. 
 Venous blood plasma concentrations of lipid mediators in whole fasting plasma are 
likely to be an insensitive marker of capacity for autacoid release and activity in specific sites of 
inflamed tissue. Nevertheless, higher circulating plasma concentrations of SPM precursor 
markers may indicate ease of bioavailability for conversion to SPM when needed, which 
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presents clear functional implications for populations with low tissue EPA and DHA stores 
(227). It is not known whether individuals with low n-3 PUFA status have increased rates of 
EPA-/DHA-derived mediators turnover as an adaptive mechanism to avoid compromising SPM 
availability. If this were the case, then it would be expected that having low pools of SPM 
precursors would have no functional consequences in vegans where the inflammatory burden is 
generally low, but could carry consequences in haemodialysis patients where the underlying 
chronic inflammation might not resolve due to not having enough tissue EPA+DHA that could 
be metabolised to anti-inflammatory lipid mediators. Future research in this area should address 
whether populations with low n-3 PUFA status are more at risk of having a pro-inflammatory 
profile, independent of underlying diseased states. In order to provide convincing evidence for 
the potential efficacy of supplementation with EPA+DHA in increasing HRV, RCTs are needed 
in populations with low tissue LC n-3 PUFA status rather than populations with above average 
proportions of EPA+DHA in erythrocyte members (>5%). 
7.3 Energy restriction/fasting and HRV 
Obesity is characterised by a chronic low-grade inflammation and is thought to increase 
the risk of SCD independently from other cardiovascular risk factors (327). Furthermore, there 
is a small amount of evidence from animal studies that a ketone body derivative, 
hydroxybutyrate, can inhibit sympathetic activity, which formed the rationale for the Met-
IER study, a RCT in centrally obese, and otherwise healthy subjects, to compare the effects of 
intermittent and continuous energy restriction diets on HRV, independent of weight loss. It was 
hypothesised that beat-to-beat HRV would increase to a greater extent following IER compared 
to CER despite equivalent weight loss, and it was theorised that this might be linked to raised 
ketone production. Contrary to the hypothesis, the results showed no superior effects of weight 
loss via an IER diet compared to a CER diet on HRV, but indicated an overall effect of weight 
loss in improving HRV, insulin sensitivity, BP and leptin, suggesting that weight loss itself may 
have a much greater effect on HRV and other markers of cardio-metabolic risk than any 
independent effect of energy restriction, or patterns of energy restriction. The possibility 
remains that the increase in ketone production/severity of the energy restriction was not enough 
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to trigger the postulated pathways that might inhibit sympathetic firing. This could be further 
investigated by comparing ketogenic (low carbohydrate) diets with normal moderate 
carbohydrate diets with the aim of maintain energy balance in a centrally obese study population 
to explore whether this had any effect on HRV parameters. Future studies will also need a 
longer duration to assess any differential effects of losing weight through CER or IER on HRV 
and cardiometabolic risk factors. 
7.4 Inflammation as a mediator of dietary impact on autonomic nervous 
system function 
Chronic low-grade inflammation is a unifying component of the diseased states explored 
in this doctoral research (CKD and central obesity) and could be a key mediating mechanism for 
the postulated impact of diet on the ANS, and consequent risk of SCD. 
A limitation of nutrition studies assessing the impact of diet on inflammation is the fact 
that the inflammatory markers are often measured in fasting blood samples, which may not 
necessarily reflect inflammation in tissue compartments, nor the inflammatory response to 
challenges (328). There are only a few studies in humans addressing the influence of diet on 
lipid mediators, and the Om3ga study was the first to publish results on LC n-3 PUFA-derived 
lipid mediators in vegans. Although the analysis was performed in fasting plasma, these 
indicated a significant difference in lipid mediator patterns between vegans and omnivores, 
being the first step towards the understanding of the impact of a low n-3 PUFA tissue status in 
the production of precursors of SPM (as SPMs were not detected) that have been shown to be 
actively involved in the resolution of inflammation. This study provides directions for future 
studies, such as postprandial measurement of lipid mediators after a high-fat meal challenge in 
vegans compared to omnivores. Inducing obesity in mice was shown to significantly reduce 17-
HDHA and dietary treatment with n-3 PUFA increased 17-HDHA and reduced obesity-
associated adipose tissue inflammation (329). A RCT assessing the effect of LC n-3 PUFA 
supplementation in severely obese nondiabetic patients showed increased production of anti-
inflammatory eicosanoids (RvE1, 17-HDHA, PD1 and RvD1) in visceral adipose tissue, and 
decreases in IL-6 in the LC n-3 PUFA supplemented group compared to the control group 
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(330). In addition, RvE1 and RvD1 was only detected in the adipose tissue from the LC n-3 
PUFA supplemented group, which might explain why resolvins were not detected in the Om3ga 
study omnivores. Since the production of SPM precursors has been associated with LC n-3 
PUFA tissue status, shown by the results of the Om3ga study, LC n-3 PUFA supplementation 
may lower inflammatory burden and thus have a beneficial impact on the ANS function. The 
modest weight loss achieved over 4 weeks in the Met-IER study did not significantly reduce 
plasma IL-6. However, the effects of weight loss in SPMs production have not been fully 
investigated, and should be considered in future studies together with measurements of a 
broader range of inflammatory markers. 
7.5 Future work directions 
 There is the potential of LC n-3 PUFAs and weight loss (independent of the type of 
diet) to improve cardiac autonomic function although further research is needed to 1) clarify 
potential benefits of supplementing populations with low LC n-3 PUFA status, such as 
populations deemed to be healthy (vegans) or those with a disease that carries a greater 
inflammatory burden compared to the general population, such as stage 5 CKD. Future work 
should include a 4-arm RCT to test the effects of LC n-3 PUFA supplementation (algal source) 
on HRV and lipid mediators in vegans (intervention and control group) and in omnivores 
(intervention and control groups) where low O3I (<5%) would be an inclusion criteria; future 
work should also directly compare the effects of fish oil vs. drugs used in primary prevention of 
CVD (such as statins and β-blockers) vs. combined treatment on HRV and inflammatory 
markers in participants screened for low O3I (<5%). 2) explore alternative biomarkers for tissue 
LC n-3 PUFA status in haemodialysis patients. Future work should assess the potential of other 
biomarkers of n-3 PUFA intake (such as adipose tissue and mononuclear cells) and assess their 
relationship with HRV, as well as assess the effects of DHA supplementation on HRV in 
haemodialysis patients as the FISHH study has suggested a compromised metabolism in the 
DHA synthesis pathway; 3) further explore the effects of intermittent fasting in RCTs with 
longer duration. Future work should assess the effect of IER on HRV using a RCT (with a 
minimum of 6 months, ideally 1 year) including a CER group and a control group where weight 
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loss does not occur. There should be a follow-up after the first month so that the effects of short-
term intermittent fasting can be compared with the longer-term effects. In addition, the effects 
of intermittent fasting should be further explored in other population groups with central obesity 
that also have additional comorbidities (such as renal disease and hypertension). 
  
 This doctoral research consisted mostly of pilot investigations, and has added a 
contribution towards the understanding of how diet may play a role in modulating ANS through 
modulating inflammation, with an eventual role in preventing CVD and SCD. The findings 
provide preliminary data that might benefit the dietary supplements/nutraceuticals industry with 
regards to the importance of increasing n-3 tissue status in non-fish-consuming populations, and 
provides valuable information for the medical community, particularly healthcare professionals 
who specialise in renal medicine. It also provides initial evidence that can be used by dietitians, 
as part of a growing body of literature, regarding the cardiovascular health benefits of different 
dietary strategies for weight loss. Finally, this work has opened future directions for research 
into the potential role of dietary interventions in preserving or improving cardiac autonomic 
function, including testing the effects of energy restriction alone or in combination with LC n-3 
PUFA supplementation in SPMs production, inflammatory markers and HRV to assess a 
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Appendix 1 – Recommendations for EPA and DHA intake in adults. 
Organisation Target population Recommendation 
World Health Organ-




General population LC n-3 PUFA: 0.5-2% daily energy intake 





mary prevention of CHD) 
Fish intake: 2-3 portions/week (150-200 g), 
including oily fish 
EPA+DHA: 250-500 mg/day 
Australian & New 
Zealand Health Au-
thorities (333) 
Men (19+ years) LC n-3 PUFA: 160 mg/day 
Men to lower chronic dis-
ease risk 
LC n-3 PUFA: 610 mg/day 
Women (19+ years) LC n-3 PUFA: 90 mg/day 
Women to lower chronic 
disease risk 
LC n-3 PUFA: 430 mg/day 
European Food Safe-
ty Authority (EFSA) 
(334) 




vention in clinical 
practice: Sixth Joint 
Task Force of the 
European Society of 
Cardiology and Oth-
er Societies on Cardi-
ovascular Disease 
Prevention in Clinical 
Practice (335) 
 Fish intake recommendations removed from 
guidelines. 
Reason: “With currently available cardiopro-
tective therapies, it debatable whether 
EPA+DHA exert a favourable effect on all-
cause, coronary artery disease and stroke 
mortality.” 
French Food Safety 
Agency (AFFSA) 
(336) 
General population EPA+DHA: 500 mg/day 
EPA: 250 mg/day 








EPA+DHA: 500-750 mg/day 
 
Superior Health 
Council of Belgium 
(337) 
General population (pri-
mary prevention of CVD) 
Fish intake: 2 portions/week (preferably oily 
fish) 
Patients with CVD (Sec-
ondary prevention) 
EPA+DHA: 1 g/day (from fatty fish or alter-
natively from fish oil capsules) 
 
Health Council of the 
Netherlands (338) 
General population Fish intake: One portion/week (preferably 
oily fish) 
Nordic Council of 
Ministers (339) 




General population Fish intake: At least two portions/week, of 
which one should be oily 
LC n-3 PUFA: 0.45 g/day 
National Institute for 
Health and Clinical 
Adults at high risk of or 
with CVD 
Fish intake: at least 2 portions per week, in-
cluding a portion of oily fish 
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Excellence (340) Do not offer LC n-3 PUFA supplements for 
prevention of CVD. 
Irish Heart Founda-
tion (341) 
General population LC n-3 PUFA: 200 mg/day 
Brazilian Society of 
Cardiology (342) 
Prevention of CVD LC n-3 PUFA supplementation not recom-
mended 
Academy of Nutrition 
and Dietetics (343) 
General population EPA+DHA: 500 mg/day 
American Heart As-
sociation (344) 
Primary prevention of 
CHD 
No recommendation 
Patients with CHD 
(secondary prevention) 
EPA+DHA: 1 g/day (preferably from oily 
fish) 
EPA+DHA supplements could be considered 
in consultation with physician 
Prevention of CVD mor-
tality in patients with dia-
betes 
LC n-3 PUFA supplementation not indicated 
Prevention of CHD 
among patients at high 
risk of CVD 
LC n-3 PUFA supplementation not indicated 
Primary prevention of 
atrial fibrillation 
No recommendation 
Secondary prevention of 
atrial fibrillation 
LC n-3 PUFA supplementation not indicated 
Health Canada (345) 
General population Fish intake: At least two portions/week (pro-
vides 0.3-0.45 g/day EPA+DHA) 
American Dietetics 
Association / Dieti-
tians of Canada (346) 
General population LC n-3 PUFA: 500 mg/day 
Ministry of Health, 
Labour and Welfare, 
Japan (347) 
General population Men (18-29 y): 2.0 g/day 
Women (18-29 y): 1.6 g/day 
Men (30-49 y): 2.1 g/day 
Women (30-49 y): 1.6 g/day 
Men (50-69 y): 2.4 g/day 
Women (50-69 y): 2.0 g/day 
Men (70+ y): 2.2 g/day 
Women (70+ y): 1.9 g/day 
  
244  






























Appendix 5 - Blood handling protocol in the Om3ga study. 
FBC, full blood count; FLIP, fasting lipid profile; KCH, Kings College Hospital; KCL, King’s College London; LFT, liver function test; RBC, red blood cells; RT, room 
temperature. 
  
Sample Tubes Ice/RT Centrifuge Separation Analytes Storage Transport to lab 
 
Screening 
4ml Fluoride  
oxalate  
Ice 15 min x 1500 g at 
4ºC Separate plasma into 2 x 
1 ml aliquots 
Glucose 
 
Freeze 1 aliquot  
send the other fresh to 
analyse 
KCH - Same day at 
room temperature  
4ml EDTA  RT No 
None 
FBC RT KCH - Same day at 
room temperature  
5ml SSTTM  
RT 15 min x 1500 g at 
4ºC 
Separate serum into  




Freeze 1 aliquot  
send the other fresh to 
analyse  




6 ml EDTA RT 15 min x 1500 g at 
4ºC Plasma (top layer) - 
Separate into 2 x 1 ml 
aliquots 
Plasma fatty acid 
composition  
Freeze 1 aliquot at 
-80ºC KCL – GC analysis 





   
RBC (bottom layer) 
Erythrocyte membrane 
phospholipid fatty acid 
composition  
Store in the fridge at 4ºC KCL – Wash RBC and 
freeze at - 20ºC until 
analysed 
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15 min x 1500 g 
at RT 
2 x 0.5 ml  
Glucose 
 
Freeze 0.5 ml 0.5 ml 
4ml EDTA No None FBC N/A Send sample without aliquoting 
5 ml SSTTM 
15 min x 1500 g 
at RT 
2 x 1 ml  
FLIP 
LFT 




15 min x 1500 g 
at 4⁰C 
4 x 0.5 ml Glucose Freeze 3 x 0.5 ml 0.5 ml 
6ml EDTA 
0.2 ml IL-6 - 0.2 ml 
0.8 ml Metanephrines - 0.8 ml 
2 x 0.5 ml Nitrates Freeze 2 x 0.5 ml - 
0.6 ml EDTA spare Freeze 0.6 ml - 
17ml  SSTTM 
(8.5ml x 2) 
0.5 ml + 0.4 ml FLIP Freeze 0.4 ml 0.5 ml 
0.2 ml Insulin Freeze 0.2 ml 
1ml vial 
2 x 0.2 ml NEFA Freeze 2 x 0.2 ml 
0.2 ml β-hydroxybutyrate Freeze 0.2 ml 
0.2 ml Leptin Freeze 0.2 ml 
0.2 ml Adiponectin Freeze 0.2 ml 
 
 
3 x 0.2 ml Klotho Freeze 3 aliquots  
Send to Prof. Sandrine at 
Institute of Psychiatry, KCH 
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Appendix 12 - International physical activity questionnaire – short form (IPAQ-SF) given to 
participants of the Met-IER study. 
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Appendix 13 - Participant's booklet on healthy eating based on a Mediterranean-type diet and 
individually personalised dietary and physical activity goals. 
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Appendix 14 - Nutritional composition of the LighterLife® foodpacks provided to the 
participants of the Met-IER study. 
 
Milkshakes per serving 
 Banana Chocolate Caramel Strawberry Vanilla 










Energy (kJ) 643  627  633  639  638  
             (kcal) 153  150  151  152  152  
Fat (g) 4.6  3.7  3.9  4.6  4.6  
Saturates fat (g) 1.9  1.4  1.4  1.9  1.9  
Carbohydrates (g) 12.7  12.6  12.5  12.7  12.5  
Sugars (g) 11.9  4.9  5.0  11.4  11.8  
Fibre (g) 3.6  7.4  7.3  3.8  3.9  
Protein (g) 13.4  12.9  12.9  13.1  13.2  
Salt (g) 1.4  1.2  1.2  1.4  1.4  
Vitamin A (μg) 200 25 259 32 261 33 200 25 200 25 
Vitamin D (μg) 1.25 25 1.7 34 1.7 34 1.25 25 1.25 25 
Vitamin E (mg) 3 25 4.3 36 4.6 39 3 25 3 25 
Vitamin K (μg) 25 33 32.2 43 32.2 43 25 33 25 33 
Vitamin C (mg) 20 25 22.5 28 22.5 28 20 25 20 25 
Thiamin (mg) 0.28 25 0.34 30 0.4 32 0.28 25 0.28 25 
Riboflavin (mg) 0.4 29 0.5 36 0.5 36 0.4 29 0.4 29 
Niacin (mg) 4.9 31 5.7 36 5.7 36 4.9 31 4.9 31 
Vitamin B6 (mg) 0.5 36 0.6 46 0.6 46 0.5 36 0.5 36 
Folic acid (μg) 50 25 50 25 63.4 32 50 25 50 25 
Vitamin B12 (μg) 0.6 25 0.9 37 0.9 37 0.6 25 0.6 25 
Biotin (μg) 12.5 25 14 28 15.5 31 12.5 25 12.5 25 
Pantothenic acid 
(mg) 
1.5 25 1.9 32 1.9 32 1.5 25 1.5 25 
Potassium (mg) 540 27 547 27 531 27 527 26 534 27 
Chloride (mg) 243 30 249 31 204 26 235 29 239 30 
Calcium (mg) 288 36 213 27 201 25 277 35 283 35 
Phosphorus (mg) 288 41 231 33 193 28 280 40 284 41 
Magnesium (mg) 105 28 106 28 93.8 25 104 28 104 28 
Iron (mg) 4.0 29 5.6 40 4.8 34 4.0 29 4 29 
Zinc (mg) 2.5 25 3.2 32 3.0 30 2.5 25 2.5 25 
Copper (mg) 0.38 38 0.55 55 0.4 43 0.38 38 0.38 38 
Manganese (mg) 0.55 28 0.65 32 0.7 32 0.55 28 0.55 28 
Fluoride (mg) 0.88 25 1.1 32 1.1 32. 0.88 25 0.88 25 
Selenium (μg) 13.8 25 17.8 32 17.8 32 13.8 25 13.8 25 
Chromium (μg) 10 25 15.7 39 12.9 32 10 25 10 25 
Molybdenum (μg) 12.5 25 16.1 32 16.1 32 12.5 25 12.5 25 
Iodine (μg) 37.5 25 48.5 32 48.5 32 37.5 25 37.5 25 
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Other foodpacks per serving 
 Soup Spaghetti 
Bolognese 
Curry Bars 
 40g % RI 40g % RI 40g % RI 46g % RI 
Energy (kJ) 633  630  634  652  
             (kcal) 150  150  151  155  
Fat (g) 5.0  4.2  4.5  4.5  
Saturates fat (g) 1.6  0.6  1.9  1.9  
Carbohydrates (g) 12.7  13.9  12.5  16.9  
Sugars (g) 4.8  2.0  4.1  9.5  
Fibre (g) 2.5  3.2  4.3  3.8  
Protein (g) 12.5  12.5  12.7  12.7  
Salt (g) 1.5  1.4  0.9  0.3  
Vitamin A (μg) 245 31 204 26 200 25 204 25 
Vitamin D (μg) 1.8 36 1.3 25 1.3 25 1.3 25 
Vitamin E (mg) 3.0 25 3.3 27 3.0 25 3.0 25 
Vitamin K (μg) 29.8 40 25 34 25 33 25 34 
Vitamin C (mg) 29.1 37 30.6 38 20 25 20 25 
Thiamin (mg) 0.3 30 0.32 29 0.3 28 0.3 25 
Riboflavin (mg) 0.5 38 0..44 31 0.4 30 0.4 29 
Niacin (mg) 4.9 31 4.8 30 5.0 31 4.6 28 
Vitamin B6 (mg) 0.6 40 0.6 39 0.5 37 0.5 36 
Folic acid (μg) 130 65 195 98 68.7 34 51 25 
Vitamin B12 (μg) 0.9 36 0.6 25 0.6 25 0.7 26 
Biotin (μg) 14.1 28 12.5 25 12.5 25 13 25 
Pantothenic acid (mg) 1.8 30 1.5 26 1.6 26 1.6 25 
Potassium (mg) 830 42 525 27 501 25 536 27 
Chloride (mg) 611 77 627 78 392 49 201 25 
Calcium (mg) 200 25 200 25 238 30 208 26 
Phosphorus (mg) 286 41 191 28 188 27 177 25 
Magnesium (mg) 104 28 98 26 96 25 95 25 
Iron (mg) 5.0 36 4.6 33 5.0 35 4.9 35 
Zinc (mg) 2.7 27 2.9 29 2.8 28 2.8 28 
Copper (mg) 0.4 42 0.3 31 0.5 48 0.5 45 
Manganese (mg) 0.5 27 0.5 26 0.6 28 0.6 30 
Fluoride (mg) 0.9 25 0.9 25 0.9 25 0.9 25 
Selenium (μg) 14.7 27 13.9 25 13.8 25 14 25 
Chromium (μg) 11.1 28 10 25 10 25 10 25 
Molybdenum (μg) 18.7 38 12.5 25 12.5 25 13 25 
Iodine (μg) 37.8 25 37.5 25 37.5 25 38.5 25 
 
